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ABSTRACT
Background: OAB is defined by subjective symptoms, rather than objective measure,
the patient’s perspective is important in managing OAB (Hung et al., 2013). As such
providers need to capture the patient’s perspective of their OAB symptoms and their
impact on the quality of life. A patient work up helps providers determine the cause of
the symptoms as well as the degree of bother to the patient (Barkin, 2016). The diagnosis
of OAB is essentially clinical and can be performed through structured questionnaires
(Juliato et al., 2016). When conducting a patient history, it is important to determine the
onset and severity of the nocturia, and also determine if the nocturia is consistent or
intermittent (Barkin, 2016). Healthcare providers should acertain any medical conditions
or drugs that may cause nocturia.
Method: A quality improvement study was designed and implemented in a retail health
clinic to determine an effective standard OAB screening tool; to determine the knowledge
level of providers regarding OAB; and measure provider’s perception of the ABSST
effectiveness in assessing for OAB in patients. An appraisal of literature published from
2006 through 2016 was conducted to determine if the use of a simple symptom screener
in primary care settings, may facilitate discussions between the patient and healthcare
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provider regarding OAB, and thereby help to identify women who could benefit from
treatment. Over 1000 potential providers were targeted to participate and of those, 153
providers agreed to participate but only 52 providers completed the study including the
pre- and post-surveys, the educational module and utilized the ABSST tool with their
patients that met the criteria.
Results: The two questions that sought to measure the provider knowledge pre-and posteducational module were not statistically significant. The questions that sought to
measure the provider perception of the ABSST effectiveness in assessing for OAB in
patients were statistically significant (N= 148; N=145 pre-survey and N=51 and N=52
post-survey). The validated overactive bladder screening tool (ABSST) was found to be
statistically significant in highlighting the presence of bladder symptoms consistent with
OAB at a 95% confidence interval (-0.8163 - -0.3366) with p< 0.0001 (N=148 pre-survey
and N=51 post survey). The ABSST was effective in facilitating critical communication
between patient and provider, was significant at 95% confidence interval (-0.8787 - 0.3995, p<0.0001) (N=145 pre-survey and N=52 post survey). Provider knowledge level
for assessing OAB post intervention was statistically significant (p=0.0004) (N=153 presurvey and N=52 post-survey).
Conclusion: Findings indicated that providers’ knowledge and awareness of OAB
symptoms and screening in adult women were increased following an educational online
module. This results suggest that the ABSST is likely to improve patient outcomes for
patients who are screened and if criteria met, to initiate treatment early.
Implications: This study created an awareness in the providers who did not routinely
screen their patients for OAB symptoms. Further recommendations would include
vi

replicating this project with a larger sample, as well as expanding the content to assess all
adults, both male and female.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE OF THE PROBLEM
Overactive bladder (OAB) is defined by the International Continence Society
(ICS) (2005) as “urgency with or without urgency incontinence, usually with frequency
and nocturia” (Levkowicz, Whitmore, & Muller, 2011). About 25 percent of young
women, 44 to 57 percent of middle-aged and postmenopausal women, and about 75
percent of older women experience some involuntary urine loss (Agency for Healthcare
Research and Quality (AHRQ), 2013). The cost of incontinence care in the United States
averaged 19.5 billion in 2004 (AHRQ, 2013). The NOBLE study showed the prevalence
of OAB in the United States was 16.9 percent in women (Eapen & Radomski, 2016). The
NOBLE study found that OAB symptoms were more common in women than in men,
younger than 60 years of age (Eapen & Radomski, 2016). The EPIC study, which was
one of the largest population based surveys that studied the prevalence of lower urinary
tract symptoms and OAB, showed an overall prevalence of lower urinary tract symptoms
(LUTS) suggestive of OAB was 12.8 percent in women.
The EpiLUTS survey done in the United States, United Kingdom and Sweden,
showed that 43.1 percent of women of 40 years and older reported urgency or urge
incontinence ‘at least sometimes’, and of these women, 67.6 percent and 38.9 percent
reported ‘somewhat’ or ‘quite a bit’ bother (De Ridder, Roumeguere, & Kaufman, 2013).
LUTS severity has been associated with decreased sexual activity and sexual satisfaction
(Coyne et al., 2008). According to Levkowicz et al. (2011), nocturia disrupts a woman’s
1

physical health and sense of normalcy and can also affect ones emotional and social
circumstances. The rising prevalence of OAB creates a burden for individuals and society
and increases the potential for impaired functional status and lower health-related quality
of life (Barile et al., 2015).
In terms of screening for OAB, many women believe that some amount of
urinary incontinence is inevitable with aging (Hartmann, McPheeters, & Biller, 2009).
The majority of women with these symptoms do not talk with their healthcare providers
concerning their bladder dysfunction and providers may not systematically inquire
(Hartmann, McPheeters, & Biller, 2009). Consequently, very few women obtain adequate
treatment for their symptoms.
The purposes of this project were to (1) determine an effective standard OAB
screening tool to be used in a retail clinic environment and to (2) determine the
knowledge level of providers regarding OAB, and (3) measure the provider’s perception
of the Actionable Bladder Screening Tool (ABSST) effectiveness in assessing for OAB
in patients.
1.1 BACKGROUND
Typical symptoms include urinating more than eight times per day (urinary
frequency) and a strong, sudden desire to urinate (urinary urgency) (Van Kerrebroek et
al., 2002; Levkowicz et al., 2011). Nocturia is described by the ICS (2005) as “sleepdisturbing voiding” (Levkowicz et al., 2011). The fundamental symptom is urgency, and
is considered to be the driver of the urological symptoms (De Ridder, Roumeguere, &
Kaufman, 2013). Daytime urinary frequency is hallmark symptom of OAB increasing
with age (Levkowicz et al., 2011). OAB is a subset of storage lower urinary tract
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symptoms characterized by urinary urgency but commonly occurring with other storage
symptoms, including frequency, nocturia, and urgency urinary incontinence (Coyne et al.,
2008). OAB is defined as bothersome urgency, usually associated with daytime voiding
frequency (more than every 2 hours) and nocturia (more than one episode per night for
adults under 65 years of age and three or more episodes for adults aged 65 years or older)
with or without urge urinary incontinence and occurring in the absence of pathologic or
metabolic conditions that might explain these symptoms (Gray & Moore, 2009, p. 122).
Risk factors for OAB and urge urinary incontinence (UI) include functional
deficits such as impaired mobility or dexterity, cognitive difficulties, and female gender
(Gray & Moore, 2009). Other risk factors to OAB are Caucasian, insulin-dependent
diabetes mellitus, increased body mass index, arthritis, depression, and age greater than
75 (Gomella, 2010). According to Gray and Moore (2009), before age of 60, OAB is
more common in women than in men, with women more likely to experience mixed UI
with OAB (Gray & Moore, 2009).
Conditions associated with OAB are neurologic disorders such as stroke,
hydrocephalus, brain tumors, dementia or parkinsonism; stress urinary incontinence;
inflammatory disorders such as urinary tract infection, bladder stones, or tumors;
idiopathic factors; and obstruction as a cause of detrusor over activity (Gray & Moore,
2009). Over activity of detrusor muscle may also be due to transient causes such as
delirium, infection, atrophic urethritis/ vaginitis, pharmaceutical, psychological,
excessive urine output, restricted mobility and stool impaction (Gomella, 2010).
Because OAB is defined by subjective symptoms, rather than objective measures,
the patient’s perspective is important in managing OAB (Hung et al., 2013). As such
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clinicians need to capture the patient’s perspective of their OAB symptoms and their
impact on the quality of life. A patient work up helps clinicians determine the cause of
the symptoms as well as the degree of bother to the patient (Barkin, 2016). The diagnosis
of OAB is essentially clinical and can be performed through structured questionnaires
(Juliato et al., 2016). When conducting a patient history, it is important to determine the
onset and severity of the nocturia, and also determine if the nocturia is consistent or
intermittent (Barkin, 2016). Healthcare providers should ascertain any medical conditions
or drugs that may cause nocturia. Medications such as diuretics, sedatives, narcotics,
antidepressants, antihistamine, calcium channel-blockers and alpha blocker can possibly
cause or worsen OAB.
The healthcare provider should order a urinalysis, a urine culture and sensitivity
test, and a urine cytology test (if indicated, because of hematuria). The following tests
should be ordered if indicated, a serum creatinine test to rule out renal failure, and an
abdominal and/or pelvic ultrasound test. It is also important to ensure when the
healthcare provider is performing a physical examination, to ensure that the patient is not
in retention (palpate supra-pubically) (Barkin, 2016). Other diagnostic procedures for
OAB include, urodynamics, uroflowmetry, urethral pressure profilometry, endoscopy/
cystoscopy, voiding and intake diaries, pad test, and post void residuals (Gomella, 2010).
First line treatment is antimuscarinics such as oxybutynin, tolterodine, trospium,
solifenacin, hyoscyamine, and fesoterodine (Gomella, 2010). The current
pharmacological approach to treating OAB mainly involves antimuscarinic agents, but
the use of these agents is limited in some individuals because of the suboptimum efficacy
or bothersome adverse events, including dry mouth, blurred vision and constipation
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(Yamaguchi et al., 2014). Alternative approaches to managing OAB have focused on
beta-adrenoceptors, such as mirabegron, which have a recognized role in mediating the
relaxation of bladder smooth muscle (Yamaguchi et al., 2014). Three beta-adrenoceptor
subtypes have been identified in the human detrusor, but it is the βᶾ-adrenoceptor subtype
that is responsible for promoting its relaxation and urine storage, and this may also inhibit
the activity of the bladder afferent nerves (Yamaguchi et al., 2014).
Additional treatments include behavioral therapy such as bladder retraining,
pelvic floor exercises (Kegel), pelvic floor biofeedback, and transvaginal/transrectal
electrical stimulation. General prevention is consuming a high fiber diet and limiting
consumption of caffeine and alcohol (Gomella, 2010). Caffeine is postulated to cause a
mild diuresis, which may result in increased urinary frequency and detrusor relaxation
during bladder filling and storage (Wells, et al., 2014). Higher caffeine intakes have been
associated with urinary incontinence, and caffeine intake has been associated with OAB
(Wells et al., 2014). Other treatment options include (1) intravesical therapies (capsaicin,
resinofentoxin), (2) estrogen (topical or oral) to increase growth of vaginal epithelium,
increase volume of submucosal plexus, and strengthen pelvic floor musculature
(Gomella, 2010). The prognosis varies according to the severity of disorder and
compliance of the patient (Gomella, 2010). About 50% to 80% of patients respond to
combination of behavioral modification, pelvic floor therapy, and pharmacotherapy
(Gomella, 2010).
1.2 SIGNIFICANCE
The condition is highly prevalent and is associated with significant economic
burden and lower health-related quality of life (Cardozo et al., 2014). To illustrate, the
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EPIC study, was one of the largest population based surveys that studied the prevalence
of lower urinary tract symptom(LUTS) and OAB in five countries (Canada, United
Kingdom, Germany, Italy and Sweden). This study showed that the prevalence of LUTS
suggestive of OAB was 10.8% in men and 12.8% in women (Eapen & Radomski, 2016).
In the USA-based NOBLE study, Stewart et al (2003), estimated the prevalence of OAB
as 16% among men and 16.9% among women, but did not collect data on the overall
prevalence of LUTS (Coyne et al. 2008). Epidemiological studies have demonstrated
that the frequency of OAB ranges from 12.4% to 53.1%, depending on the target
population and definition of OAB, and the number increases with advancing age (Hung et
al., 2013). The total cost in the USA was estimated to be 65.9 billion in 2007, 22.1% of
which was accounted for by indirect costs (Cardozo et al., 2014). Indirect costs include
impaired work productivity and activity, and statistically higher rates of OAB-related
surgery, hospitalizations, physician visits and pad use (Tang et al., 2013; Cardozo et al.,
2014).
Urinary incontinence is associated with poorer quality of life, impaired work
productivity and activity, and statistically high rates of OAB-related surgery,
hospitalizations, provider visits and pad use (Cardozo et al., 2014). Despite the negative
impact of OAB on healthcare quality of life, an online survey study conducted across
multiple countries showed that a substantial proportion of patients never consulted a
provider regarding their bladder symptoms (Cardozo et al., 2014). Moreover, the study
found that those patients who did consult a provider waited a number of years before
doing so and generally had to initiate the consultation themselves (Cruz, Denys, Signori,
& Globe, 2012).
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It is suggested that urinary incontinence has the potential to substantially lower
ones’ health related quality of life (Ng Pooi Yee, Chow Yeow, & Tan Khon, 2011).
Despite urinary incontinence being described as a problem, current research has indicated
a low proportion of 6-12% of the population sought medical advice and treatment for
urinary incontinence (Ng Pooi Yee, Chow Yeow, & Tan Khon, 2011). Given the high
prevalence of OAB in women, in conjunction with the fact that many patients fail to
mention their problems during clinical consultations, women may benefit from screening
for symptoms of OAB, including urinary urge incontinence (Cardozo et al., 2014).
Thus, it is important for healthcare providers to screen patients for OAB.
Moreover, providers have an obligation to explore behavioral as well medication therapy
in the management of OAB. Healthcare providers in primary care settings are in a
position to create a public health education plan to improve patient knowledge about
OAB including nocturia and understanding the treatment options available.
1.3 SCOPE OF PROBLEM
According to the Walgreens Healthcare Education department, the clinics do not
adequately assess adult women who may potentially present with OAB issues. According
to Walgreen data, the average age of most patients who visit the Walgreens clinics are
between ages 18-49. The majority of these patients are female. Walgreens Healthcare
Clinics do not screen adult women for OAB. However, the clinic providers treat women
for urinary tract infections. Many times, some of these women may have normal
urinalysis tests, but complain of nocturia and urgency. These women are not likely to
divulge this information unless the providers ask them pointedly the critical and simple
question: “When you get up at night to void – do you pass a lot of urine each time or just
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a small amount?” (Barkin, 2016). Based on literature, many women believe that some
amount of incontinence is inevitable with aging and the majority of women with these
symptoms do not talk with their health care providers about their concerns with bladder
function (Hartmann, McPheeters, & Biller, 2009). As a result, many women with OAB
experience delays in treatment (Levkowicz et al., 2011).
1.4 BEST PRACTICES
Several articles on OAB were appraised to provide confidence to implement the
project; the evidence was then combined with different aspects within an area of provider
utilization and patient acceptance. The study by Sumardi et al. (2012), evaluated the testretest reliability of OAB Symptom Score (OABSS), which was original developed and
validated in Japanese population. The OABSS showed excellent test-retest reliability in
Indonesian OAB patients, and the simplicity of the tool made it useful and feasible for
clinical practice that had limited time and resources. The results of the study suggest
some utility for the OABSS to provide useful information on OAB symptoms which
would otherwise have been gained from completion of a voiding diary; as such, solitary
or complementary application of OABSS may considerably simplify the management of
OAB (Sumardi et al., 2012).
The study by Basra et al. (2012), compared the value of two validated
questionnaires: the Bladder Control Self-Assessment Questionnaire (B-SAQ) and the
Overactive Bladder Awareness Tool (OAB-V8). Both questionnaires were found to
perform well in identifying and screening for OAB symptoms in clinical setting. The
OAB-V8 was validated in the USA in a predominantly primary care population; the BSAQ was validated in the secondary care population (Basra et al., 2012). Both the B-
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SAQ and the OAB-V8 performed well in detecting symptoms of OAB and mixed urinary
symptoms (Basra et al., 2012). The B-SAQ performed better in detecting symptoms of
stress incontinence than the OAB-V8 (Basra et al., 2012). However, the OAB-V8 was
unable to screen for hematuria (Basra et al., 2012).
In the study by Coyne et al. (2008), the Center for Epidemiologic Studies
Depression Scale (CES-D), the Patient Perception of Bladder Condition (PPBC), and the
work productivity related to a specific health problem (WPAI-SHP), were questionnaires
used to assess the prevalence and impact of OAB and lower urinary tract symptoms
(LUTS). This study was conducted in five countries with a large sample size. The OAB
and LUTS classifications used in this study were based entirely on patient-reported
symptoms. This study found that the diagnosis and treatment of OAB should be
considered in conjunction with LUTS, to maximize treatment options and optimize
patient outcomes.
Cardozo et al. (2014) had 100 women complete the Actionable Bladder Symptom
Screening Tool (ABSST). The tool was validated in non-neurogenic females and found to
be a reliable, valid and sensitive tool for screening women with urinary urge incontinence
and OAB (Cardozo et al., 2014).
1.5 STATEMENT OF PURPOSE
The purposes of this project were to (1) determine an effective standard OAB
screening tool that could be used in a retail clinic environment and to (2) determine the
knowledge level of providers regarding OAB, and (3) measure the provider’s perception
of the ABSST effectiveness in assessing for OAB in patients.
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A substantive integrative review of literature on tools that can assess OAB
problems in adult women over age 40 years was conducted to analyze the literature for
comparing the different tools and determine the best screening tool that providers could
use to assess women who presented in the clinical setting. This tool was used by
healthcare providers to screen women who may potentially have OAB and initiate
treatment and referral as necessary. The tool would allow healthcare providers to assist
patients with the best practice management of non-neurogenic OAB by setting realistic
goals with patients for improving symptom control and quality of life.
1.6 PICOT QUESTION
An extensive review and analysis of literature published from 2006 through 2016
was conducted to answer the following PICOT question: Healthcare providers providing
primary care in Walgreens clinics (P), does an educational model to teach providers the
use of a standard OAB screening tool (ABSST) (I), as compared to the use of no
symptom screening tool (C), improve knowledge regarding the use of screening of OAB
as measured by (1) the provider’s knowledge of OAB pre and post educational
intervention, (2) the provider perception of the ABSST effectiveness in assessing for
OAB pre and post educational intervention (O), over 3 month’s period (T)? Refer to
Table 1.1
Table 1.1: Evidence Based Practice Clinical Question
Population
Intervention
Comparison
Outcome
Intervention
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Time
Frame

Healthcare

Educational

No use of

Improved knowledge

providers

model to teach

symptom

regarding the use of

providing

providers the

screening tool

the screening of OAB

primary care

use of a

in Walgreens

standard OAB

clinics

screening tool

knowledge of

(ABSST)

OAB pre-and

as measured by:
•

The provider’s

posteducational
intervention
•

The provider’s
perception of
the ABSST
effectiveness
in assessing for
OAB pre-and
posteducational
intervention

1.7 PICOT DEFINITION AND DESCRIPTIONS
1. Adult women: any female over the age of 40 years.
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3months

2. Intervention: An assessment tool that providers utilized to assess women for nonneurogenic OAB symptoms including urinary frequency (both daytime and
nighttime) and urgency, with or without urgency incontinence, in the absence of UTI
or other obvious pathology that are reported as bothersome (Gormley et al., 2012).
3. Best Practice: The use of interventions that were grounded on Evidence-based
research and improve bladder function and quality of life.
4. Healthcare Provider: refers to advance practice registered nurses (APRNs) and
physician assistants (PAs) that managed the care of women in Walgreens clinics.
5. Non-neurogenic Overactive Bladder (OAB) is loss of bladder control because the
bladder detrusor muscles contract often and at the wrong time ("Pri-med Institute,"
2006). This causes the sudden urge to urinate immediately ("Pri-med Institute,"
2006). Loss of bladder control is called incontinence, but “overactive bladder” refers
specifically to “urge incontinence” ("Pri-med Institute," 2006). The other types of
incontinence (stress incontinence and overflow incontinence) are not caused by
problems with the detrusor muscle ("Pri-med Institute," 2006).
6. Assessment tools: a review literature for validated short form questionnaires to assess
symptoms severity in women with incontinence. The assessment tool was piloted
with providers and feedback received from the providers on the effectiveness of the
tool in detecting OAB in women over 40 years.
7. OAB: nocturia, frequency, urgency, detrusor muscles overactivity, urge incontinence,
bladder control (Gormley et al., 2012). OAB is defined as bothersome urgency,
usually associated with daytime voiding frequency (more than every 2 hours) and
nocturia (more than one episode per night for adults under 65 years of age and three
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or more episodes for adults aged 65 or older) with or without urge urinary
incontinence and occurring in the absence of pathologic or metabolic conditions that
might explain these symptoms (Gray & Moore, 2009).
8. Nocturia: According to the International Continence Society (ICS), nocturia is
defined as “The complaint that the individual has to wake at night one or more times
to void. Each void is preceded and followed by sleep.” (Barkin, 2016).
9. Frequency: is defined as of more than eight times per day while urgency is defined as
a strong, sudden desire to urinate (Van Kerrebroek et al., 2002; Levkowicz et al.,
2011).
10. Detrusor muscles overactivity is defined as the occurrence of an involuntary
contraction during the filling phase, which may be spontaneous or provoked (Abrams
et al., 2002; Al-Ghazo et al., 2011). The urodynamic characteristics of OAB is
detrusor overactivity (Eapen & Radomski, 2016).
11. Urge incontinence(UI) is defined as urine loss associated with a precipitous desire to
urinate caused by an overactive detrusor contraction (Gray & Moore, 2009). UI is
also defined as urine leakage before one can get to the toilet (Wells et al., 2014)
12. Bladder control is defined as having no nocturia, frequency, urgency, detrusor
muscles
overactivity, or urge incontinence.
13. Outcomes: improved knowledge regarding the use of screening of OAB as measured
by (1) the provider’s knowledge of OAB pre-and post-educational intervention, (2)
the provider’s perception of the ABSST effectiveness in assessing for OAB pre-and
post-educational intervention.
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1.8 ASSUMPTIONS
1. OAB impairs quality of life.
2. Providers will use the OAB tool to assess patients for OAB.
3. Providers will use the data from the assessment tool to manage patients for OAB.
4. Providers knowledge and comfort of managing OAB will increase.
1.9 SUMMARY
This was a quality improvement project to: (1) determine an effective standard
OAB screening tool used in a retail clinic environment and to (2) determine the
knowledge level of providers regarding OAB, and (3) measure the provider’s perception
of the ABSST effectiveness in assessing for OAB in patients. The ultimate goal is for
providers to conduct a valid diagnostic process and establish treatment goals that
maximize symptom control and patient quality of life while minimizing adverse events
and patient burden (Gormley et al., 2012). Despite a significant reduction in healthrelated quality of life in patients suffering from urinary dysfunction, many do not seek
medical help, possibly out of embarrassment or because they do not believe that
treatment is available, even when seen by a clinician for other conditions (Cardozo et al.,
2014). The use of a validated bladder symptom screener tool in women with incontinence
due to OAB, presenting at the Healthcare Clinics in Walgreens may facilitate discussions
between the provider and patient, and thereby help to identify women who could benefit
from treatment (Cardozo et al., 2014).
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CHAPTER 2
LITERATURE REVIEW
Currently, the Healthcare Clinics in Walgreens do not adequately assess adult
women who may potentially present with overactive bladder (OAB) issues. These
women may not likely divulge this information unless the providers ask them pointedly.
Many women believe that some amount of incontinence is inevitable with aging and the
majority of women with these symptoms do not talk with their health care providers
about their concerns with bladder function (Hartmann, McPheeters, & Biller, 2009). As a
result, many women with OAB wait longer than needed to seek treatment (Levkowicz,
Whitmore, & Muller, 2011).
The purposes of this project were to (1) determine an effective standard OAB
screening tool to be used in a retail clinic environment, and to (2) determine the
knowledge level of providers regarding OAB, and (3) measure the provider’s perception
of the ABSST effectiveness in assessing for OAB in patients.
2.1 SEARCH STRATEGY
According to Melnyk & Fineout-Overholt (2015), searching the literature back 5
years is considered by some sufficient, this may not be adequate to discover evidence that
can address the clinical issue. An extensive review and analysis of literature published
from 2006 through 2016 was conducted to answer the following PICOT question:
Healthcare providers providing primary care in Walgreens clinics (P), does an
educational model to teach providers the use of a standard OAB screening tool (ABSST)
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(I), as compared to the use of no symptom screening tool (C), improve knowledge
regarding the use of screening of OAB as measured by (1) the provider’s knowledge of
OAB pre-and post-educational intervention, (2) the provider’s perception of the ABSST
effectiveness in assessing for OAB pre-and post-educational intervention (O), over 3
month’s period (T)?
The literature search strategy began with a review of library resources, with
assistance of the librarian. Peer-reviewed journal articles and textbooks were assessed to
try to answer the PICOT question. A systematic search was done on nine databases:
Google Scholar, PubMed, National Institutes of Health and Care Excellence, National
Guideline Clearinghouse, CINAHL, Web of Science, PsyInfo, EBSCOhost, and Ovid.
Searching subject-specific databases that index peer-reviewed research journals was the
next step in the research of the literature. Any journal articles that were not available
could be accessed through interlibrary loan. Tutorial videos were provided by the
librarian for how to use Joanna Briggs Institute, Web of Science, CINAHL, and PubMed;
and they were all carefully reviewed and used to assist in the search of the literature.
Only databases that provided mainly full text of many types of documents were
utilized. The first strategy was to search the literature using keywords: “nurse
practitioner”, “provider”, “family nurse practitioner” ,“urinary incontinence”,
“knowledge”, “perceptions”, “perceptions of OAB by NP”, “barriers”, “attitudes of
APRNs”, “knowledge of OAB”, “barriers to assess OAB”, “overactive bladder”, “OAB
in women”, “OAB assessment tool”, “urinary”, “nocturia”, “urinary frequency”, “urinary
urgency”, “incontinence”, “non-neurogenic OAB symptoms”, “loss of bladder control”,
“detrusor muscles”, “OAB questionnaires”, “assessment tools”, and “symptoms severity
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in women with incontinence”. Searches included searches of titles, abstracts and
keywords. The subject headings and abstracts of the articles were reviewed using
Medical Subject Headings (MESH). In some cases, truncation with special symbols in
combination with words, or word parts to increase the likelihood of finding appropriate
studies. Another strategy, utilized was the title search, which used the P, I and O terms in
the title so as to help find any citations and studies that were useful. Subject headings,
keywords, and Boolean operators AND or OR were used to search databases such as
EBSCOhost. The “limit” function to narrow down a large list of citations to the more
relevant studies. The inclusion criteria included relevant studies of nurse practitioner or
provider knowledge and perceptions, overactive bladder assessment tools, adult women
over 40 with non-neurogenic OAB symptoms, articles in English only, urinary
incontinence and lower urinary tract symptoms. Articles from other countries were
included if they were in English. Articles that included both men and women were also
included. The exclusion criteria included studies that had pediatric or men as the primary
research and articles older than 10 years. Articles dealing with provider knowledge and
perceptions of urinary incontinence, randomized studies comparing OAB medications to
placebo were also included. Three randomized clinical trial study articles were found,
that did not discuss an assessment tool, but focused on comparison studies of
anticholinergic therapy, solifenacin and β3-adrenoceptor agonist mirabegron. These
articles did have information about OAB screening tools. Refworks was used to manage
the citations. Thirty-one articles were included in this analysis. See the Evidence Table
1.1. Appendix B.
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In the next step, research and non-research evidence was appraised for evidence
level and quality (Dearholt & Dang, 2012, p. 47). See Appendix A. According to
Dearholt & Dang, 2012, the evidence rating is rated from Level I to Level V with a
quality rating from A: High, B: Good, and C: Low or Major Flaws. The articles were
reviewed for each piece of evidence and quality. Any evidence with a quality rating of
low-major flaws was discarded and not used in the evidence table. Most of the articles
the researcher found were level II or III. According to Dearholt & Dang, 2012, when
appraising individual research studies, three major components come into play: study
design, which has been discussed as the level of evidence; study quality, which refers to
study method and execution, with particular attention to study limitations, and reflects the
appraiser’s confidence the estimates of an effect are adequate to support
recommendations (Balshem et al., 2011); and directness, or the extent to which subjects,
interventions, and outcomes measures are similar to those of interest.
2.2 ANALYSIS OF LITERATURE
After appraising the literature on OAB to provide confidence to implement the
project, the evidence was then combined with different aspects within an area of provider
utilization and patient acceptance. There were 31 articles whose evidence was appraised.
According to Dearholt & Dang (2012), the John Hopkins evidence and quality guide, (see
Appendix A), eight articles were found to have evidence level I, six had evidence level II,
twelve had evidence level III, and four had evidence level IV and one had evidence level
V. All articles were of good and high quality.
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2.3 LEVEL ONE
The study by Sumardi et al. (2012), evaluated the test-retest reliability of OAB
symptom Score (OABSS), which was originally developed and validated in Japanese
population. This test-retest reliability was examined in patients in Indonesia using the
internal correlation coefficient and the weighted Kappa coefficients between the first and
second applications of the OABSS. Patients age 18 years and older with established
OAB completed 3-day micturition diaries and questionnaires, International Prostate
Symptom Score (IPSS), and Patient Perception of Bladder Condition (PPBC) on 2
separate visits. It was an observational study that had 50 patients enrolled with a return
rate of 100%. T-testing of the instrument was conducted at a level of significance of 0.05
and internal correlation demonstrated a coefficient of 0.83. The test-retest reliability of
the Indonesian OABSS was found to be excellent for each of the four individual items of
the Indonesian OABSS, the weighted Kappa coefficients were 0.55-0.65, representing
moderate to good agreement. The OABSS total score showed a moderate degree of
correlation with the IPSS total score (Spearman correlation coefficient = 0.41 at Visit 1
and 0.45 at Visit 2). The OABSS showed excellent reliability with an evidence level I,
with good quality, and the simplicity of the tool made it useful and feasible for clinical
practice that had limited time and resources. However, the generalizability of the findings
from one hospital to another was found to be a potential threat. Moreover, validated tools
have demonstrated clinical use with a certain range, but one common shortcoming is they
do not evaluate actual symptoms.
In the study by Coyne et al. (2008), the Center for Epidemiologic Studies
Depression Scale (CES-D), the Patient Perception of Bladder Condition (PPBC), and the
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work productivity related to a specific health problem (WPAI-SHP), were questionnaires
used to assess the prevalence and impact of OAB and lower urinary tract symptoms
(LUTS). This was a symptom prevalence study (prospective study), that identified 1434
participants. A nested case-control analysis was performed on men and women with
(cases) and without (controls) OAB, from the EPIC study. Based on their responses to
questions about (LUTS) cases were classified into five groups: continent OAB, OAB
with incontinence, OAB + post-micturition, OAB + post-mictirition + voiding. A
population based, cross sectional telephone survey of adults age over 18 years, was
conducted in five countries (Canada, Germany, Italy, Sweden and the UK). The Center
for Epidemiologic Studies Depression Scale (CES-D) had confirmed reliability and
validity. The Patient Perception of Bladder Condition (PPBC) was found to have good
construct validity, responsiveness to change and test-retest reliability among patients with
OAB. The OAB and LUTS classifications used in this study were based entirely on
patient-reported symptoms. However, controls were not asked any questions, which
limits the case-control comparisons. Another limitation was the OAB and LUTS
classifications used were based entirely on patient self-reported symptoms; there was no
urodynamic testing to confirm the type of LUTS, nor was there confirmation by a
medical professional. This study found that the diagnosis and treatment of OAB should
be considered in conjunction with LUTS, to maximize treatment options and optimize
patient outcomes. This article was an evidence level I, of good quality.
A systematic review (evidence level I and good quality) done by Kinsey et al.
(2016), generated 3699 electronic searches, of which 32 articles on psychological impact
of OAB were included in the review. The electronic databases searched were: Web of
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Knowledge, PsycINFO, MEDLINE, and CINAHL. All the studies were cross-sectional.
Most studies in this review were assessed using self-report questionnaire, which may
sometimes lead to participants being included or excluded from OAB group on the basis
of different individual views of “urgency” skewing the results. The research suggests that
there is disagreement among physicians in the way OAB should be defined. The lack of
clarity about the definition of OAB may also create difficulties in researching the
condition, particularly as OAB’s key symptoms, urgency, cannot be assessed objectively.
According to Kinsey et al. (2016), this review provides an overview of the current
research on the psychological impact of OAB. Psychological health should be considered
an important aspect of managing OAB, and further research is required to determine how
to best provide psychological care and support in this area (Kinsey et al., 2016).
Another systematic review (evidence level I), was conducted by Gormley et al.
(2015). The article discusses the 2014 amendments to the American Urological
Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital
Reconstruction (AUA/SUFU) guidelines. Data extraction was conducted as part of the
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment
Number 187 titled Treatment of Overactive Bladder in Women (2009). The report
searched the following databases: PubMed, MEDLINE, EMBASE, and CINAHL for
English language studies published from January 1966 to October 2008. The AUA
conducted additional literature searches to capture populations and treatments not
covered in detail by the AHRQ report and relevant articles published through December
2011. The review yielded 151 treatment articles after application of inclusion/exclusion
criteria. An additional systematic review conducted in February 2014 identified 72
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additional articles relevant to treatment and made up the basis for the 2014 amendment.
The amendment focused on four topic areas: mirabegron, peripheral tibial nerve
stimulation (PTNS), sacral neuromodulation and botulinum toxin A (BTX-A). The
additional literature provided the basis for an update of current guidelines statements as
well as the incorporation of new guideline statements related to the overall management
of adults with OAB symptoms. The treatments guidelines were divided in into first-,
second-, and third-line groups. First line treatments discussed behavioral therapies may
be combined with pharmacologic management. Second-line treatments discussed that
clinicians should offer oral anti-muscarinics or oral βз-adrenoceptor agonists. If a patient
experiences inadequate symptom control and/or unacceptable adverse drug events with
one anti-muscarinic medication, then a dose modification, or a different anti-muscarinic
medication, or a βз-adrenoceptor agonist may be tried. Clinicians should use caution in
prescribing these second-line treatments in the frail OAB patient. Patients who are
refractory to behavioral and pharmacologic therapy should be evaluated by an
appropriate specialist if they desire additional therapy. Third-line treatment, such as
intradetrusor onabotulinumtoxin A, PTNS, and sacral neuromodulation, required careful
patient selection and appropriate patient counseling. The expert opinion further discussed
that if the therapies that do not demonstrate efficacy after then adequate trial should be
ceased. New evidence-based statements and expert opinion supplemented the original
guidelines published in 2012, which provided guidance for the diagnosis and overall
management of OAB in adults.
The FINNO study by Tikkinen et al. (2009), was a case control study with
prevalence sampling, where the authors explored the correlates for nocturia and their

22

population-level impact. Tikkinen et al. (2009), randomly identified 6000 subjects (ages
18-79) from the Finnish Population Register (62.4% participated, 53.7% were female).
They answered questionnaires assessing nocturia and quality of life. The factors with the
greatest impact at the population level were (urinary) urgency (attributable
number(AN)/1000 subjects (AN=24), benign prostatic hyperplasia (AN=19), and snoring
(AN=16) for men and overweight and obesity (AN=40), urgency (AN=24), and snoring
(AN=17) for women. This attributable number study generalizability was limited as it
was done in a Finnish population and the impact measures generally are context specific.
Alcohol consumption reporting was incomplete, yet nocturia prevalence did not vary by
alcohol consumption among those reporting this information Although several correlates
were identified, none accounted for a substantial proportion of the population burden,
highlighting the multifactorial etiology of nocturia (Tikkinen et al., 2009). The
questionnaire mailing round did not affect correlate prevalence. However, four
exceptions emerged (age adjusted). First-round responders reported more nocturia and
urgency than responders in subsequent rounds (P for trend = 0.04), and first-round female
responders were slightly less obese than those in subsequent rounds (P for trend = 0.05).
However, the odds ratio estimates for these factors were similar for each round,
suggesting absence or systematic error. This study was an evidence level I and of high
quality.
A double-blind randomized, crossover study with evidence level I and with good
quality was done to study the effects of newly diagnosed women with OAB with a
history of caffeine consumption (Wells et al., 2014). The women were randomly assigned
to two groups, each group taking decaffeinated and caffeinated drinks for 14 days. The
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periods were preceded by a 14-days run-in period and interspersed with a 14-days
washout period. The primary outcomes were episodes of urgency, frequency, volume per
void, and incontinence obtained each period on 3-day bladder diaries. Secondary
outcomes measures were OAB symptoms severity and health-related quality of life
(QOL) recorded each period using International Consultation on IncontinenceOveractive Bladder Module (ICIQ-OAB-Quality of Life (ICIQ-OABqol) tools. Effects of
caffeine reduction were measured each day using visual analogue scales. The sample size
was small with only 11 participants completing the study. A significant reduction in
urgency (p<0.01) and frequency (p< 0.05) of urinary voids on day 3 of the diary, total
ICIQ-OAB score (p<0.01), and a non-significant directional change for the total ICIQOABqol score (P=0.065) was found using sign tests for the period of decaffeinated
compared to caffeinated drink intake. No significant differences were found for any
caffeine withdrawal measures. The small sample size was a threat to the validity and
reliability as the results could not be generalized. Another limitation was that there were
no power calculations undertaken in order to determine sample size. There was also no
trial to consider the value of episodic analysis of compliance over the entire treatment
period. Nevertheless, the pilot study demonstrated that reducing caffeine intake may
alleviate the severity of some symptoms and health-related quality of life factors
associated with OAB (Wells et al., 2014).
Jafarabadi et al. (2015), evaluated the response of women over 45 years with
OAB and detrusor overactivity to a 12-week course of oxybutynin or tolterodine
treatment. This randomized, double-blind, parallel group trial was designed to determine
the effectiveness of oxybutynin (5mg immediate release {IR} tablet three times a day)
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versus tolterodine (2 mg IR tablet every 12 hours) in a 12-week treatment of OAB in
women over 45 years. The study was performed in a women’s clinic in Tehran, Iran.
There were 410 patients screened and 301 randomized to oxybutynin group (n=151) and
tolterodine group (n=151). There was a mean improvement in terms of urgency (P=0.64)
and urge incontinence (P=0.75. The study showed that both medications significantly
decreased the incidence of frequency, urinary incontinence and urgency. According to the
3-day urinary diaries, after treatment with oxybutynin, the daytime frequency and the
nocturia episodes decreased 39.3% (P = <0.001) and 40.1% (P<0.001), respectively. In
the tolterodine group, the daytime frequency and the nocturia episodes decreased 36.5%
(P = 0.001) and 54.3% (P< 0.001), respectively. The evaluation of urinary urgency
showed a significant decrease in both groups. The urinary urgency and nocturnal urinary
urgency were decreased by 30.7% (P < 0.001) and 39.7% (P = 0.001), respectively, in the
oxybutynin group and 28.2% (P = 0.002) and 41.2% (P < 0.001), respectively, in the
tolterodine group. There was a statistically significant decrease in episodes of moderate
and severe incontinence with oxybutynin (40.6%; P < 0.001); there was also a significant
decrease in patients treated with tolterodine (39.1%; P = 0.009). A limitation of this study
was a small sample size, short follow-up duration and subjective nature of the follow-up.
This study found both drugs had similar efficacy on daytime symptoms of OAB and
similar side effects in perimenopausal patients (Jafarabadi et al., 2015). The study did,
however, find that tolterodine was preferred for chief complaint of nocturnal frequency
(Jafarabadi et al., 2015). This article was an evidence level I and of good quality.
A randomized, double-blind, placebo-controlled phase III study enrolled 1139
Japanese patients experiencing OAB symptoms for ≥ 24 weeks. The purpose of the study
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was to evaluate the efficacy and safety of the βз-adrenoceptor agonist mirabegron, in a
Japanese population with OAB. Men or women aged ≥ 20 years, with OAB symptoms
for ≥ 24 weeks, entered an initial 2-week, single-blind, placebo run-in period. Key OABrelated exclusion criteria included a diagnosis of genuine stress incontinence, an average
total daily urine volume > 3000 ml during the 3-day pre-treatment micturition diary
period, and a post-void residual urine volume of at least 100ml when measured before
treatment. Patients with ≥ 8 micturitions/24 hours or ≥1 urgency incontinence episode/24
hours were randomized to once daily placebo, mirabegron 50mg or tolterodine 4mg (as
an active comparator, without testing for non-inferiority of efficacy and safety) for 12
weeks. The primary endpoint was change in mean number of micturitions/24 hours from
baseline to final assessment. The demographic and baseline characteristics were similar
for the groups receiving placebo, mirabegron and tolterodine. Mirabegron was found to
be significantly superior to placebo in terms of mean (SD) change from baseline in
number of micturitions/24 hours (-1.85) [2.555] vs -1.37 [3.191]; P=0.025), incontinence
episodes/24 hours (-1.01 [1.338] vs -0.60 [1.745]; P=0.008), and volume voided/
micturition (24.300 [35.4767] vs 9.715 [29.0864] ml; P<0.001). The generalizability of
this study to other diverse populations may be a limitation. This study may have some
bias as it was sponsored by industry. The incidence of adverse events in mirabegron
group was similar to that of the placebo group. Most adverse events were mild and none
were severe. Mirabegron 50mg once daily was found to be an effective treatment for
OAB symptoms, with low occurrence of side effects (Yamaguchi et al., 2015). This
article was an evidence level I and of good quality.
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The SUNRISE study was a randomized, double-blind, 16-week, placebocontrolled, rising dose trial conducted to examine the effects of the antimuscarinic agent
solifenacin on urinary urgency. There were 863 patients in the study that was conducted
105 centers in 14 European countries and was conducted in accordance with the
principles of Declaration of Helsinki (1996 version) and the International Conference on
Harmonization Guidelines for Good Clinical Practice (Cardozo et al., 2008). The primary
efficacy variable was the change from baseline to endpoint in the number of episodes of
severe urgency with or without urgency incontinence per 24 hours, as measured using the
Patient Perception of Intensity of Urgency Scale, grade 3+4. The secondary efficacy
variables included patient-reported outcomes for bladder condition, urgency bother and
treatment satisfaction. A 3-day voiding diary was used to record micturition frequency
and episodes of urgency and incontinence. A 7-day diary was used to assess speed of
onset of effect. Solifenacin 5/10mg was significantly more effective than placebo in
reducing the mean number of episodes of severe urgency with or without incontinence
per 24 hours from baseline to endpoint (-2.6 vs 1.8, P<0.001). There were statistically
significant differences in favor of solifenacin 5/10mg over placebo for all secondary
variables measured at endpoint, including patient-reported outcomes. There was a
significant improvement in urgency as early as day 3 of treatment. Treatment-emergent
adverse events with solifenacin 5/10 mg were mainly mild or moderate in severity, and
only led to discontinuation in 3.6% of patients. The study was found to have potential
bias as it was supported by industry. The study found that Solifenacin 5/10 mg
significantly reduced the number of urgency episodes and the extent of urgency bother
(Cardozo et al., 2008). Solifenacin was well tolerated and was found to be effective as
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early as day 3 of treatment (Cardozo et al., 2008). This article was an evidence level I and
of good quality.
2.4 LEVEL TWO
Juliato et al. (2016), performed a descriptive, exploratory, cross-sectional study to
assess OAB symptoms on quality of life in Brazilian women. The dependent variable was
OAB and the independent variables were socio-demographic data, health related habits
and problems with self-perception of health, and gynecological background. It was a
simple random sample of 749 participants ages 45 to 60 years and who resided in the
metropolitan region of Campinas. The mean age was 52.5 and with regard to
menopausal, 16% were premenopausal, 16% perimenopausal, and 68% postmenopausal.
The prevalence of OAB was 7.8% with the vast majority of women having only urinary
urgency. Only two women who responded to the interview reported urge incontinence. In
the final statistical model, vaginal dryness (Poisson Regression 2.21; 95% CI 1.11-4.40;
p=0.025) were associated with greater prevalence of OAB. However, the reliability of
some variables such as genital prolapse, the presence of bacteriuria and complains of
LUTS may have been a threat to the study. Moreover, some women may have
minimized urinary symptoms with in-person interview. As such, the results may have
been incongruent as they were based on self-reporting. The study showed that health
professionals should adopt proactive behavior in surgically menopausal women and those
with a history of genital atrophy to identify and treat OAB, thus contributing to an
improved quality of life and healthier aging. The study had evidence level II and good
quality.
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Qian-Sheng & Hann-Chorng (2010), conducted a prospective study on Chinese
patients that showed a strong correlation between the Overactive Bladder Symptom Score
(OABSS) and Urinary Severity Score (USS) questionnaires based on a voiding diary
noted in patients with OAB. The changes in these two measures were similar after
solifenacin 5mg daily for one month was given to participants. The OABSS questionnaire
was linguistically validated. There were 170 patients recruited, 98 men and 72 women. A
high OABSS total score was significantly associated with a high grade of USS. There
was a significant correlation between the two scores (R²=0.5520, p<0.0001). The main
contributions of the OABSS in patients with low USS were daytime frequency and
nighttime frequency. The contribution of urgency and urgency urinary incontinence
became significant in patients with high urgency grades. The changes in the USS and
OABSS were significant at 1 month. The change in frequency was significant in the
daytime as well as at nighttime. A limitation of the study was that the OABSS and the
Urogenital Distress Inventory short form, measures the frequency and urgency episodes
during a given period, but the severity of urgency is not assessed as a quantitative
measure of reflecting real life conditions. The findings from these articles were evidence
level II and good quality.
Hung et al. (2011), performed a randomized clinical trial on 60 patients with
OAB who visited different hospitals in Taiwan. These patients were tested using the
Chinese OABSS. Patients were randomized either incontinent (OAB wet, n=31) or
continent (OAB dry, n=29). The test-retest reliability of the Chinese OABSS was
moderate to good, with weighted kappa coefficients of 0.515-0.721 for each symptom
score and 0.610 for the total symptom score. Each symptom score correlated positively
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with the total OABSS (Spearman’s rho 0.365-0.793) and was internally consistent
(Cronbach’s alpha 0.674). The distribution of the OABSS showed clear separation
between OAB wet (average 11.4, range 7-15) and OAB dry (average 7.97, range 4-10)
subgroups (Wilcoxon exact test, p<0.05). In addition, the OABSS items correlated
positively with the corresponding bladder diary variables (Spearman’s rho 0.504-0.879)
and the degrees of agreement improved with study visits except for nighttime frequency.
The Chinese OABSS tended to underestimate the frequency of nighttime voiding. The
Chinese OABSS was developed and validated as a reliable instrument for assessing OAB
symptoms. OABSS can be an alternative to, but not a replacement for, 3-day bladder
diary for assessing patients. This was an evidence level II and of high quality.
Cardozo et al. (2014), had 100 women complete the Actionable Bladder Symptom
Screening Tool (ABSST). The ABSST was initially developed to identify patients with
multiple sclerosis (MS) who could benefit from lower urinary tract assessment and
treatment. This was a prospective, observational study performed in 6 gynecological
clinics located in the USA. The women completed the ABSST, OAB Questionnaire Short
Form (OAB-q SF), and the patient global impression of severity (PGI-S) scale. Half of
the sample had urinary urgency incontinence (UUI), while the other half did not.
Descriptive statistics, reliability, and validity were examined, as was sensitivity and
specificity of the previous cut-off score established in patients with multiple sclerosis.
Fifty-three women with UUI/OAB and 47 controls took part (71% Caucasian). Patients
with UUI/OAB were older (54.6 vs 40.4years), had a higher body mass index (31.1 vs
26.4 kg/m²), and more comorbid conditions. The Cronbach’s alpha reliability of ABSST
was 0.90. High correlations with OAB-q SF Symptom Bother and Health Related Quality
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of Life (r=0.83 and -0.81 respectively) supported concurrent validity. Using the PGI-S
severity scores as a reference, the ABSST was able to distinguish patients with differing
severity levels (known-group validity). The study found that a score of 3 on ABSST may
highlight the presence of bladder symptoms consistent with OAB and facilitate critical
communication between the patient and their healthcare provider and further evaluation
when warranted. The tool was validated in non-neurogenic females and found to be a
reliable, valid and sensitive tool for screening women with urinary urge incontinence and
OAB (Cardozo et al., 2014). The results from this study demonstrated that a cut-off
ABSST score of 3 distinguished between patients who should be treated for urge urinary
incontinence or OAB vs those who did not require treatment. This article was evidence
level II and of good quality.
A mixed-method qualitative/quantitative needs assessment of patients with
overactive bladder and/or urinary symptoms was conducted by Filipetto et al. (2014).
Primary care providers may lack training in OAB or lack clinical awareness of effective
evaluation and management strategies. Inadequate communication between patients and
providers has limited successful diagnosis, treatment, and management of OAB. Another
barrier to effective management of OAB is poor patient adherence or persistence to
treatment. The causes of non-adherence are multifactorial and may include unclear or
unrealistic treatment goals, side effects or inconvenience of therapy, cost, or simply
forgetting to follow the treatment regimen. A sample of 194 interviewees were
prescreened for a history of OAB and/or urinary incontinence. The data analyses for
survey responses was conducted using SPSS. Descriptive statistics such as mean and
frequencies were provided. Differences in knowledge scores for respondent gender,
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respondents age (41-60 and ≥ 61 years), provider gender, and provider specialty were
determined using analysis of covariance (ANCOVA) to control for the lag time between
the respondents first noticed symptoms and when he/she talked with a provider about
their symptoms. Analysis of variance (ANOVA) was used to determine the difference in
knowledge score with frequency of communication between the patient and provider and
type of educational material utilized. On average, respondents had experienced urinary
and bladder symptoms for 9 years (SD=9.3) while only being under a provider’s care for
these symptoms for 5.8 (SD=6.0) years, resulting in an average time gap of 3.5 years
between symptom onset and treatment initiation. The survey results showed that only
14% of survey participants reported that ‘my provider asked me about urinary or bladder
symptoms’. Interviewees reported that they felt providers were quick to prescribe
medication even when the patient did not necessarily think it was needed. Only 29% and
31% of surveyed participants reported being provided bladder training and pelvic floor
exercises, respectively. Interviewees reported overall dissatisfaction with clinicians’
frequency and quality of communication regarding OAB. Forty-one percent said they
discussed urinary or bladder symptoms ‘occasionally’, while 32% reported discussions
‘nearly every visit’. These findings were similar to interview responses where follow-up
conversations initiated by either patient or provider after initial diagnosis and treatment
rarely occurred. Patients preferred regular discussions on OAB with their provider, with
75% of those surveyed rating this issue as ‘very important’. Limitations to this study was
the survey was not pilot tested and was not validated. The responses were developed
using responses from the qualitative interviews. Participants were also recruited using a
company that compiles panels of participants. This study may have limited
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generalizability due to selection bias of participants. This study was an evidence level II
and of good quality.
2.5 LEVEL THREE
The study by Basra et al. (2012), compared the value of two validated
questionnaires: Bladder Control Self-Assessment Questionnaire (B-SAQ) and the
Overactive Bladder Awareness Tool (OAB-V8). This was a comparison study whose aim
was to compare the value of two validated questionnaires: Bladder Control SelfAssessment Questionnaire (B-SAQ) and the Overactive Bladder Awareness Tool (OABV8). Two hundred and twenty-three women were recruited on the basis of their
presenting symptoms. The mean age of the women was 49 years (range 19-84). Only
fully completed questionnaires were used for statistical analysis and 219 responses were
used for data analysis. The receiver operating curve (ROC) identifying stress
incontinence was 0.85 and 0.68 for the B-SAQ and OAB-V8, respectively, which shows
that the B-SAQ is a good test and the AOB-V8 is poor test for stress incontinence.
Cohen’s Kappa calculations in patients with a clinical diagnosis of OAB showed values
of 0.2 for both B-SAQ and OAB-V8 questionnaires (P=.01); indicating fair agreement
between both questionnaires and the clinical diagnosis. The B-SAQ lower urinary tract
screening questionnaire was found to be a better test for stress and mixed urinary
incontinence identification than OAB-V8. The study was found to have some selection
bias as all patients were from general gynecology and urology clinics and not primary
care settings. Limitation of the study were only English-speaking patients were included;
and OAB-V8 was found to be a poor test for stress incontinence and a fair test for mixed
incontinence; and OAB-V8 was too specific and may lead to exclusion of a large affected
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population. The study had an evidence level III and good quality. Both questionnaires
were found to perform well in identifying and screening for OAB symptoms in clinical
setting.
A Belgian study done by de Ridder et al. (2013), used the validated Bladder
Control Self-Assessment Questionnaire (B-SAQ) and complemented with a question on
stress urinary incontinence (SUI) and bladder bother to assess the prevalence of OAB.
This epidemiological study had general practitioners collect data on OAB and SUI
prospectively on women 40 years and older during a regular visit for any reason. The
presence of mild bladder control symptoms (BCS) was defined as an overall B-SAQ
symptom score (OSS) ≥ 4 and an overall bother score (OBS) ≥ 1. The data was collected
on 7193 women, with a mean (SD) age of 61.0 (12.6) years. About 33.9% had mild BCS.
Most women reported overall mild OAB symptoms (46.9) and 34.9% had moderate-tovery severe symptoms. The prevalence of moderate-severe urgency, frequency or
nocturia was higher than that of moderate-severe incontinence. Urgency and nocturia
were considered the most bothersome symptoms. Moderate-severe stress urinary
incontinence affected 17.7% of women. About 16.4% of women reported to be
moderately-severely bothered by their bladder in everyday life. The risk of severe
symptoms and bother increased with age. About 10% of women had clinically significant
BCS (OSS ≥ 7 and OBS ≥ 4). A limitation of the study was some women may have felt
hindered or embarrassed to indicate their problems in the presence of the provider,
causing underreporting. The B-SAQ is not a diagnostic questionnaire and does not assess
whether the symptoms experienced are actually caused by OAB or whether other pelvic
disorders are present. The study found that a significant proportion of women aged 40
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years and older do not only have OAB symptoms, but also consider these bothersome in
daily life. This article was evidence level III with good quality.
Fujimura et al. (2011), had 318 Japanese female patients, ages ranging from 15-91
years complete three questionnaires: Core lower urinary tract symptoms (CLSS);
International Prostate Symptom Score (IPSS); and OABSS. The quality of life (QOL)
was determined as per IPSS quality of life index. The clinical diagnoses were OAB,
mixed incontinence, pelvic organ prolapse, interstitial cystitis, bacterial cystitis,
underactive bladder and other. All symptoms scores were significantly increased in
symptomatic women. The CLSS described the symptom profile of patients with distinct
conditions. The scores of corresponding symptoms on the three questionnaires were
significantly correlated (r=0.51-0.85; all p < 0.0001). Multivariate logistic regression
modeling proved five CLSS symptoms (daytime frequency, nocturia, urgency
incontinence, straining, and urethral pain) as independent predictors of poor QOL, with
hazard ratios ranging from 2.0 to 4.2. The IPSS included only two (urgency and
straining) significant symptoms. The IPSS was designed for men with BPH and may have
limited ability to illustrate female LUTS, such as incontinence symptoms. The IPSS alone
was found not to fully evaluate female LUTS, with a possible negative impact on quality
of life. Using the CLSS questionnaire was found to enable simple and comprehensive
assessment of female LUTS. This comparative study was found to have evidence level III
with good quality.
Jongen et al. (2015), had 141 multiple sclerosis (MS) patients (ages ranging from
24 to 73 years), complete the ABSST. This observational non-interventional web based
study, assessed retest reliability and concurrent validity of a Dutch version of the English
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ABSST. The test compared the test performance of the simplified scoring with a cut-off
point 3, with that of a cut-off point 2, using cut-off point 6 as the gold standard. A total
score of ≥ 3 showed sensitivity of 0.79 and a specificity of 0.98 with respect to the
clinician-based assessment of whether or not treatment was needed. Their findings
suggest that in MS patients the simplified ABSST scoring is more accurate with cut-off
point 2 than with cut-off point 3, especially by substantially reducing false negative
outcomes; and that in MS the original ABSST scoring seemed preferable (Jongen et al.,
2015).However, in a study on women with incontinence due to OAB, it was
demonstrated that the use of the ABSST with a cut-off score 3 strongly distinguishes
between patients who should be treated versus those who do not require treatment. This
article was evidence level III and of high quality. However, in a study in women with
incontinence due to OAB, it was demonstrated that the use of the ABSST with cut-off
score 3 strongly distinguishes between patients who should be treated versus those who
do not require treatment (Cardozo et al., 2014).
Lekskulchal et al. (2008), retrospectively reviewed records of a largely Caucasian
female population, who had undergone an interview, clinical examination, multichannel
urodynamic studies and translabial ultrasound examination. The detrusor wall thickness
measurements were taken at the bladder dome, after bladder emptying. The receiveroperator characteristics(ROC) analysis was used to identify the optimal cut-off of
detrusor wall thickness in predicting detrusor overactivity. The researchers reviewed 686
records of women who had attended a tertiary urodynamic center. They found that the
average detrusor wall thickness in the detrusor overactivity group was 4.7+/- 1.9 mm
(mean +/- SD), compared with 4.1 +/- 1.6 mm in the non-detrusor overactivity group (p<
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0.001). Using a cut-off of detrusor wall thickness of 5.0 mm gave a sensitivity of 37%
and a specificity of 79% for diagnosing detrusor overactivity. The ROC analysis revealed
an area under the curve (AUC) of 0.606 (95% CI 0.56-0.65). This diagnostic method did
not yield high specificity or sensitivity. The researchers did not use a transvaginal
ultrasound and only measured the dome. Lekskulchal et al. (2008), found that
measurement of detrusor wall thickness should not be used as a diagnostic parameter for
detrusor over-activity in women.
Palma et al. (2013), performed an epidemiological study to verify the presence of
OAB symptoms in premenopausal women and related them with child-bearing data.
There were 1052 women of child-bearing age (20-45 years) in Brazil, who were asked to
complete the International Consultation on Incontinence Questionnaire- Overactive
Bladder (ICIQ-OAB) questionnaire. A validated ICIQ-OAB Portuguese version, with
specific questionnaire for the specific demographics was utilized. Multiparous and
primiparous women showed significantly higher scores in the ICIQ-OAB questionnaire
than nulliparous women. Multiparous women presented more frequency than nulliparous
women (P < 0.0001). No significant difference was found in urgency (P = 0.0682), and
multiparous women presented more urgency incontinence than nulliparous ones (P=
0.0313). The study was performed in mostly public places and as such made it impossible
to perform physical assessments in participants. Their study found that nulliparous
women presented with less OAB symptoms than primiparous women; while multiparous
women symptoms were more than the other two groups (Palma et al.,2013). There were
no significant differences (P = 0.0743), between the mode of delivery (cesarean or
vaginal) (Palma et al., 2013). This was an evidence level III and of good quality.
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A retrospective study was done to evaluate the relationship between urodynamic
detrusor overactivity (DO) and OAB symptoms in men and women by Al-Ghazo et al.,
2011. Two hundred and nine patients’ records (117 men and 92 women) in a tertiary
referral center in Jordan were reviewed for urodynamic evaluation of OAB syndrome
symptoms with the presence or absence of DO. Incidence of DO was 76.1% and 58.7% in
male and female OAB patients, respectively. Of men 63% and 61% of women with
urgency (OAB dry) had DO, while 93% of men and 69.8% of women with urgency and
urgency urinary incontinence (OAB wet) had DO. Of men, 58% who were OAB wet had
stress urinary incontinence symptom with 26.4% having urodynamic stress incontinence.
While 6% of men and 6.5% of women with OAB symptoms had urodynamic diagnosis of
voiding difficulties with post-void residual greater than 100ml. Combination of
symptoms is more accurate in predicting DO in OAB patients. The multivariate disease
model for males included urge urinary incontinence (UUI) and urgency while for females
it included UUI and nocturia. The results were statistically evaluated using MannWhitney and Fisher’s exact probability tests for comparison of the findings between DO
and no DO patients, and for comparison between symptoms and urodynamic findings.
The results showed that there was a better correlation between OAB symptoms and the
urodynamic diagnosis of detrusor overactivity in men than in women, more so in OAB
wet than in OAB dry (Al-Ghazo et al., 2011). Limitations to the study compared
subjective symptoms with objective parameters; follow-up data was lacking in some
patients; and there was not adequate information regarding whether or not urodynamic
findings altered management for these patients. This was an evidence level III and of
good quality.
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Reynolds et al. (2015), performed a systematic review and meta-analysis of the
original research on community dwelling women with non-neurogenic OAB undergoing
pharmacotherapy with medication available in the USA. They reviewed randomized
controlled trial for meta-analysis and cohort, case-control, and case series for harms data.
Five data sources were reviewed, and they included MEDLINE, EMBASE, Cumulative
Index of Nursing and Allied Health Literature, and ClinicalTrials.gov. The objective of
the review was to summarize evidence about reduction in voiding and resolution of urine
loss in OAB comparing data from the active drug arms with the placebo arms of
randomized trials (Reynolds et al., 2015). Multiple team members performed data
extraction independently with secondary review of data entry to ensure quality and
validity. This article was an evidence level III and of good quality. No individual
medication demonstrated superiority over another and anticholinergic management for
OAB showed modest and rarely full resolution of symptoms (Reynolds et al., 2015).
A cross-sectional, descriptive, correlational design was used to study to examine
the level of knowledge and the attitudes and perceptions of APRNs regarding urinary
incontinence in older adult women by Keilman & Dunn, (2010). Eligible participants had
completed a master’s degree in nursing from an accredited university, had achieved
national certification as a nurse practitioner, clinical nurse specialist, or midwife, and
worked with older adult women. The study sample was 54 or 75% response rate, with
initially 72 APRNs initially agreeing to participate. Approximately 57% (n=31) of the
APRNs reported they diagnose UI in their clinical practice. Of the APRNs who diagnose
UI, 60% also treat, manage, educate, and counsel patients regarding with condition.
Approximately 54% (n=29) of the APRNs answered they were taught about UI in their
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graduate program. Only 48% felt their education on the topic was adequate. This group of
APRNs reported learning more about UI through attending conferences where UI was
offered as a topic (n=30, 72.2%), consulting a UI specialist (n=21, 38.9%), or acquiring
specific information through professional journals (n=48, 88.9%). UI guidelines were
used regularly in practice by only 24.1% (n=13) of the APRNs. Most of the participants
understood that UI is not a normal part of the aging process (M=1.87, SD=1.03). All
participants (N=54) strongly agreed that UI was an important health concern that should
be handled by APRNs. Thirty-eight of the APRNs (70.3%) reported they always asked
about UI when performing a health assessment. However, the participants did not
necessarily feel confident in their assessment/diagnostic skills related to UI (M=3.50,
SD=0.95) and in managing and/or treating UI independently (M=3.06, SD=1.05). The
respondents also knew education was a crucial component in the management of UI
(M=4.61, SD=0.50). Most of the APRNs (M=4.02, SD=0.63) recognized that prompted
voided improves symptoms of urge and mixed UI and can be recommended as a
noninvasive treatment. Respondents were not sure of the pharmacologic effects on
symptoms of detrusor overactivity in women (M=3.41, SD=0.81) and were not aware of
the pharmaceutical classifications of drugs that could potentially cause UI (M=2.94,
SD=1.05). Participants also reported not feeling comfortable assessing older women’s
motivation for learning (M=3.87, SD=0.78). Providing anticipatory guidance and/or
counseling for women with UI was not strong with this group of APRNs (M=3.28,
SD=1.10). An education index (EI) was computed that reflected the type of education of
the APRNs reported receiving on UI. A statistically positive correlation was found
between EI and age (r=0.47). APRNs that were older reported higher levels of education
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regarding women with UI than younger APRNs. In addition, a statistically significant
correlation was found between the total scale score and EI (r=0.40), the knowledge
subscale score and EI (r=0.27), and the Attitudes/Perceptions subscale score and EI
(r=0.51). APRNs who reported a higher level of education regarding UI had more
accurate perceptions, more positive attitudes, and more knowledge regarding older adult
women with UI than those who reported lesser level of education. The reliability of the
KAPUIOW scale was estimated by Cronbach’s alpha. Total scale estimate was α= 0.86,
with α=0.81 for the Attitudes/Perception subscale, and α=0.77 for the knowledge
subscale. Limitations to this study was it was self-reported data, lengthy questionnaire
that took approximately 1-2 hours to complete and the small sample size that was not
randomly sampled. According to Keilman & Dunn (2010), the single most important
action that APRNs can take is to ask every older adult about UI and then follow with the
basic approaches to evaluation and management of UI.
Nguyen et al. (2016), investigated family physicians’ knowledge of, attitudes
towards, and understanding of UI, as well as their perceptions of barriers to continence
care, as a foundation for designing interventions to improve service provision for those in
northern Alberta who suffer from UI. A descriptive survey using a standardized
instrument was used. The survey instrument was complete either by telephone interview
or a paper copy faxed back to the researcher. Hundred and fifty-eight participants in
Alberta, Canada, were randomly selected from the publicly available directory published
by the College of Physicians and Surgeons of Alberta using a computer-generated
random-number list. UI was thought to affect quality of life to some extent or a great
extent by 85.5% of physicians, ranking behind depression, arthritis, and chronic pain.

41

Among the 158 participants, 53.8% (85 of 158) indicated that they proactively discussed
incontinence with most or all of the patients they suspected had incontinence problems;
29.7% (47of 158) indicated that they proactively discussed incontinence with some of
their patients, and 15.2% (24 of 158) indicated that did not discuss incontinence with
anyone unless the patients raised the issue themselves. After initial management, such as
providing lifestyle advice, prescribing medication, recommending incontinence products,
or providing referral to specialist, 78.5% (124 of 158) of physicians sometimes, if not
always, arranged follow-up appointments specifically to deal with the incontinence;
21.5% (34 of 158) rarely if ever arranged follow-up. Reasons for lack of confidence in
management included concerns about the level of training, drug side effects, a lack of
support services in the area, and the general embarrassment around UI. In total, 70.9%
(112 of 158) of family physicians reported that improving the treatment and management
of patients with incontinence was a fairly high if not a high priority to them personally,
with 25.9% (41 of 158) reporting it to be either a fairly low or a low priority. Limitations
to the study was the response rate of the physicians was low and the researchers finding
may not be generalizable. This article was an evidence level III and of good quality.
Another study by Duralde et al. (2016), sought to conduct an observational cohort
study to identify clinical and sociodemographic determinants of patient-provider
discussion and treatment of incontinence among ethnically diverse, community-dwelling
women. The women were aged 40-80 years enrolled in Kaiser Permanente Northern
California. Clinical severity, type, treatment, and discussion of incontinence were
assessed by structured questionnaires. Mean age of the participants was 59.9 years and
55% were racial/ethnic minorities (171 black, 233 Latina, 133 Asian or Native
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American). Fifty-five percent reported discussing their incontinence with a health care
provider, 36% within 1 year of symptom onset, and with only 3% indicating that their
provider initiated the discussion. More than half (52%) reported being at least
moderately bothered by their incontinence. Of these women, 324 (65%) discussed their
incontinence with a clinician, with 200 (40%) doing so within 1 year of symptom onset.
In a multivariate analysis, women were less likely to have discussed their incontinence if
they had a household income <$30,000 vs ≥ 120,000/year (adjusted odds ratio [AOR],
0.49, 95% confidence interval (CI), 0.28-0.86) or were diabetic (AOR, 0.71, 95% CI,
0.51-0.99). They were more likely to have discussed incontinence if they had clinically
severe incontinence (AOR, 3.09, 95% CI, 1.89-5.07), depression (AOR, 1.71, 95% CI,
1.20-2.44), pelvic organ prolapse (AOR, 1.98, 95% CI,1.13-3.46), or arthritis (AOR,
1.44, 95% CI, 1.06-1.95). Among the subset of women reporting at least moderate
subjective bother from incontinence, black race (AOR, 0.45 95% CI, 0.25-0.82, vs white
race) and income < $30000/ year (AOR, 0.37, 95% CI 0.17-0.81, vs ≥ $120000/year)
were associated with a reduced likelihood of discussing incontinence. Those with
clinically severe incontinence (AOR, 2.93, 95% CI, 1.53-5.61, vs low to moderate
incontinence by the Sandvik scale) were more likely to discuss it with a clinician. A
limitation of the study was that it relied on participant report for incontinence status. The
study did not include women who had previously suffered from incontinence, underwent
evaluation, and were successfully treated or those with less frequent incontinence. The
study findings suggest that even among women with frequent incontinence and
streamline and affordable access to primary care and specialist services, the rates of
patient-provider discussion of incontinence remain low, and rates of provider initiated
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screening for incontinence are even lower. This was an evidence level III and of good
quality.
Teunissen et al. (2015), conducted an observational study to determine the
effectiveness of introducing a nurse practitioner in UI care and to explore women’s
reasons for not completing treatment. Sixteen nurse practitioners working with a GP’s
office in the Netherlands, undertook a training program in which they learned how to
manage female patients with UI. All patients were examined and referred by the General
Practitioner (GP) to the NP working in the same practice. At baseline the severity of the
UI (Sandvik-score), the impact of the quality of life (IIQ) and the impressed severity
(PGIS) was measured and repeated after three months. Differences were tested by the
paired t and the NcNemar test. Reasons for not completing treatment were documented
by the nurse practitioner and differences between the group that completed treatment and
the drop-out group were tested. Hundred and three women were included, mean age 55
years (SD 12.6). The Sandvik severity categories improved signinficantly (P<0.001), as
did the impact on daily life (2.54 points, P=0.012). Among the IIQ score the impact on
daily activities increased 0.73 points (P=0.032), on social functioning 0.60 points
(P=0.030) and on emotional well-being 0.63 points (P=0.031). The PGIS -score improved
in 41.3% of the patients. The most important reasons for not completing the treatment
were lack of improvement of the UI and difficulties in performing the exercises. Women
who withdrew from guidance by the nurse practitioner perceived more impact on daily
life (P=0.036), in particular on the scores for social functioning (P=0.015) and emotional
well-being (P=0.015). Limitations to the study were dropout rate in this study was 32%
which is considered high; no control group was involved as a RCT which received care
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by the GP and the training program for patients with UI is time consuming, and not
always easy to sustain and difficult to implement in daily life. Treatment by a trained NP
seems to have a small positive affect the severity of the UI and the impact on the quality
of life. NPs involved in the care of patients generally leads to an improvement of health
outcomes and patient satisfaction. Women who did not complete treatment suffer from
more impact on quality of life, experience not enough improvement and mention
difficulties in performing exercises. This was an evidence level III and of good quality.
2.6 LEVEL FOUR
Barkin (2016), discusses the pervasiveness of nocturia in men and women who
present with LUTS. Barkin (2016) article is an evidence level IV and of good quality. Dr.
Barkin gives his expert opinion in this article, exploring the different causes and types of
nocturia, then describes how to diagnose different types of nocturia (including use of
frequency-volume charts), and discusses different approaches to managing nocturia
(including the use of desmopressin), depending on the type and cause. The article
discusses the importance of taking a patient’s history to determine the onset and severity
of nocturia, and also find out if nocturia is consistent or intermittent. Clinicians should
rule out the other medical and non-medical causes of LUTS. All appropriate tests –
urinalysis, urine culture and sensitivity test, urine cytology test (if indicated), serum
creatinine test to rule out renal failure (if indicated), abdominal/or pelvic ultrasound (if
indicated), and frequency-volume charts. Barkin (2016), finds that nocturia is pervasive
in both genders who present with LUTS. Once it is determined that a patient has
nocturnal polyuria based on the frequency-volume chart, clinicians can then safely offer a
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new, low-dose, effective synthetic oral disintegrating tablet of desmopressin (Nocdurna),
which has few side effects (Barkin, 2016).
An article by Carcio (2014), takes a nurse practitioner perspective on OAB. This
article is a level IV and of good quality. OAB is not life threatening, but it is lifestyle
threatening. Carcio (2014), discusses the importance APRNs identifying patients using
assessment of health history, a focused examination, and office based tests. Fifty percent
of women with bladder problems do not mention them at patient visits. The article
discusses a survey done by the National Association of Nurse Practitioners in Women’s
Health that surveyed 300 APRNs, and found that although most respondents could
identify common symptoms of OAB and its’ adverse effect on quality of life, more than
half reported that they lacked confidence in their ability to accurately identify OAB and
more than half reported lacking sufficient knowledge to effectively treat OAB. APRNs
are ideally suited to educate patients about OAB, as well as diagnose and treat OAB. If
the patients are more knowledgeable about OAB, they would recognize it when it arises
and understand that treatment is available. With continued emphasis on OAB in academic
programs and national conferences, APRNs can educate themselves to face this challenge
Eapen & Radomski (2015), discuss four studies, the EPIC study, the National
Overactive Bladder Evaluation(NOBLE) study, the Epidemiology of Lower Urinary
Tract Symptoms (EpiLUTS) study, and the MILSOM study, that assess the impact of
OAB symptoms, their findings and prevalence and impact on quality of life. According to
the EPIC study which was conducted in five countries, showed the prevalence of OAB
and its symptoms increases with increasing age in both genders. Looking specifically at
urinary incontinence (UI), women had a much higher rate of any UI (urge, mixed, stress
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and other) than men (13.1% versus 5.4%). The NOBLE study showed an overall OAB
prevalence of approximately 16% with no significant differences between the two sexes
(16% in men, 16.9% in women). The study also found an association between OAB with
UI and body mass index (BMI)in women but not men. Women with BMI > 30 were 2.2
times more likely to have OAB with UI than women with BMI <24. The EpiLUTS study
conducted in the United States, United Kingdom and Sweden, showed the prevalence of
OAB symptoms “sometimes” and “often” were 27.2% and 15.8% respectively, whereas
in women, the prevalence of OAB symptoms “sometimes” and “often” was 43.1% and
32.6%, respectively. Women had an overall higher prevalence of symptoms such as
urgency, UI or both. The MILSOM study conducted in France, Germany, Italy, Spain,
Sweden and United Kingdom, found an overall prevalence of OAB symptoms of 16.6%.
In the MILSOM study, the overall prevalence of frequency and urgency were comparable
irrespective of gender. These studies also found that older patients (over age 65) were
more likely to consult a clinician than younger patients with OAB. Treatment for OAB
should take on a multidisplinary approach with the implementation of lifestyle
modifications, behavioral therapies and pharmacotherapy for the most optimal outcome
(Eapen & Radomski, 2015). This article was an evidence level IV and of high quality.
A study by Alber-Heitner et al.(2010), explored the experiences and attitudes of
nurse specialists in primary care regarding their role in care for patients with urinary
incontinence (UI), thereby identifying facilitators and barriers for wider implementation.
This study was a level IV and of good quality. A focus group was conducted with six
female nurse practitioner specialists who were trained in caring for patients with UI. The
study was carried out from May 2005 until March 2008 in four Dutch regions. These
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nurse specialists followed patients in a RCT (n=384) for 12 months. At the end of the
intervention period, nurse specialist experiences and attitudes were explored in one focus
group study. Prior to the focus group study, a short questionnaire was sent to the
participants to collect demographic data, education and nursing experience. To increase
dependability and confirmability, the interview was transcribed verbatim. To improve
consistency and reliability of the analyses, the external moderator and the researcher
analyzed the transcript independently of each other. The findings showed that most nurse
specialists main reason to participate was to enhance their professional role, provide more
than patient care, develop a new specialty and look for new challenges. Nurse specialists
felt that most patients with UI were satisfied and happy with their care and therefore
seemed to accept this care by nurse specialists. The trained nurse specialist appeared to
feel competent and satisfied to support physicians in care for patients with UI. There
were some limitations to this study. The researchers chose only one a qualitative focus
group discussion with only six nurse specialist. Because the nurse specialists knew the
researchers had an interest in the intervention they may have made socially desirable
comments, and as such creating a bias. The limited number of nurse specialists may limit
the generalizability of the results to similar situations in the primary care setting in a new
context.
2.7 LEVEL FIVE
A descriptive cross-sectional study was performed by Levokowicz et al. (2011),
1111 American women internet users (ages 40-65), were surveyed online. A sample of
611 women in same age bracket with symptoms of OAB was surveyed regarding their
experiences and attitudes about treatment. Women with nocturia in the study tended to
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prolong seeking treatment. They found women with OAB, including nocturia, were more
likely than women with OAB, excluding nocturia, to alter their behavior in social
situations, refrain from physical activity and intimacy, and cancel social plans because of
their condition. The results of this study showed that women with OAB almost always
got up to urinate at night, but 1 in 5 (n=121 of 611 [20%]) respondents typically
experienced severe nocturia, necessitating four or more trips to the bathroom during the
night. Most women surveyed (n=586 of 611 [96%]) got up at least one time during the
night to urinate. Despite their more severe symptoms, respondents with OAB including
nocturia, surprisingly were no more likely to consider themselves proactive about seeking
treatment for their symptoms than women without nocturia. In fact, nearly 2 in 5 (n=172
of 478 [36%] of women with nocturia surveyed had never sought treatment for symptoms
of OAB, whereas 29% (n=39 of 133) of those with OAB but without nocturia reported
they had not sought treatment. Interestingly, those who had nocturia, 76% (n=365 of 478)
reported that they waited longer than they should to consult a provider versus 65% (n=86
of 133) of women without nocturia. Roughly one-third of women with OAB in the
sample survey experienced nocturia regardless of whether or not they were in treatment;
149 of 478 (31%) were in treatment, 157 of 478 (33%) had stopped treatment, and 172 of
478 (36%) had never treated their OAB. Moreover, 63% (n=316 of 500) of nationally
representative American women reported that not getting enough sleep throws off their
sense of “normalcy.” In addition, 60% (n=300 of 500) of women reported that when one
aspect of life is thrown off, it disrupts other areas of life. The results of this study suggest
how nocturia, in particular, impacts quality of life considerations, and thus, could
represent a factor disrupting a person’s sense of normalcy. A limitation of this study, is
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participants had to have access and knowledge of a computer to answer the survey
questions. The generalizability of this survey may be questioned as it may not be
representative of the general US population in the target age group and across all desired
demographics (Levokowicz et al., 2011). They found more public health education was
needed to improve consumer knowledge about OAB including nocturia and
understanding of all treatment options for its symptoms. The article evidence level was V
and good quality.
2.8 SYNTHESIS OF THE LITERATURE
A review of the literature was conducted and evidence table developed to enable
an understanding of the studies and to determine their evidence level and quality per the
John Hopkins evidence guidelines (Dearholt & Dang, 2012). After reviewing several
articles, a hierarchy of baseline characteristics and outcome measures were developed:
nocturia, frequency, urgency, detrusor muscle overactivity, urge incontinence, bladder
control, quality of life, urodynamic measures and assessment tools. All articles were
reviewed for validity and reliability. The evidence table is presented in its’ entirety in
Appendix B.
The evidence table was created to support a systematic tabulation and assessment
of study characteristics including, (1) a brief reference, type of study and quality rating,
(2) methods, (3) threats to validity/reliability, (4) sample, sample size and setting, (5)
study findings that help answer the evidence based practice question, (6) limitations, and
(7) conclusions. This allowed for identification of common threads in reporting across the
articles. The experience of having OAB is a constellation of self-reported events,
symptoms, and the impact they have on an individual’s life (Hartmann et al., 2009).
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Thus, measures of quality of life, interference with daily activities, degree of distress
from symptoms, and satisfaction with the outcomes of treatment are also common and
helpful metrics in this literature (Hartmann et al., 2009).
2.9 SUMMARY
Despite the evidence showing the impact of OAB on quality of life, many women
delay seeking treatment for their symptoms (Eapen & Radomski, 2015; Levokowicz et
al., 2011). Four studies, the EPIC study (Coyne et al., 2008), the National Overactive
Bladder Evaluation(NOBLE) study, the Epidemiology of Lower Urinary Tract Symptoms
(EpiLUTS) study, and the MILSOM study, assessed the impact of OAB symptoms on
quality of life (Eapen & Radomski, 2016). The EPIC study showed a prevalence of LUTS
suggestive of OAB 10.8% in men and 12.8% in women. The NOBLE study showed a
prevalence of 16% in men and women. The EpiLUTS study found an overall higher
prevalence of symptoms such as urgency, UI or both in women. The MILSOM study
found a prevalence of 15.6% in men and 17.4% in women with OAB symptoms.
Various articles have discussed validated OAB screening tools that have been
retested in various countries and populations. Some tools are more specific to OAB
symptoms while other tools assess urinary incontinence. The ABSST, OABSS, CES-D,
IPBC, PPBC, WPAI-SHP, CLSS, B-SAQ, OAB-V8, IPSS, ICIQ-OAB-Quality of life,
are all validated screening tools that have been used in several settings to assess patients
with urinary incontinence and OAB symptoms (Basra et al., 2012; Cardozo et al., 2014;
Coyne et al., 2008; De Ridder et al., 2013; Fujimara et al.,2011; Hung et al., 2011; QuianSheng & Hann-Chorng, 2010; Sumardi et al., 2012).
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Wells et al., (2014), pilot study demonstrated that reducing caffeine intake may
alleviate the severity of some symptoms. Juliato et al. (2016), study showed that when
clinicians are assessing women who are menopausal, premenopausal, peri-menopausal or
post-menopausal; they should adopt a proactive behavior in surgically menopausal
women and those with a history of genital atrophy to identify and treat OAB symptoms.
Palmas et al. (2013), found that there was no significant difference (P=0.0743) in OAB
symptoms, between mode of delivery (cesarean or vaginal). Lekskulchai & Dietz (2008),
found that when evaluating detrusor overactivity, the measurement of detrusor wall
thickness should not be used as a diagnostic parameter. Al-Ghazo et al. (2011), did
however find a better correlation in detrusor overactivity between OAB symptoms and
the urodynamic diagnosis of detrusor overactivity in men than in women, more in OAB
wet than in OAB dry.
Oral antimuscarinics agent, such as tolterodine, and solifenacin were not found to
demonstrate superiority over another in the systematic review done, and anticholinergic
agents showed modest and rarely full resolution of symptoms (Reynolds et al., 2015).
The efficacy of a βз-adrenoceptor agonist mirabegron 50mg was found to be effective in
treatment of OAB symptoms, with a low occurrence of side effects in a Japanese
population (Yamaguchi et al, 2014).
The National Association of Nurse Practitioners in Women’s Health (NPWH)
surveyed 300 NPs to ascertain their own level of recognition and treatment of OAB in
their practice, and found most respondents could identify common symptoms of OAB
and its adverse effects on quality of life (Carcio, 2014). However, more than half reported
that they lacked confidence in their ability to accurately identify OAB and more than half
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reported lacking sufficient knowledge to effectively treat OAB (Carcio, 2014). Barriers to
changing practice may include a lack of provider confidence in discussing UI, lack of
training in clinical examination, and diagnosis and treatment of OAB. APRNs who
reported a higher level of education regarding UI had more accurate perceptions, more
positive attitudes, and more knowledge regarding older adult women with UI than those
who reported lesser levels of education (Keilman & Dunn, 2010). APRNs can make a
difference in the management of UI in women if they are taught the essentials and UI and
OAB practice guidelines, and have the assessment tools at hand to quickly assess patients
for UI and OAB (Keilman & Dunn, 2010). With proper screening for OAB,
communication between provider and patient about OAB, most, if not all, of the patients
with this condition can be identified and treated (Albers-Heitner et al., 2010; Carcio,
2014; Duralde et al., 2016; Filipetto et al., 2014; Keilman & Dunn, 2010; Nguyen et al.,
2013; Teunissen et al., 2015).
2.10 DISCUSSION OF BEST PRACTICE
A review of current literature supports OAB screening by primary care providers
to aid in recognizing OAB early and initiating appropriate treatments, thus decreasing the
time women wait to seek treatment (Barkin, 2016; Basra et al., 2012; Cardozo et al.,
2014; Coyne et al.,2008; De Ridder et al., 2013; Eapen & Radomski, 2016; Fujimura et
al., 2011; Hung et al., 2011; Jongen et al., 2015; Juliato et al., 2016; Kinsey et al., 2016;
Levkowicz et al., 2011; Palma et al., 2013; Quian-Sheng & Hann-Chorng, 2010; Sumardi
et al., 2012; Tikkinen et al., 2009). The potential impact of this quality improvement
project was to increase the provider’s knowledge about OAB symptoms; and assess the

53

provider perception of the ABSST effectiveness in assessing OAB symptoms in their
patients’.
Successful OAB treatment requires a willing participant who is informed
and engaged in the treatment process, understands that OAB has a variable and chronic
course likely requiring multiple management strategies over time with no single ideal
treatment and understands that treatment vary in invasiveness, risk of adverse effects and
reversibility (Gormley et al., 2012). Most OAB treatments improve patient symptoms but
are unlikely to eliminate all symptoms (Gormley et al., 2012). Explaining what is normal
can help the patient understand their condition and give a comparator for establishing
mutually-identified and realistic goals for treatment (Gormley et al., 2012). Education
empowers the patient to participate in their treatment, an essential factor when
interventions rely on behavior change.
It is believed that the use of a simple urinary symptom screener in primary care
settings, may facilitate discussions between the patient and healthcare provider regarding
OAB, and thereby help to identify women who could benefit from treatment (Cardozo et
al., 2014). A validated OAB screening tool would be useful to healthcare providers in
monitoring disease progression, as well as response to treatment.
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CHAPTER 3
METHODS
The purpose of this chapter is to present the methodology used to conduct
the DNP project. The methodology included description of the design, units of analysis,
sample, setting, outcomes to measure, the theoretical framework utilized, strategies to
reduce barriers and increase support, the procedure, and the data analysis. The purposes
of this project were to (1) determine an effective standard OAB screening tool to be used
in a retail clinic environment (see Appendix A), (2) determine the knowledge level of
providers regarding OAB, and (3) measure provider’s perception of the ABSST
effectiveness in assessing for OAB in patients.
3.1 DESIGN
This descriptive exploratory pre- and post-test design assessed the knowledge
level of providers regarding OAB. The investigator conducted a pre- and post-test design
to ascertain the providers’ perception of the ABSST effectiveness in assessing for OAB
following an educational model to teach how to use the ABSST.
3.2 UNIT OF ANALYSIS
The researcher utilized descriptive statistical analysis to describe the sample of
providers. Most providers in the Walgreens clinic are advance practice nurse practitioners
(APRNs). T-testing was used to assess the means, and descriptive statistics was used to
analyze data pre- and post-test design for measuring the provider’s knowledge level and
perception of the effectiveness in assessing for OAB using the ABSST. The descriptive
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statistics demographic data included years in practice, gender, age, and role (NP, PA).
The provider’s knowledge and perception of the screening tool effectiveness
survey (see appendix B), assessed the provider’s pre-and post-knowledge of OAB. The
survey also captured data regarding the perceptions of the providers in the ABSST
effectiveness in assessing for OAB. The combined survey consisted of seven questions
on OAB and as based on a five-point Likert Scale ranging from Strongly Agree (5) to
Strongly Disagree (1). For example, a question asked the providers if OAB condition
affects many women globally and in the U.S.A. Another question asked the provider if
women with urinary incontinence problems often seek treatment immediately. The
providers were asked to utilize the ABSST tool and rate its’ effectiveness in highlighting
the presence of OAB symptoms and whether it facilitated communication between them
and the patient. Barriers to providers initiating the conversation with patients was also
assessed using a five-point Likert scale. This tool was not a validated research tool and
had no psychometric findings in the literature.
3.3 SAMPLE
The sample size included 153 providers, who were asked to utilize the Actionable
Bladder Symptom Screener Tool (ABSST) (see Appendix C) with at least 50% of their
patients whom they saw for UTI symptoms, who meet the inclusion criteria. Inclusion
criteria included providers with prescriptive authority directly involved in providing
episodic and primary care to adults in Walgreens clinics. Another inclusion criteria, was
providers who would be able to utilize the language line for patients whom English is a
second language, to assist in answering the questions on the tool. Fulltime, part-time
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providers and providers who worked as needed, and had access to a computer for the
online training module, either in the clinic or from home were also be included.
The investigator reached out to the Walgreens education team, the Atlanta market
educator, and asked their assistance in gaining access to all Walgreen providers’ emails.
3.4 INSTITUTIONAL BOARD APPROVAL
Upon receiving approval from USC IRB, written information about the study was
sent by the researcher to potential participants via Walgreens email. The email invited
the potential subjects to participate in the evidence based project. In the email, the
researcher explained the purpose of the quality improvement project, the educational
module, the pre- and post-test data collection procedures. The subjects were also given
time frames to complete surveys and estimated time to complete the pretest survey,
educational modules, and post-test survey. A link for the online Class Climate survey for
providers to access to complete their pre-test knowledge and post-test of OAB was
provided. The survey also captured data pre-test regarding the perceptions of the provider
in the ABSST effectiveness in assessing for OAB, if any. Participation in the survey was
voluntary and all responses were anonymous. Participation implied consent to participate.
The researcher used the subject providers’ mother’s birthdate, using month and year, as
in 10-1940, for example, to be able to link the pre-and post-survey. The pre-and postsurveys was merged by their mother’s birthdate.
3.5 SETTING
The setting for the DNP project and implementation of the OAB assessment tool
was online via Walgreens email server. There were over 400 clinic sites throughout the
country. Walgreens retail clinics provide a range of services from immunizations,
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physicals, treatment of acute illnesses to chronic disease management. The clinics
provide care to male and female patients from ages 18 months and older.
3.6 DATA COLLECTION PROCEDURE
There were two phases for the data collection procedure. The first phase included
a pre-test survey which the provider completed online via Class Climate survey. The
provider’s knowledge and perception of the screening tool effectiveness survey (see
appendix B), was distributed online via Class Climate to assess the provider’s pre-test
knowledge of OAB. The survey also captured data pre-test regarding the perceptions of
the provider in the ABSST effectiveness in assessing for OAB, if any.
Once the provider subject completed the pre-test, they were provided a link to
access and complete the educational component of the program. This was conducted via
Grand Rounds on the online educational department website, to teach providers strategies
for managing OAB in women presenting to the clinics. The ABSST was also presented to
the providers as a validated tool that could be utilized to screen for OAB symptoms. The
ABSST is a validated tool with psychometric properties and findings in the literature
(Cardozo et al., 2014; Jongen et al., 2015). The subject providers were asked to provide
their mother’s birthdate, using the month and year only, to link the pre-and post-survey to
the same provider.
The researcher with the assistance of the educational team at the Walgreens
clinics presented a Grand Rounds educational session on OAB via the online meeting
center called Genesys (See Appendix H). All providers were invited to view and listen to
the power point presentation recorded on October 27th, 2016. The presentation was
approximately 40 minutes in length. The providers who participated in the OAB grand
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round session were eligible for one credit hour of continuing education (CE) credit
offered by Rush University. Rush University is accredited as a provider of continuing
nursing education by the American Nurses Credentialing Center’s Commission on
Accreditation (ANCC). Providers subjects who participated in the grand rounds were
asked to email the date of completion to the researcher.
Once the educational module was completed, the providers were asked to
complete an online post-test survey, the provider’s knowledge and perception of the
screening tool effectiveness survey (see appendix D), via Class Climate survey. They
were able to access the post-test survey by a link that was emailed to all subjects who
were initially invited to participate in the project. Once the participant linked with Class
Climate survey, each participant would receive a written introduction again about the
survey that explained the purpose of the project, protection of subjects, and consent. All
responses were anonymous. The providers were asked to provide their mother’s
birthdate, asking only for the month and year, to link the pre- and post- survey.
Participation was voluntary in the survey and implied consent.
Once the subject completed the module, a second online post-test survey was sent
to the same group of potential subjects. The provider’s knowledge and perception of the
screening tool effectiveness post-test survey (see Appendix C) was distributed online via
Class Climate to assess the provider’s post-test knowledge of OAB. The survey also
captured data post-test regarding the perceptions of the provider in the ABSST
effectiveness in assessing for OAB, if any. All responses were anonymous for pre- and
post-test. However, the researcher asked the providers for the mother’s birthdate, asking
only for the month and year, to link the pre- and post-test to each provider. Participation
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was voluntary in the survey and implied consent. Providers did not receive any financial
incentive to participate.
3.7 OUTCOMES MEASURED
The outcomes measured were increased knowledge regarding the use of screening
of OAB as measured by (1) the provider’s knowledge of OAB pre-and post-educational
intervention, (2) the provider’s perception of the ABSST effectiveness in assessing for
OAB pre- and post-educational intervention.
3.8 THEORETICAL FRAMEWORK
This project was based on the theoretical framework of the Model for Evidencebased Practice Change (Rosswurm & Larrabee, 1999). There are six steps that help the
DNP student progress through evidence-based project, on improving outcomes for
patients with OAB.
Step 1. Assess the need for change in practice
The identified problem was that providers in the Walgreens Healthcare Clinics may not
routinely screen women who may potentially present with OAB symptoms. A standard
OAB assessment tool was utilized by the providers to assess women over 40 years of age
who may potentially need further treatment or referral. The Healthcare Clinics at
Walgreens are now able to manage primary care problems and having a validated,
standard OAB assessment tool, would further assist providers in screening their patients.
There was no data provided by Walgreens as to how many women present with OAB
symptoms. Having a standard OAB assessment tool that is simple may potentially
increase awareness by providers of the problem and help patients improve their quality of
life.

60

Step 2. Locate the best evidence
The evidence that was used was a validated, standard OAB assessment tool. Sources of
evidence included electronic bibliographic databases, websites, journals and textbooks.
The databases utilized were CINAHL, Joanna Briggs, NIH, Google Scholar, National
Guidelines Clearinghouse, PubMed, The Cochrane Collaboration, Web of Science and
Turning Research into Practice (TRIP) database. The John Hopkins Evidence Level and
Quality Guide was used evaluate the evidence of the sources. The John Hopkins Nursing
Evidence-Based Practice process occurs in three phases and can be simply described as
Practice question, Evidence, and Translation (PET), which uses a five-level scale to
determine the type, level, and quality of evidence (Dearholt & Dang, 2012).
Step 3: Critically Analyze the Evidence
Most articles were appraised and judged for their evidence and found to be of good
quality but the levels of articles ranged from level I through level V. Issues that promote
the feasibility of this EBP project are that the study can be conducted in about 3 months
and the researcher can potentially get good sample size of providers to participate, and
approval has been obtained from the Walgreens education team and the chief nursing
officer (CNO). Of concern to the researcher a good sample size of provider participation.
Another concern will be provider acceptance of the ABSST.
Step 4: Design Practice Change
An OAB assessment tool was provided to the providers in the retail setting.
The researcher involved the CNO and market educators to champion the project
with the providers. Providers were notified via email (see Appendix C) of the study and
request participation in the study. Providers who accepted to be in the study were asked
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to participate in an educational session known as Grand Rounds, and an anonymous Class
Climate pre-and post-survey that was sent to each provider to assess improved knowledge
after utilizing the standard OAB screening tool.
Step 5: Implement and Evaluate Change in Practice
The researcher assessed provider knowledge and got feedback
on the effectiveness of the OAB tool, using Class Climate survey. The
providers’ feedback was used to make minor adjustments in the implementation
plan, if necessary ((Melnyk & Fineout-Overholt, 2015, p. 289). Based on the feedback of
the providers, Walgreens would be asked to adapt, adopt, or reject the new OAB
assessment tool.
Step 6: Integrate and Maintain Change in Practice
3.9 STRATEGIES TO REDUCE BARRIERS AND INCREASE SUPPORT
A major advantage of survey research was that there was the potential for a large
sample size due to the fact that Walgreens clinics were in multiple market. According
to Melynk & Fineout-Overholt (2015), before embarking on a study, important questions
to ask regarding feasibility are:
1. Can the study be conducted in a reasonable amount of time?
2. Are there an adequate number of potential subjects to recruit into the study?
3. Have the settings for recruitment been identified and is accessibility a concern?
4. Does the lead person (PI) have sufficient time and expertise to spearhead the effort?
5. Are there major ethical or legal constraints to undertaking this study?
6. Are there adequate resources available at the institution or clinical site to conduct the
study? If the answer is no, what is the potential for obtaining funding?
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Five issues that promoted the feasibility of this evidence based project were: (1)
could the study be conducted in about 3 months or less, (2) would the providers in the
clinics can complete the online educational modules, (3) would the providers complete
the Class Climate survey online, (4) how would the investigator obtain emails for
providers who are employed in the Walgreens Clinics for provider recruitment, and (5)
would the same providers complete the online survey pre- and post.
The answers to all five issues was yes. The researcher anticipated it may take
more time to carry out the project than originally projected and had incorporated a buffer
period (i.e., extra time) in case of IRB approval delay, access to subject recruitment took
longer than anticipated. Walgreens education team provided the emails for all providers
working in the clinics. The market educators, Walgreens IRB team, and Chief Nursing
Officer approval of the project also facilitated the researcher’s consideration in whether it
would be feasible. The researcher anticipated provider “buy-in” to the project.
3.10 DATA ANALYSIS
Once the survey data was returned, the researcher, in collaboration with a
statistician, reviewed the data and, created data in the form that would be useable in SAS
9.4 for analysis. The researcher utilized descriptive statistical analysis to describe the
sample. Descriptive statistics include frequency tables for categorical variables and
means, standard deviation, and range for continuous variables. Matched-paired t-test was
used to examine the increase of knowledge after the introduction of the education tool.
Also, inferential statistics including parametric test (t-test) and non-parametric test (sign
ranked test) were used to examine the difference in means for knowledge and perception
of the providers over a 3-month period for this quality improvement study.
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3.11 SUMMARY
Once all the data for the study was collected and analyzed, the researcher planned
to share the recommendations about the adaptability of the OAB tool in the clinics with
the market educators, chief nursing officer and the providers. The researcher also shared
the findings with University of South Carolina College of Nursing and planned to
publish. The researcher used the data gained from the survey to design an in-service
education workshop to enhance the providers’ knowledge and skills in this area. This inservice was conducted via Genesys (an online center utilized by providers for educational
needs at the Walgreens retail clinic setting). The researcher would continue to
communicate with the champions and participants and keep them abreast of the progress
being made and actions that have resulted from the research. The researcher would ensure
the relationship was maintained after research was concluded by giving feedback to the
participants.

64

CHAPTER 4
RESULTS
The purpose of this project was to (1) determine an effective standard screening
tool to be used in a retail clinic environment, (2) determine the knowledge level of
providers regarding OAB, and (3) measure provider’s perception of the ABSST
effectiveness in assessing for OAB in patients. Descriptive statistics were used to
describe the sample. Inferential statistics included parametric test (T-test) and nonparametric test (sign ranked test) to examine the difference in means for providers’
knowledge of OAB and perception of their effectiveness in assessing OAB pre-and postintervention. This quality improvement project was conducted over a 3-month period.
The researcher obtained IRB approval from both Healthcare Clinics in Walgreens
and University of South Carolina prior to initiating the study in the clinic setting. The
researcher then obtained support from the clinic stakeholders – the market educators,
providers and assistant area directors – to encourage participation. After obtaining
providers’ email from the Healthcare Clinic Directors, the initial recruitment invite with
the consent and Class Climate survey was sent on December 2nd, 2016 (See Appendix E).
The recruitment phase was completed on December 23rd, 2016. Those providers who
emailed the researcher upon completing the pre-survey, were then asked to complete the
educational module on OAB online (See Appendix H) and email the researcher.
Thereafter, the providers were sent the ABSST (See Appendix C), and asked to use with
their patients that met the criteria for 4 weeks. The researcher then sent out weekly
65

remainder emails (See Appendix F) to participants to continue using the tool with
patients’ who met the criteria. After the utilizing the ABSST in the clinic for 4 weeks, the
participants were sent the post survey (See Appendix G). The providers were sent
reminders every 3 days to complete the post survey with the final day on February 16th,
2016. The purpose of this chapter was to present the findings of the project.
4.1 DESCRIPTION OF SAMPLE
Over 1000 potential providers were targeted to participate and of those, 153
providers agreed to participate but only 52 providers completed the study including the
pre- and post-surveys, the educational module, and utilized the ABSST tool with their
patients that met the criteria. The mean age of the sample was 50 years old. See Table 4.1
for characteristics of the respondents who completed the pre-survey and post-survey.
Table 4.1 Frequency and percentage of respondents to the online pre-survey and postsurvey
Characteristic
Pre-survey (N=153)
Post survey (N=52)
N

%

N

%

Male

8

5.52

1

2

Female

136

93.79

49

98

Gender

Age Range
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25-35

17

11.26

2

3.9

36-45

41

27.16

19

37.92

46-55

47

31.13

16

31.37

>55

46

30.46

14

27.45

1-3 years

39

26

10

19.23

4-7 years

39

26

14

26.92

>8 years

72

48

28

53.85

NP

145

96.03

49

98

PA

6

3.97

1

2

Years of NP Practice

Title

Findings indicated that 16 participants correctly linked their pre- and post-survey
using their mother’s date of birth. See Table 4.2 for characteristics of the 16 matched
respondents pre-survey and post-survey.
Table 4.2 Frequency and percentage of the 16 matched respondents pre-survey and postsurvey
Characteristic
Pre-survey (N=16)
Post-survey (N=16)
N

%
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N

%

Gender
Male

1

6.67

1

6.25

Female

14

93.33

15

93.75

Age Range
25-35 years

3

18.75

1

6.25

36-45 years

6

37.50

7

43.75

46-55 years

4

25

5

31.25

>56 years

3

18.75

3

18.75

1-3 years

5

31.25

4

25

4-7 years

6

37.50

4

25

>8 years

5

31.25

8

50

NP

15

93.75

14

93.33

PA

1

6.25

1

6.67

Years of NP Practice

Title

4.2 KNOWLEDGE OF OAB
The knowledge of the participants was assessed utilizing Class Climate pre-and
post-survey (See Appendix D). Findings indicated between age groups, there were no
statistically significant mean differences in pre-and post-survey (N= 151 pre-survey, and
N=51 post-survey). Moreover, there were no statistically significant mean differences in

68

mean age between pre-and post-survey (N= 151 pre-survey, and N=51 post-survey). See
Table 4.3 for survey items pre-and post-survey.
Table 4.3. Sample (N), Mean, Standard Deviation (STD) for pre-and post-survey
between age groups
Survey
Pre
Post
T-test
Item
OAB is a

N

Mean

STD

N

Mean

STD

(p-value)

153

4.16

.86

52

4.35

.71

0.154

150

2.07

.81

49

1.90

.65

0.171

common
condition
affecting
many
women
globally and
in the US
Women
with urinary
incontinence
problems
often seek
treatment
immediately
P value <0.05
4.3 PROVIDER’S PERCEPTION OF THE SCREENING TOOL EFFECTIVENESS
The results of the T-test indicated significant mean differences for pre-and postintervention for ABSST effectiveness (P<0.0001) (N=148 pre-survey and N= 51 postsurvey), effectiveness in facilitating critical communication (P <0.0001) (N=145 presurvey and N=52 post-survey), and patient uncomfortable bringing up the topic
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(P=0.0244) (N= 152 pre-survey and N= 52 post-survey). The results did not reveal any
statistically significant difference for survey items (1) OAB is a common condition
affecting many women globally and in the US (N= 153 pre-survey and N= 52 postsurvey); (2) women with urinary incontinence problems often seek treatment immediately
(N= 150 pre-survey and N= 49 post-survey). See Table 4.4 for survey items pre-and postsurvey.
Table 4.4 Sample (N), Mean, Standard Deviation (STD) for pre-and post-survey between
age groups
Survey Item

Pre
25 years ≥ 56 years
N

The validated

Mean

STD

Post

T-test

25 years ≥ 56 years

(p-value)

N

Mean

STD

148

3.56

.69

51

4.14

.89 <0.0001*

145

3.57

.74

52

4.21

.78 <0.0001*

overactive
bladder
screening tool
(ABSST) is
effective in
highlighting the
presence of
bladder
symptoms
consistent with
OAB
The ABSST is
effective in
facilitating
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critical
communication
between patient
and provider
Lack of

151

3.73

.79

51

3.82

.77 0.4556

152

3.89

.86

52

4.02

.90 0.3482

152

4.03

.75

52

4.29

.61 0.0244*

provider
information
about OAB
symptoms
Not enough
time
Patients are
uncomfortable
bringing up the
topic
*P value <0.05
Non-parametric results were similar to the T-test results. Findings indicated that
the mean differences between pre-and post-survey and provider age groups were not
significantly different (p=0.943). Results indicated significant differences for ABSST
effectiveness (P<0.0001), effectiveness in facilitating critical communication (P
<0.0001), and patient uncomfortable bringing up the topic (P=0.0109) among providerage groups pre-and post-intervention. The results did not reveal any statistically
significant differences between other survey items in Table 4.5 by age group. See Table
4.5 for non-parametric sample (N), mean, standard deviation (STD), and Wilcoxon Test
for survey items pre-and post by age groups.
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Table 4.5 Non-parametric sample (N), mean, standard deviation (STD) for pre-and postsurvey between age groups
Survey Item
Pre
Post
Wilcoxon Two25 years ≥ 56 years
N
OAB is a

Mean

25 years ≥ 56 years
Mean

STD

sample test
(p-value)

STD

N

153 100.06

332.29

52

111.66

332.29

0.0878

150

102.31

301.51

49

92.93

301.51

0.1256

148

88.59

325.94

51

133.11

325.94

<0.0001*

common
condition
affecting many
women
globally and in
the US
Women with
urinary
incontinence
problems often
seek treatment
immediately
The validated
overactive
bladder
screening tool
(ABSST) is
effective in
highlighting
the presence of
bladder
symptoms
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consistent with
OAB
The ABSST is

145

86.98

151

99.73

152

152

321.57

52

132.50

321.57

<0.0001*

306.70

51

106.75

306.70

0.1916

99.91

336.98

52

110.07

336.99

0.1218

97.76

313.99

52

116.36

313.99

0.0109*

effective in
facilitating
critical
communication
between
patient and
provider
Lack of
provider
information
about OAB
symptoms
Not enough
time
Patients are
uncomfortable
bringing up the
topic
*P<0.05
The matched paired for 16 participants showed an increased mean score for the
providers’ knowledge between pre-and post-survey (N=16). The result of matched-paired
T-test (p = .0306) and sign rank test (p = .0451) were similar (N=16). The results
revealed on average a 2.38-unit increase in the provider’s knowledge from pre-survey to
post-survey (N=16). See Table 4.6 for mean knowledge scores.
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Table 4.6 Mean, STD, and 95% CI for the difference knowledge scores (post – pre)
Variable
95% CI

Total OAB

N

Mean

STD

Mean

16

2.38

3.98

0.25 – 4.4

P value
0.0306*

*P<0.05
For providers’ age group, mean scores were different pre-and post-testing but they
were not statistically significant for age groups 25-35, 36-45 and 46-55 (N=3, N=6, N=4
respectively). For providers’ greater than 56 years of age, there was a statistically
significant increase in the mean score of 5 and p=0.0340 (N= 3), indicating an increase in
the provider’s knowledge and use of the OAB post intervention. See Table 4.7 below for
the total OAB scale for age groups.
Table 4.7. The total OAB scale for age
Variable 25-35 years
36-45 years

46-55 years

>56 years

N Mean STD N Mean STD

N Mean STD

N Mean STD

value

3

4 0.50 2.38

3

0.0340*

Total

-2

1

6 4.50 4.04

5

3

P

OAB
*P<0.05
Providers’ years of experience was not statistically significant for mean score
differences in pre-and post-testing. However, providers’ years or experience in the
primary care setting for the matched paired design showed an increased mean score for
all experience groups 1-3 years, 4-7 years and greater than 8 years between pre-and posttesting. Providers with more than 8 years of experience had the largest increase in mean
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score (3.60), even though it was not statistically significant p=0.6737 (N=5). See Table
4.8 below for the total OAB scale for number of years in primary care setting.
Table 4.8 The total OAB scale for number of years in primary care setting
Years in
1-3 years
4-7 years
8 years or more
Primary
Care

N

Mean

STD

Mean

N

Mean

5

3.60

STD

P value

2.88

0.6737

STD

Setting
Total

N

5

2.4

5.22

6

1.33

4.03

OAB
P<0.05
4.4 ANALYSIS OF PICO
Among healthcare providers providing primary care in Walgreens clinics, does an
educational model to teach providers the use of a standard OAB screening tool (ABSST),
as compared to the use of no symptom screening tool, improve knowledge regarding the
use of screening of OAB? The project PICOT sought to measure by (1) the provider’s
knowledge of OAB pre-and post-educational intervention, (2) the provider perception of
the ABSST effectiveness in assessing for OAB pre-and post-educational intervention,
over a 3-month period.
The post survey was emailed to79 participants upon utilizing the OAB tool for
one month in the clinic with 52 participants completing the survey. Upon analyzing the
pre-and post-survey data, only 16 participants correctly linked from the pre- and postsurvey using their mother’s date of birth. Both the researcher and the statistician
reviewed the data for accuracy and gaps. Table 4.9 and Table 4.10 show the results by
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percentages of responses for the pre-and post-survey by the respondents (N= 153 for pre,
N = 52 post).
Table 4.9. Percentage of responses to the OAB and perceptions of ABSST effectiveness
pre-survey(N=153)
Survey Item

SD

D

N

A

SA

OAB is a common condition affecting many

2.61

1.96

8.50

50.98

35.95

19.33

62.67

10.67

6.00

1.33

1.35

0.68

45.27

45.95

6.76

2.76

0.69

39.31

51.03

6.21

0.66

9.27

16.56

63.58

9.93

Not enough time

0.66

7.24

17.11

52.63

22.37

Patients are uncomfortable bringng up the

1.32

3.29

9.21

63.82

22.37

women globally and in the U.S
Women with urinary incontinence problems
often seek treatment immediately
The validated OAB screening tool (ABSST) is
effective in highlighting the presence of
bladder symptoms consistent with OAB
The ABSST is effective in facilitating critical
communication between patient and provider
Lack of provider information about OAB
symptoms

topic of OAB

Table 4.10. Percentage of responses to the OAB and perceptions of ABSST effectiveness
post-survey (N=52)
Survey Item

SD

OAB is a common condition affecting many

1.92

women globally and in the U.S
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D

N

A

SA

1.92

0

53.86

42.31

Women with urinary incontinence problems

24.49

63.27

10.20

2.04

0

3.92

0

9.80

50.98

35.29

1.92

0

0

51.92

36.54

often seek treatment immediately
The validated OAB screening tool (ABSST) is
effective in highlighting the presence of
bladder symptoms consistent with OAB
The ABSST is effective in facilitating critical
communication between patient and provider
Lack of provider information about OAB

0

9.80

9.80

68.63

11.76

Not enough time

0

9.62

9.62

50

30.77

Patients are uncomfortable bringng up the

0

1.92

1.92

61.54

34.62

symptoms

topic of OAB

Table 4.11 and Table 4.12 show results by percentage of matched responses preand post-survey by respondents (N=16).
Table 4.11. Percentage of responses to the OAB and perceptions of ABSST effectiveness
pre-survey (N=16)
Survey Item

SD

D

N

A

SA

OAB is a common condition affecting many

0

0

6.25

31.25

62.50

0

women globally and in the U.S
Women with urinary incontinence problems

37.50

50

0

12.50

0

0

42.86

35.71

21.43

0

0

50

42.86

7.14

often seek treatment immediately
The validated OAB screening tool (ABSST)
is effective in highlighting the presence of
bladder symptoms consistent with OAB
The ABSST is effective in facilitating critical
communication between patient and provider
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Lack of provider information about OAB

0

6.67

20

66.67

6.67

Not enough time

0

0

25

50

25

Patients are uncomfortable bringng up the

0

0

12.50

symptoms

56.25

31.25

topic of OAB

Table 4.12. Percentage of responses to the OAB and perceptions of ABSST effectiveness
post-survey (N=16)
Survey Item

SD

D

N

A

SA

OAB is a common condition affecting many

0

0

0

56.25

43.75

31.25

50

women globally and in the U.S
Women with urinary incontinence problems

18.75

0

0

often seek treatment immediately
The validated OAB screening tool (ABSST)

0

0

12.50

50

37.50

0

0

12.50

31.25

56.25

0

0

18.75

62.50

18.75

Not enough time

0

25

12.50

37.50

25

Patients are uncomfortable bringng up the

0

0

6.25

56.25

37.50

is effective in highlighting the presence of
bladder symptoms consistent with OAB
The ABSST is effective in facilitating critical
communication between patient and provider
Lack of provider information about OAB
symptoms

topic of OAB ͨ

The results from the T test pre-to post survey revealed a statistically significant
increase in the ABSST effectiveness in highlighting OAB symptoms (p<0.0001) (N=148
pre-survey and N=51 post survey); and a statistically significant increase in the ABSST
facilitating communication (p<0.0001) (N=145 pre-survey and N=52 post survey). The
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results demonstrated that patients are uncomfortable approaching and discussing OAB
(p=0.0109) (N= 152 pre-survey and N=52 post survey). Other survey items were not
statistically significant. See Table 4.13 for N, mean, STD pre-and post for each survey
item.
Table 4.13. The N, mean, STD pre- and post for each survey item
Survey Item
Pre

OAB is a common condition

Post

N

Mean

STD

N

Mean

STD

153

4.16

0.86

52

4.45

0.71

150

2.07

0.81

49

1.90

0.65

148

3.56

0.69

51

4.14

0.89

145

3.57

0.74

52

4.21

0.78

151

3.73

0.79

51

3.82

0.77

152

3.89

0.86

52

4.02

0.90

affecting many women
globally and in the U.S
Women with urinary
incontinence problems often
seek treatment immediately
The validated OAB
screening tool (ABSST) is
effective in highlighting the
presence of bladder
symptoms consistent with
OABª
The ABSST is effective in
facilitating critical
communication between
patient and provider ᵇ
Lack of provider information
about OAB symptoms
Not enough time

79

Patients are uncomfortable

152

4.03

0.75

52

4.29

0.61

bringng up the topic of OAB

ͨ
a. P value = <0.0001 b. P value = <0.0001

c. P value = 0.0109

The results revealed a significant change at a 95% confidence interval that the total mean
difference between pre and post survey for matched T-test is between 0.2536 and 4.4964,
with p=0.0306 (N=16). This findings indicates that providers’ knowledge and awareness
of OAB symptoms and screening in adult women were increased following an
educational online module. See Table 4.14 for N, mean, STD pre-and post-total OAB
survey pre-and post.
Table 4.14. The N, mean, STD pre-and post-total OAB survey difference pre-and post.
Survey
N
Mean
STD
P value
16

Total OAB

2.375

3.981

0.0306*

*P<0.05
The two questions that sought to measure provider knowledge pre to post
educational module were not statistically significant. See Table 4.14 for the N, mean,
STD for survey items measuring provider knowledge pre- and post survey.
Table 4.15. The N, mean, STD for survey items measuring provider knowledge pre- and
post survey
Pre
Post
Survey Item

N

Mean

OAB is a common

153

4.16

STD
0.86

condition affecting
many women globally
and in the U.S
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N

Mean

STD

P value

52

4.35

0.71

0.1542

Women with urinary

150

2.07

0.81

49

1.90

0.65 0.1713

incontinence problems
often seek treatment
immediately

P<0.05
The two questions that sought to measure the provider perception of the ABSST
effectiveness in assessing for OAB in patients were statistically significant (N=148;
N=145 pre survey and N=51; N=52 post survey). The validated overactive bladder
screening tool (ABSST) was found to be statistically significant in hightlighting the
presence of bladder symptoms consistent with OAB at a 95% confidence interval (0.8163 - -0.3366) with p< 0.0001 (N=148 pre-survey and N=51 post survey). The
ABSST is effective in facilitating critical communication between patient and provider
was signigicant at 95% confidence interval (-0.8787 - -0.3995, p<0.0001) (N=145 presurvey and N=52 post survey). See Table 4.16 for the N, mean, STD for survey items
measuring provider perception pre- and post survey.
Table 4.16. The N, mean, STD for survey items measuring provider perception pre- and
post survey
Pre
Post
Survey Item

N

Mean STD

N

Mean

STD

P value

The validated OAB

148

3.56

51

4.14

0.89

<0.0001*

0.69

screening tool
(ABSST) is
effective in
highlighting the
presence of bladder
symptoms
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consistent with
OAB
The ABSST is

145

3.57

0.74

52

4.21

0.78

<0.0001*

effective in
facilitating critical
communication
between patient and
provider

*P<0.05
The researcher noted some limitations to the study. The small sample size could
not provide a robust analysis of the study. The recruitment phase was conducted during
vacation time and during company restructuring which may have affected the reponse
rate. The study required the providers to complete a pre survey and educational teaching
module, utilize the ABSST tool in clinic, and then complete the post survey. Complicated
and time consuming steps may have also impacted the response rate leading to a more
than 50% attrition rate. While surveys are are direct measures that are versatile, they are
prone to bias when respondents provide the socially acceptable answer rather than their
true opinion (Moran et al., 2014).
4.5 SUMMARY
Most women with OAB symptoms do not discuss with their healthcare providers
bladder dysfunction and providers may not systematically inquire (Hartmann,
McPheeters, & Biller, 2009). The rising prevalence of OAB creates a burden for
individuals and society and increases the potential for impaired functional status and
lower health-related quality of life (Barile et al., 2015). The use of a validated bladder
symptom screener tool in women over 40 years of age presenting in the Healthcare
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Clinics in Walgreens was found to facilitate discussion between the provider and patient,
and thereby identify women who could benefit from treatment or referral. Assessment of
OAB symptoms in women is an important component of chronic disease management.
This study created an awareness in the providers who did not routinely screen their
patients for OAB symptoms. It was found that at a 95% confidence interval there was a
statistically significant increase (p< 0.0001) in the ABSST effectiveness in highlighting
the presence of bladder symptoms consistent with OAB (N=145 pre-survey and N=52
post survey). In regards to provider knowledge level assessing for OAB in patient; there
was significant increase following the educational module (p=0.0004) (N=153 pre-survey
and N=52 post-survey).

83

CHAPTER 5
DISCUSSION
The prevalence of OAB in the United States is 16.9 percent in women, according
to the NOBLE study (Eapen & Radomski, 2016). The rising prevalence of OAB creates a
burden for individuals and society and increases the potential for impaired functional
status and lower health-related quality of life (Barile et al., 2015). The evaluation of OAB
symptoms by providers should be addressed as part of the routine primary care visit,
however, it is often not assessed or documented. This quality improvement project goal
was to create an awareness of the importance of routinely screening patients for OAB
symptoms in primary care settings. The use of the ABSST could facilitate further
discussion between provider and patient. The study created an awareness in the providers
who did not routinely screen their patients for OAB symptoms. The ABSST was effective
in highlighting OAB symptoms. The ABSST questionnaire is an option available for
providers to use in clinic to evaluate symptoms of OAB. The OAB grand rounds
educational module (See Appendix H), which the participants viewed, discussed how to
use the questionnaire and the criteria for treatment or referral.
The researcher cited some limitations to the study project. The small sample size
could not provide a robust analysis of the study. There were more female respondents
than males, and there were more NPs respondents than PAs.There were no physician
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participants in the study. A large and fairly equal sample size based on the characteristics
would have helped the study findings. Another limitation was the recruitment phase was
conducted during vacation time for providers and during company restructuring, which
may have affected the reponse rate. The study required the providers to complete a pre
survey, educational teaching module, utilize the ABSST tool in clinic, and complete a
post survey. Complicated and time consuming steps may have also impacted the response
rate leading to more than 50% attrition rate. Some of the providers did not complete the
survey correctly, lending the study to an even smaller matched sample size from pre to
post survey. The researcher did not record how often the providers used the tool with
their patients. However, the researcher did ask the providers to use it with at least 50% of
their female patients who met the criteria. The researcher was not able to match the
provider with the survey they completed, as it was anonymous. The study was for a 3month period; and a longer time in clinic may also have lent itself to a more robust
study. While surveys are direct measures that are versatile, they are prone to bias when
respondents provide the socially acceptable answer rather than their true opinion (Moran
et al., 2014).
The focus of the DNP degree is expertise in clinical practice (Chism, 2013). This
quality improvement project is inclusive of the Essentials of Doctoral Education for
Advance Nursing Practice as outlined by the American Association of Colleges of
Nursing (2006). Each Essential is addressed as it relates to this quality improvement
scholarly project. The purpose of this chapter is show how the the Essentials of Doctoral
Education in Advance Nursing Practice guided the DNP graduate. According to
Donabedian (1990), seven attributes of health care define its quality: (a) efficacy: the
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ability of care to improve health; (b) effectiveness: how well health improvements are
realized; (c) efficiency: the facility to obtain the best health improvements at the lowest
cost; (d) optimally: balancing costs and benefits; (e) acceptability: taking into account
patient preferences; (f) legitimacy: accord with social preferences concerning all the
above; and (g) equity: fair distribution of care (Holly, 2014).
5.1 THE SCIENTIFIC UNDERPINNING FOR PRACTICE
This was addressed as evidenced by the research of a reliable and validated
questionnaire; and peer reviewed journals, articles and textbooks that identify science
based theories and concepts related to the prevalence of OAB symptoms in women over
40 years. The project addressed Essential I through developing an educational module on
OAB that the providers were able to access via the Healthcare clinic webbased
educational forum and then utilizing the ABSST in clinic setting. The pre and post survey
data showed statitical significance in the ABSST effectiveness and ABSST facilitating
communication between patient and provider. There was no statistical significance found
in increasing the knowledge of providers from pre to post testing. This quality
improvement project was implemented through researching science based evidence and
concepts to identify health care delivery actions and strategies to facilitate better
assessment of OAB symptoms.
5.2 ORGANIZATIONAL AND SYSTEMS LEADERSHIP FOR QUALITY
IMPROVEMENT AND SYSTEMS THINKING
This was integrated in this project through the researcher identifying a need for a
quick and simple questionnaire in clinic to assess for OAB symptoms for women who
may not necessarily have urinary tract infections, and present for primary care in the
86

Healthcare clinics. Encouraging providers to be proactive in inquiring about OAB
symptoms in their patients, may lead to a improvement in health related quality of life of
the women whose symptoms are addressed promptly.
5.3 CLINICAL SCHOLARSHIP AND ANALYTICAL METHODS FOR EVIDENCEBASED PRACTICE
For this quality improvement project, the researcher critically evaluated existing
literature and determined the best evidence for practice and the implementation and in
clinic setting. The researcher presented an educational module on the Walgreens
Healthcare University site entitled “Overactive Bladder: Strategies for Assessment and
Managing Symptoms” See Appendix H for powerpoint presentation done on October
27th 2016. The pre and post survey data were compared to determine the impact of the
educational module presented. The questions that sought to measure provider knowledge
pre to post educational module were not statistically significant. However the two
questions that sought to measure the provider perception of the ABSST effectiveness in
assessing for OAB in patients were statitically significant. Based on the significance of
the ABSST effectiveness, continued reinforcement to utilize the questionnaire needs to be
encouraged in assessing symptoms and educating patients.
5.4 INFORMATION SYSTEM/TECHNOLOGY AND PATIENT CARE
TECHNOLOGY FOR THE IMPROVEMENT AND TRANSFORMATION OF
HEALTH
The DNP graduate is required to be knowledgeable and proficient in information
technology regarding how to use powerpoint presentation in a virtual classroom. This
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quality improvement utilized web-based communication such as email and the online
educational module which was done using powerpoint presentation. The information
technology was a cost effective and critical component to send out the pre survey, post
survey via the work emails.
5.5 HEALTHCARE POLICY FOR ADVOCACY IN HEALTH CARE
DNP graduates are in a position to be powerful advocates for healthcare policy
through their practice experiences at all levels.This quality improvement project
discussed health polices related to OAB symptoms, promotion of health for patients, and
reinforced to providers the importance to screen and educate their patients. Furthermore,
doctoral prepared advance nurse practitioners are in a position to advance the health of
populations by influencing politicians through organizing communities, advocating for
healthy public policy, promoting effective regulation, and pursuing fair taxation and
public service (Davidson, 2014).
5.6 INTERPROFESSIONAL COLLABORATION FOR IMPROVING PATIENT AND
POPULATION HEALTH
The researcher participated in effective communication with the leadership team,
education team and IRB team at Walgreens Healthcare clinics for the need to implement
the quality improvement project in the Walgreens clinics. Approval was then given to
proceed with study in the clinics.The results of the pre and post survey showed that the
ABSST was an effective tool in facilitating critical communication. The researcher
communicated with the Walgreens education team the quality improvement study
findings; and encouraged them to make the ABSST tool easily accessible online for
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providers who may chose to use it to screen their patients for OAB symptoms. The
director for education and development at the Healthcare Clinics thought it was a great
project and stated she would share the tool with the EPIC and clinical practice teams to
see if it could possibly be added to the EPIC electronic medical record, in the future.
5.7 CLINICAL PREVENTION AND POPULATION HEALTH FOR IMPROVING
THE NATION’S HEALTH
There are a number of major underlying causes of health disparities, determinants
of population health, which lead to health inequalities (Davidson, 2014). Improving
patient experience of care, reducing per capita cost and improving population health are
described as the Triple Aim by the Institute for Healthcare Improvement and are a
roadmap to assess overall population health. (Stiefel & Nolan, 2012). Urinary
incontinence (UI) and OAB are common conditions affecting women in the United States
(Newman & Wein, 2009). Most health care providers often times fail to screen for UI and
OAB (Newman & Wein, 2009). The retail clinics in Walgreens are anexcellent entry
point of intervention for women who may present with OAB. Individual health is
influenced by whether an individual can afford the care and cope with the stigma that for
some causes embrassment and shame. This often times leads to a delay in seeking
treatment from their providers. Provider support is essential in education patients about
their health conditions.
5.8 ADVANCED NURSING PRACTICE
This was demonstrated with this quality improvement project through
comprehensively assessing the health and illness parameters related to OAB in women
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and interventions and treatments that can be incorporated in assisting this population. The
educational module assisted providers in the use of the ABSST, which in turn they could
utilize with their patients to screen for OAB symptoms.
5.9 FURTHER STUDIES
More studies need to be conducted in both male and female patients utilizing the
ABSST and comparing it to other reliable and validated questionnaires. Further studies
assessing perceptions of physicians, physician assistants and nurse practitioners in acute
care, urgent care, primary care and retail settings, in regard to OAB symptoms in their
patients would also be beneficial. Moreover, further research aimed at identifying
patients who may have OAB symptoms is needed, to help reduce the delay in seeking
treatment from their providers.
5.10 RECOMMENDATIONS
Further recommendations for this study would include replicating this study with
a larger sample, as well as expanding the content to assess all adults, both male and
female. Many studies have found the prevalence of OAB and it symptoms increases with
age in both genders (Eapen & Radomski, 2016). The utilization of the ABSST helped
facilitate an increased awareness by the providers at the Healthcare Clinics in Walgreens,
to rountinely screen their patients for OAB symptoms. The educational module on OAB
showed no significance for providers increasing their level of knowledge. However,
provider support is essential in educating and screening patients about their OAB
condition. Patient awareness of symptoms can reduce stress and improve quality of life.
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Providers need to be encouraged to routinely screen their patients for OAB symptoms
and incoporate it into their daily practice.
5.11 PRACTICE IMPLICATIONS
This study represents an initial starting entry point in raising awareness about the
prevalence of OAB and importance of providers initiating the discussion with their
patients. This can empower patients to know when to seek help from their providers. This
results suggest that the ABSST is likely to improve patient outcomes for patients who are
screened and if criteria met, treatment is started early. The rising prevalence of OAB
creates a burden for individuals and society and increases the potential for impaired
functional status and lower health-related quality of life (Barile et al., 2015). The indirect
costs include impaired work productivity and activity, clinically and statistically poorer
general and disease-specific health related quality of lif, and statistically higher rates of
OAB-related surgery, hospitalizations, physician visits and pad use (Cardozo et al.,
2014). The study results suggest that the use of ABSST in adult patients can lead to
enhancing patient care and an increased patient awareness of OAB symptoms.
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Evidence Levels

Quality Guides

Level I
Experimental study, randomized controlled trial (RCT)
Systematic review of RCTs, with or without meta-analysis
Level II
Quasi-experimental study
Systematic review of combination of RCTs and quasiexperimental, or quasi-experimental studies only, with or
without meta-analysis
Level III
Non-experimental study
Systematic review of a combination of RCTs, quasiexperimental
and non-experimental studies, or non-experimental studies only,
with or without meta-analysis
Qualitative study or systematic review with or without a metasynthesis

A High quality: Consistent, generalizable results; sufficient
sample size for the study design; adequate control; definitive
conclusions; consistent recommendations based on
comprehensive literature review that includes thorough reference
to scientific evidence
B Good quality: Reasonably consistent results; sufficient
sample size for the study design; some control, fairly definitive
conclusions; reasonably consistent recommendations based on
fairly comprehensive literature review that includes some
reference to scientific evidence
C Low quality or major flaws: Little evidence with
inconsistent results; insufficient sample size for the study design;
conclusions cannot be drawn

Level IV
Opinion of respected authorities and/or nationally recognized
expert committees/consensus panels based on scientific evidence
Includes:
• Clinical practice guidelines
• Consensus panels
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Level V
Based on experiential and non-research evidence
Includes:
• Literature reviews
• Quality improvement, program or financial evaluation
• Case reports

A. High quality: Material officially sponsored by a
professional, public, private organization, or government
agency; documentation of a systematic literature search
strategy; consistent results with sufficient numbers of
well-designed studies; criteria-based evaluation of
overall scientific strength and quality or included studies
and definitive conclusions; national expertise is clearly
evident; developed or revised within the last 5 years
B. Good quality: Material officially sponsored by a
professional, public, private organization, or government
agency; reasonably thorough and appropriate systematic
literature search strategy; reasonably consistent results,
sufficient numbers of well-designed studies; evaluation
of strength and limitations of included studies with fairly
definitive conclusions; national expertise is clearly
evident; developed or revised within the last 5 years
C. Low quality or major flaws: Material not sponsored by
an official organization or agency; undefined, poorly
defined, or limited literature search strategy; no
evaluation of strengths and limitations of included
studies, insufficient evidence with inconsistent results,
conclusions cannot be drawn; not revised within the last
5 years
Organizational Experience:
A High quality: Clear aims and objectives; consistent results
across multiple settings; formal quality improvement, financial
or program evaluation methods used; definitive conclusions;
consistent recommendations with thorough reference to
scientific evidence

•

Opinion of nationally recognized expert(s) based on
experiential evidence

B Good quality: Clear aims and objectives; consistent results in
a single setting; formal quality improvement or financial or
program evaluation methods used; reasonably consistent
recommendations with some reference to scientific evaluation
C Low quality or major flaws: Unclear or missing aims and
objectives; inconsistent results; poorly defined quality
improvement, financial or program evaluation methods;
recommendations cannot be made
Literature Review, Expert Opinion, Case Report,
Community Standard, Clinician Experience, Consumer
Preference:
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A High quality: Expertise is clearly evident; draws definitive
conclusions; provides scientific rationale; thought leader(s) in
the field
B Good quality: Expertise appears to be credible; draws fairly
definitive conclusions; provides logical argument for opinions
C Low quality or major flaws: Expertise is not discernable or
is dubious; conclusions cannot be drawn
©The Johns Hopkins Hospital/The John Hopkins University
Adapted from Dearholt, S.L., & Dang, D. (2012). John Hopkins Nursing Evidence-Base Practice: Model and Guidelines (2nd ed.).
Indianapolis, IN: Sigma Theta Tau International.
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validity/
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Setting
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Limitations

Conclusions

Observational
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the validity
could be
generalization of the
findings from
one hospital
to another.

84 subjects
screened.

Descriptive
statistics.

50 patients
enrolled in the
study and the
return rated of
questionnaire
was 100%.

All statistical tests
were two-tailed and
conducted with a
significant level of
0.05.

The 3-day
micturition
diaries can be
troublesome
for some
patients and
data are not
immediately
amenable for
statistical
analysis in the
research
setting.

The testretest
reliability
was
excellent
for
OABSS
total
score.

Quality
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the original
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Japanese
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study done
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patients, and
as such, there

Exclusion
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was for any
patients with
(1) significant

All analyses used
the Statistical
Package of Social
Sciences (SPSS).

The
simplicity
of this tool
might
make it
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version of the
overactive
bladder
symptom
score
(OABSS) and
its correlation
with standard
assessment
tools. The
Indonesian
Journal of
Internal
Medicine,
44(3):214-221
Retrieved
from
http://wwwncbi-nlm-nihgov.pallas2tcl.
sc.edu/pubme
d/22983076

Observational

Bladder Society,
the OABSS was
validated in
Japanese
population and
translated to local
languages of
interest.
Patients ≥ 18
years with
established
overactive
bladder, (OAB)
completed 3-day
micturition
diaries and
questionnaires
for the OABSS,
International
Prostate
Symptom Score
(IPSS), and
Patient
Perception of
Bladder
Condition

was concern
about
translation to
local
language of
interest

stress
incontinence or
mixed
stress/urge
incontinence as
the
predominant
factor, (2)
indwelling
catheter, (3)
symptomatic
urinary tract
infection (4)
previous pelvic
radiation
therapy or
current
malignant
disease of the
pelvic organs,
(5) treatment
for OAB that
started,
stopped or
changed within
4 weeks of the
screening

Internal correlation
coefficient (ICC)
was 0.83.
The test-retest
reliability of the
Indonesian OABSS
was found to be
excellent and for
each of the four
individual items of
the Indonesian
OABSS, the
weighted Kappa
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representing
moderate to good
agreement.
The correlations
with a 3-day
micturition diary of
total pads used
based on 3-day
micturition diary of
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Validated tools
have
demonstrated
clinical use
with a certain
range, but one
common
shortcoming is
that they do
not evaluate
actual
symptoms.

useful and
feasible
for
clinical
practice
that has
limited
time and
resources.

Study
Evidence
Level: IIb
Quality: Good

(PPBC) on 2
separate visits.
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Test-retest
reliability was
examined using
the internal
correlation
coefficient (ICC)
and weighted
Kappa
coefficients
between the first
and second
applications of
the OABSS.
Pearson or
Spearman
correlation
coefficients were
calculated to test
the correlation of
OABSS with
IPSSS, IPSS
Quality of Life
(QOL) item,
PPBC and

period, (6)
diabetic
neuropathy,
and (7)
patient’s
receiving
certain drugs
such as
anticholinergic
or
antispasmodic
drugs.
Recruited from
3 hospitals in
Indonesia from
12/11/09 to
9/20/10

total voided volume
and frequency of
nocturia were weak
(Pearson correlation
coefficient were
0.22—0.44 at Visit
1, and 0.10-0.27 at
Visit 2).
The OABSS total
score showed a
moderate degree of
correlation with the
IPSS total score
(Spearman
correlation
coefficient = 0.41 at
Visit 1 and 0.45 at
Visit 2).

clinical variables
of the 3-day
voiding dairy.
2
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Basra, R.K.,
Cortes, E.,
Khullar, V., &
Kelleher, C.
(2012). A
comparison
study of two
lower urinary
tract
symptoms
screening
tools in
clinical
practice: The
B-SAQ and
OAB-V8
questionnaires
. Journal of
Obstetrics and
Gynaecology,
32(7), 666671).

The aim of the
study was to
compare the
value of two
validated
questionnaires:
Bladder Control
Self- Assessment
Questionnaire
(B-SAQ) and the
Overactive
Bladder
Awareness Tool
(OAB-V8).
Patient were not
recruited on the
basis of
presenting
symptoms. All
female patients
attending the
clinics were

Threats to
the validity
was the
selection bias
as all patients
were from
general
gynecology
and urology
clinics and
not primary
care setting.

223 women
participated
and were
recruited from
general
gynecology
and
urogynecology
clinics in two
London
teaching
hospitals.

Study results were
analyzed using
SPSS version 15.
Only fully
completed
questionnaires were
used for statistical
analysis and 219
responses were
used for data
analysis. (Four
patients left
incomplete
responses).

The mean age
of women was
49 years (range
The receiver
19-84).
operating curve
(ROC) curve
identifying stress
incontinence was
0.85 and 0.68 for
the B-SAQ and
OAB-V8,

Patients unable
to read or
understand
English were
excluded.
OAB-V8 is a
poor test for
stress
incontinence
and a fair test
for mixed
incontinence.
A condition
specific
questionnaire
such as OABV8 may be too
specific and
lead to
exclusion of a

The study
confirms
that both
the BSAQ and
OAB-V8
perform
well in
identifyin
g OAB
symptoms
, and as
such, are
suitable to
screen for
OAB in
both the
clinical
and
research
setting.

Retrieved
from
http://dx.doi.o
rg/10.3109/01
443615.2012.
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Comparison
Study
Evidence
Level: IIIb
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Quality: Good

handed the study
pack consisting
of a patient
information
leaflet and
consent form,
standardized
questionnaire
detailing
patient’s
demographic data
and the B-SAQ
and OAB-V8
questionnaire.
B-SAQ is an 8item
questionnaire that
evaluates the
symptoms of
urinary
frequency,
urgency, nocturia
and urinary
incontinence and
associated bother.

respectively, which
shows that the BSAQ is a good test
and the OAB-V8 is
poor test for stress
incontinence.
Cohen’s Kappa
calculations in
patients with a
clinical diagnosis of
OAB showed
values of 0.2 for
both B-SAQ and
OAB-V8
questionnaires
(p<0.01); indicating
fair agreement
between both
questionnaires and
the clinical
diagnosis.
The B-SAQ lower
urinary tracts
screening
questionnaire was

large affected
population.
.

found to be a better
test for stress and
mixed urinary
incontinence
identification than
the OAB-V8.

The OAB-V8 is
an 8-item
questionnaire that
assesses
symptom bother
and quality of life
(QoL) impact of
OAB.
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Data was
collected from
patients who
agreed to take
part in the study.
All patients fully
completed the BSAQ
questionnaire
3

Juliato, C.R.,
Baccaro, L.F.,
Pedro, A.O.,
Costa-Paiva,
L., Lui-Filho,
J., Pinto-Neto,
A.M.(2016).

A descriptive,
exploratory,
cross-sectional
study.
The dependent
variable was

Threat to the
reliability
was some
variables
such as
genital
prolapse, the

820 women
invited to
participate.
749 women
participated.

Mean age was 52.5.
With regard to
menopausal, 16%
were
premenopausal,
16%
perimenopausal and

Some women
may minimize
urinary
symptoms with
in-person
interviews.

Health
profession
als should
adopt
proactive
behavior
in
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Subjective
urinary
urgency in
middle age
women: A
populationbased study.
Maturitas,
85(82-87).
Retrieved
from
http://wwwncbi-nlm-nihgov.pallas2.tcl
.sc.edu/pubme
d/26857885

OAB and the
independent
variables were
sociodemographi
c data, health
related habits and
problems, selfperception of
health, and
gynecological
background.

All analyses
were performed
using IBM SPSS
version 20 and
Stata version 7.
Bivariate analysis
using the chiDescriptive,
square test, and
exploratory,
Poisson
cross-sectional regression using
study
back selection
criteria.
Evidence
Level: IIb

presence of
bacteriuria
and
complains
associated to
lower urinary
tract
symptom.

Inclusion
criteria were
native
Brazilian
women, aged
45-60 years
and residing in
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metropolitan
region of
Campinas.

68%
postmenopausal.
The prevalence of
OAB was 7.8%.
The vast majority
of women had only
urinary urgency.
Only two women
who responded to
the interview
reported urge
incontinence. In the
final statistical
model, vaginal
dryness (Poisson
Regression 2.21;
95% Clinical
Interval 1.11-4.40;
p=0.025) were
associated with
greater prevalence
of OAB.

The results
were based on
self-reporting
and
uncertainties
may have
occurred.

surgically
menopaus
al women
and those
with a
history of
genital
atrophy to
identify
and treat
OAB, thus
contributi
ng to an
improved
quality of
lift and
healthier
aging.
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Coyne, K.S.,
Sexton, C.C.,
Irwin, D.E.,
Kopp, Z.S.,
Kelleher, C.J.,
Milsom, I.
(2008). The
impact of
overactive
bladder,
incontinence
and other
lower urinary
tract
symptoms on
quality of life,
work
productivity,
sexuality and
emotional
well-being in
men and
women:
results from

A nested casecontrol analysis
was performed
on men and
women with
(cases) and
without
(controls) OAB,
from the EPIC
study. Based on
their responses to
questions about
lower urinary
tract symptoms
(LUTS) cases
were classified
into five groups:
continent OAB,
OAB with
incontinence,
OAB +
postmicturition,
OAB + voiding,
and OAB

The CES-D
scale has
confirmed
reliability
and validity
and has been
used in both
continent and
incontinent
OAB
populations.
The PPBC
has a good
construct
validity,
responsivene
ss to change,
and testretest
reliability
among
patients with
OAB.

Many
questionnaires
used to
evaluate the
impact of
LUTS were
OAB-specific,
as an objective
of this study
was to explore
the prevalence
A populationand impact of
based, cross
OAB. It is
sectional
possible that
telephone
the use of a
survey of
less OABThere were
adults aged
specific
significant
over 18, was
measures
conducted in in differences between would yield a
cases and controls
five countries
different
in all reported
(Canada,
pattern of
LUTS.
Germany,
results.
Italy, Sweden,
The OAB +
and the UK).
postmicturition +
Of the EPIC
participants,
1434 identified
OAB cases
were matched
by age, gender
and country,
with 1434
designated as
controls.

Comorbid
conditions differed
significantly by
case/control status,
with cases reporting
significantly greater
rates of chronic
constipation,
asthma, diabetes,
high blood
pressure, bladder or
prostate cancer,
neurological
conditions and
depression.

The
diagnosis
and
treatment
of OAB
should be
considered
in
conjunctio
n with
LUTS, to
maximize
treatment
options
and
optimize
patient
outcomes.

the EPIC
study. BJU
International
101(13881395).
Retrieved
from
http://scholar.
google.com
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doi:10.1111/j.
1464410X.2008.07
60x

Symptom
prevalence
study
(prospective
cohort).

Evidence
Level: Ib

+postmicturition
+ voiding. Both
control and cases
were asked
questions about
symptom bother
(OAB-q), generic
quality of life
QoL (EQ-5D),
work
productivity
(Work
Productivity and
Activity
Impairment,
WPAI),
depressive
symptoms
(Center for
Epidemiologic
Studies
Depression Scale,
CES-D), sexual
satisfaction, and
erectile
dysfunction (men
only) using the

No threats to
validity/relia
bility were
noted

voiding group
reported
significantly greater
symptom bother,
worse HRQoL,
higher rates of
depression and
decreased
enjoyment of
sexual activity, than
the other
subgroups.

Controls were
not asked any
questions,
which limits
the casecontrol
comparisons.
The OAB and
LUTS
classifications
used are based
entirely on
patientreported
symptoms;
there was no
urodynamic
testing to
confirm the
type of LUTS,
nor was there
confirmation
by a medical
professional.

Massachusetts
Male Aging
Study. Case
answered
additional
conditionspecific questions
HRQol (OAB-q
short form),
Patient
Perception of
Bladder
Condition,
PPBC, and work
productivity
related to a
specific health
problem (WPAISHP). General
linear models
were used to
evaluate group
differences.

de Ridder, D.,
Roumeguere,
T., Kaufman,

Data on OAB
and SUI were
prospectively

110

Quality: Good

5.

Possible
threat was
the external

Data was
collected on
7193 women,

About 33.9% had
mild BCS. Most
women reported

The study
population
consisted of

A
significant
proportion

111

L. (2013).
Overactive
bladder
symptoms,
stress urinary
incontinence
and associated
bother in
women aged
40 and above;
a Belgian
epidemiologic
al survey.
International
Journal of
Clinical
Practice,67(3)
,198-208.
Retrieved
from
https://eds.b.e
bscohost.com.
pallas2tcl.sc.e
du/ehost
doi:http://dx.d
oi.org.pallas2t

collected among
women ≥ 40
years by general
practitioners
(GP) during a
regular visit for
any reason. The
validated Bladder
Control SelfAssessment
Questionnaire
(B-SAQ) was
used and
complemented
with a question
on SUI and
bladder bother.
The presence of
mild bladder
control
symptoms (BCS)
was defined as an
overall B-SAQ
symptom score
(OSS) ≥ 4 and an

validity of
the
conclusions,
involve
generalizatio
ns of
research
findings to
other
settings.

with a mean
(SD) age of
61.0 (12.6)
years

overall mild OAB
symptoms (46.9)
and 34.9% had
moderate-to-(very)
severe symptoms.
The prevalence of
moderate-severe
urgency, frequency
or nocturia was
higher than that of
moderate-severe
incontinence.
Urgency and
nocturia were
considered the most
bothersome
symptoms.
Moderate-severe
stress urinary
incontinence (SUI)
affected 17.7% of
women. About
16.4% of women
reported to be
moderatelyseverely bothered
by their bladder in

women aged
≥40 years who
visited a GP
for any reason.
This sample
may not be
representative
of the general
population of
women ≥40
year and may
over-represent
women with
co-morbidities.

of women
aged 40
years and
older do
not only
have OAB
symptoms
, but also
consider
these
bothersome in
daily life.
Physicians
should be
Women may
proactive
have also felt
and
hindered or
engage in
embarrassed to conversati
indicate their
ons about
problems in the bladder
presence of the control
GP, causing
symptoms
underreporting. and
The B-SAQ is available
not a

cl.sc.edu/10.1
111/ijcp.1201
5

overall bother
score OBS ≥1.

Descriptive
Epidemiologic statistics were
al study
performed.
Evidence
Level: IIIb
Quality: Good
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6.

Qian-Sheng,
K., HannChorng, K.
(2010). Strong
correlation
between the
overactive
bladder
symptom
score and
urgency
severity score
in assessment

Patients with
clinical
symptoms of
frequency and
urgency were
prospectively
enrolled in this
study. The
Chinese version
of the OABSS
questionnaire,
which has been
linguistically

The OABSS
questionnaire
was
linguistically
validated

A total of 170
patients were
enrolled - 98
men and 72
women with a
mean age of
64.1 years.

everyday life. The
risk of severe
symptoms and
bother increased
with age. About
10% of women had
clinically
significant BCS
(OSS ≥ 7 and OBS
≥ 4).

diagnostic
questionnaire
and does not
assess whether
the symptoms
experienced
are actually
caused by
OAB or
whether other
pelvic
disorders are
present.

treatment
options.

A high OABSS
total score was
significantly
associated with a
high grade of USS.
There was a
significant
correlation between
the two scores
(R²=0.5520,
p<0.0001). The
main contributions
of the OABSS in

The OABSS
and the
Urogenital
Distress
Inventory short
form (UDI-6),
measure the
frequency and
urgency
episodes
during a given
period, but the
severity of

A strong
correlation
between
the
OABSS
and USS
based on a
voiding
diary was
noted in
patients
with OAB
and the

validated, and the
urgency severity
score (USS)
based on a 3-day
voiding diary
were recorded at
baseline. Patients
with clinically
diagnosed OAB
Retrieved
were treated with
from
solifenacin 5mg
Retrieved
daily for 1
from
month, and the
http://scholar. OABSS and USS
google.com
were repeated at
http://www.tz 1 week and 1
uchimedjnl.co month. The
OABSS and USS
m/
were compared at
doi:10.1016/s1 baseline, 1 week
016and 1 month after
3190(10)6004 treatment.
5-6

of patients
with
overactive
bladder
syndrome. Tzu
Chi Medical
Journal,22(2),
82-86.
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Prospective
study

patients with a low
USS were daytime
frequency and
nighttime
frequency. The
contribution of
urgency and
urgency urinary
incontinence
became significant
in patients with
high urgency
grades. The
changes in the USS
and OABSS were
significant at 1
month. The change
in frequency was
significant in the
daytime as well as
at nighttime.

urgency is not
assessed as a
quantitative
measure
reflecting real
life conditions.

changes in
these two
measures
were
similar
after
solifenacin
treatment.

Evidence
Level: IIb
Quality: Good
7.
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Tikkinen,
K.A.,
Auvinen, A.,
Johnson,
T.M., Wiess,
J.P., Keranen,
T., Tiitinen,
A., Polo, O.,
Partinen,M.,
Tammela,
T.L. (2009). A
systematic
evaluation of
factors
associated
with nocturia
– The
population
based FINNO
study.
American
Journal of

In a case-control
with prevalence
sampling, the
authors explored
the correlates for
nocturia and their
population-level
impact.
Questionnaires
contained items
on medical
conditions,
medications,
lifestyle,
sociodemographi
c and
reproductive
factors, urinary
symptoms, and
snoring. Nocturia
was defined as
≥2 voids/night. In

Threats to
the validity
include of
self-report
has not been
established
for all
characteristic
s considered.
The Finnish
population
may not be
directly
generalizable
to other
ethnicities
because
impact
measures
generally are

6000 subjects
(aged 18-79)
were randomly
identified from
the Finnish
Population
Register
(62.4%
participated,
53.7% were
female)

The factors with the
greatest impact at
the population level
were (urinary)
urgency
(attributable
number/1000
subjects (AN=24),
benign prostatic
hyperplasia
(AN=19), and
snoring (AN=16)
for men and
overweight and
obesity (AN=40),
urgency (AN=24),
and snoring
(AN=17) for
women.
Correlates included
prostate cancer and
antidepressant use

Alcohol
consumption
reporting was
incomplete, yet
nocturia
prevalence did
not vary by
alcohol
consumption
among those
reporting this
information.
There was no
information on
physical
activity,
although
physical
activity has not
previously

Although
several
correlates
were
identified,
none
accounted
for a
substantial
proportion
of the
population
burden,
highlighti
ng the
multifacto
rial
etiology
of
nocturia.

age-adjusted
analyses, factors
associated with
nocturia were
Retrieved
entered into a
from
multivariate
https://eds.b.e model. Backward
bscohost.com. elimination was
pallas2tcl.sc.e used to select
du/ehost/detail variables for the
final model, with
Doi:
http://dx.doi.o adjustments for
rg.pallas2.tcl.s confounding.
c.edu/aje/kwp
133

Epidemiology,
170(3), 361368.

context
specific.

for men, coronary
been related to
artery disease and
nocturia.
diabetes for
women, and restless
legs syndrome and
obesity for both
sexes.
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Case-control
study
Evidence
Level: 1a
Quality: High
8.

Barkin, J.
(2016).
Nocturia:
diagnosis and

The article
explores the
different causes
and types of

None noted

The article
discussed a
study based on
a survey of

When taking a
patient history, it is
important to
determine the onset

None noted

Nocturia
is
pervasive
in men

management
for the
primary care
physicians.
The Canadian
Journal of
Urology,
23(1),16-19.
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nocturia, then
describes how to
diagnose
different types of
nocturia
(including use of
frequencyvolume charts),
and last,
Retrieved
discusses
from
different
www.ncbiapproaches to
nlmmanaging
nih.gov.pallas nocturia
2.tcl.sc.edu/pu (including the use
bmed/269245 of desmopressin),
91
depending on the
Evidence level type and cause.
IVa
Clinical
practice
guidelines

more than
1400 people
diagnosed with
OAB.

and severity of the
nocturia, and also
find out if nocturia
is consistent or
intermittent.
Physicians need to
look for any
medical conditions
or drugs that may
cause nocturia.
Physicians should
then order all
appropriate testsurinalysis, urine
culture and
sensitivity test,
urine cytology test
(if indicated),
serum creatinine
test to rule out renal
failure (indicated),
order abdominal/or
pelvic ultrasound
(if indicated), and

and
women
who
present
with
LUTS.
Providers
need to
rule out
the other
medical
and nonmedical
causes of
LUTS.

frequency-volume
charts.
9.
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Hung, M.J.,
Chou, C.L.,
Yen, T.W.,
Chuang, Y.C.,
Meng, E.,
Huang, S.S.,
Kuo, H.C.
(2011).
Development
and validation
of the Chinese
overactive
bladder
symptom
score for
assessing
overactive
bladder
syndrome in a
RESORT
study. Journal
of the
Formosan
Medical

The Chinese
OABSS was
developed by
linguistic
validation of the
original version.
It reliability and
validity and
correlations with
a 3-day bladder
diary were tested
on patients with
OAB in a
multicenter study
conducted in
Taiwan (the
RESORT study).

A threat to
the Chinese
OABSS it
may not be
generalizable
to other
Mandarinspeaking
areas due to
the
difference in
simplified
and
traditional
Chinese
characters.

60 patients
with OAB who
visited
different
hospitals in
Taiwan were
enrolled in the
study. Patients
were
randomized
either
incontinent
(OAB wet,
n=31) or
continent
(OAB dry,
n=29)

The test-retest
reliability of the
Chinese OABSS
was moderate to
good, with
weighted kappa
coefficients of
0.515-0.721 for
each symptom
score and 0.610 for
the total symptom
score. Each
symptom score
correlated
positively with the
total OABSS
(Spearman’s rho
0.365-0.793) and
was internally
consistent
(Cronbach’s alpha
0.674). The
distribution of the
OABSS showed a

One concern is
that the
Chinese
OABSS was
developed and
validated in
Taiwan using
Taiwanese
patients and
traditional
Chinese
characters.
There are,
however many
differences
between
simplified
Chinese and
traditional
Chinese
characters. It
cannot be
applied
directly to

The
Chinese
OABSS
has been
developed
and
validated
as a
reliable
instrument
for
assessing
OAB
symptoms
. OABSS
can be an
alternative
to, but not
a
replaceme
nt for, a 3day
bladder
diary for

Association,
112, 276-282.
Retrieved
from
http://scholar.
google.com
Doi:10.1016/j.
jfma.2011.09.
020
Randomized
clinical trial
118

Evidence
level: IIa
Quality: High

clear separation
between OAB wet
(average 11.4,
range 7-15) and
OAB dry (average
7.97, range 4-10)
subgroups
(Wilcoxon exact
test, p<0.05). In
addition, the
OABSS items
correlated
positively with the
corresponding
bladder diary
variables
(Spearman’s rho
0.504-0.879) and
the degrees of
agreement
improved with
study visits except
for nighttime
frequency. The
Chinese OABSS
tended to
underestimate the

other
Mandarinspeaking areas.

assessing
patients.

frequency of
nighttime voiding.
10.
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Records of
women were
retrospectively
reviewed. The
patients had
undergone an
interview,
clinical
examination,
multichannel
urodynamic
studies and
translabial
ultrasound
examination.
Retrieved
Detrusor wall
from
thickness
http:eds.b.ebsc measurements
ohost.com.pall were taken at the
as2tcl.sc.edu/e bladder dome,
host/detail/det after bladder
emptying.
ail
Receiveroperator
Lekskulchal,
O., Dietz, H.P.
(2008).
Detrusor wall
thickness as a
test for
detrusor
overactivity in
women.
Uitrasound
Obstetrics &
Gynecology,
32(4):535539.

It was largely
a Caucasian
population
and there
may be
generalizabili
ty issues to
other races.

686 women’s
who attended a
tertiary
urodynamic
service from
November
2002 to
January 2006

Average detrusor
wall thickness in
the detrusor
overactivity group
was 4.7+/- 1.9mm
(mean +/- SD),
compared to 4.1 +/1.6mm in the nondetrusor
overactivity group
(p<0.001). Using a
cut-off of detrusor
wall thickness of
5.0mm gave a
sensitivity of 37%
and a specificity of
79% for diagnosing
detrusor
overactivity. The
ROC analysis
revealed an area
under the curve
(AUC) of 0.606

Urodynamic
testing is
invasive,
expensive,
time
consuming and
may be
technically
difficult.
The diagnostic
method did not
yield high
specificity or
sensitivity.
The
researchers did
not use a
transvaginal
ultrasound and
only measured
the dome.

Measurem
ent of
detrusor
wall
thickness
should not
be used as
a
diagnostic
parameter
for
detrusor
overactivit
y in
women.

Retrospectivel
y Review
study
Evidence
Level: IIIb
Quality: Good

11.
120

Levokowicz,
R., Whitmore,
K. E., Muller,
N. (2011).
Overactive
bladder and
nocturia in
middle-age
American
women:
Symptoms and
impact are
significant.
Urologic
Nursing.

characteristics
(ROC) analysis
was used to
identify the
optimal cut-off of
detrusor wall
thickness in
predicting
detrusor
overactivity.
American women
internet users
were surveyed
online from
March 18th to
March 31st 2009.
In addition, a
sample of 611
women were
surveyed in
regards to their
experiences and
attitudes about
treatment.

(95% CI, 0.560.65).

Threats to
the validity
were
generalizabili
ty may be
questioned
because the
sample was
drawn from
female users
of the
internet and
may not be
representativ
e of the
general US

1111 women
ages, 40 to 65
years of age,
online users

Women with
nocturia in this
study tended to
prolong seeking
treatment. Women
with OAB,
including nocturia,
were more likely
than women with
OAB, excluding
nocturia , to alter
their behavior in
social situations,
refrain from
physical activity
and intimacy, and

Participants
need to be able
to have access
and knowledge
of a computer
to answer
survey
questions

More
public
health
education
is needed
to
improve
consumer
knowledg
e about
OAB
including
nocturia
and
understan
ding of all

population in
the target age
group and
across all
desired
demographic
s

31(2):106111.
Retrieved
from
http://eds.b.eb
scohost.com.p
allas2.tcl.sc.ed
u/ehost/detail

cancel social plans
because of their
condition.

treatment
options
for its
symptoms
.

Descriptive,
cross-sectional
survey
121

Evidence
Level: Vb
Quality: Good
12.

Wells, M. J.,
Jamieson, K.,
Markham, T.
C.W., Green,
S.M, Fader,
M. J. (2014).
The effects of
caffeinated
versus

Newly diagnosed
women with
OAB and a
history of
caffeine
consumption
were randomly
allocated two
groups. Each

Threats to
the validity/
reliability the
small sample
size and
generalizabili
ty of the
findings

14 recruited,
but 11
completed the
study

A significant
reduction in
urgency (p<.01)
and frequency
(p<.05) of urinary
voids on day 3 of
the diary, total
ICIQ-OAB score
(p<.01), and a non-

Small sample
size of 11
participants.
No power
calculations
were
undertaken in
order to

The pilot
study
demonstra
ted that
reducing
caffeine
intake
may
alleviate

group taking
decaffeinated and
caffeinated
drinks for 14
days. The
periods were
preceded by a 14day run-in period
and interspersed
with a 14-day
washout period.
Retrieved
Primary
from
outcomes were
http://ovidssp.t episodes of
x.ovid.com.pal urgency,
las2.tcl.sc.edu/ frequency,
sp-3.18.Ob
volume per void,
Double-blind, and incontinence
obtained each
randomized,
period on 3-day
crossover
bladder diaries.
study
Secondary
Evidence
outcomes
Level: Ib
measures were
OAB symptoms
Quality: Good
severity and
health-related

decaffeinated
drinks on
overactive
bladder.
Journal of
Wound,
Ostomy &
Continence
Nursing.
41(4)371-378.
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significant
directional change
for the total ICIQOABqol score
(P=.065) was found
using sign tests for
the period of
decaffeinated
compared to
caffeinated drink
intake. No
significant
differences were
found for any
caffeine withdrawal
measures.

determine
sample size.
The trial did
not consider
the value of
episodic
analysis of
compliance
over the entire
treatment
period.

the
severity of
some
symptoms
and
healthrelated
QOL
factors
associated
with
OAB.

123

quality of life
(QOL) recorded
each period using
International
Consultation on
IncontinenceOveractive
Bladder Module
(ICIQ-OABQuality of Life
(ICIQ-OABqol)
tools. Effects of
caffeine
reduction were
measured each
day using visual
analogue scales.
13.

Gormley,
E.A.,
Lightner, D.J.,
Faraday, M.,
Vasavada,
S.P. (2015).
Diagnosis and
treatment of
overactive

Data extraction
None noted
conducted as part
of the Agency for
Healthcare
Research and
Quality Evidence
Report/Technolo
gy Assessment
Number 187

The reviewed
yielded 151
treatment
articles after
application of
inclusion/
exclusion
criteria. A
systematic

The amendment
focused on four
topic areas:
mirabegron,
peripheral tibial
nerve stimulation,
sacral
neuromodulation
and BTX-A. The

None noted

New
evidencebased
statements
and expert
opinion
supplemen
t the
original

bladder (nonneurogenic) in
adults:
AUA/SUFU
guidelines
amendment.
The Journal of
Urology. 193,
1572-1580.

124

titled Treatment
of Overactive
Bladder in
Women (2009).
That report
searched
PubMed,
MEDLINE,
EMBASE and
CINAHL for
Retrieved
English language
from OVID
studies published
http://dx.doi.o from January
rg/10.1016/j.ju 1966 to October
ro.2015.01.08 2008. The AUA
conducted
7
additional
Systematic
literature
review
searches to
capture
Evidence
populations and
Level Ib
treatments not
Quality: Good covered in detail
by the AHRQ
report and
relevant articles
published

review
conducted in
February 2014
identified 72
additional
articles
relevant to
treatment and
made up the
basis of the
2014
amendment.

additional literature
provided the basis
for an updated of
current guidelines
statements as well
as the incorporation
of new guideline
statements related
to the overall
management of
adults with OAB
symptoms.

guidelines
published
in 2012,
which
provided
guidance
for the
diagnosis
and
overall
manageme
nt of OAB
in adults.

through
December 2011.
14.

125

Fujimura, T.,
Kume, H.,
Tsurumaki,
Y.,
Yoshimura, Y,
Hosoda, C.,
Suzuki, M.,
Fukuhara, H.,
Enomoto, Y.,
Nishimatsu,
H., Homma,
Y. (2011).
Core lower
urinary tract
symptom
score (CLSS)
for the
assessment of
female lower
urinary tract
symptoms: A
comparative
study.
International

Three
questionnaires:
Core lower
urinary tract
symptoms
(CLSS);
International
Prostate
Symptom Score
(IPSS); and
Overactive
Bladder
Symptom Score
(OABSS), were
completed.
Quality of life
(QOL) was
determined as per
IPSS quality of
life Index. The
clinical diagnoses
were overactive
bladder, mixed
incontinence,

Japanese
women were
studied and
the
generalizabili
ty of this
study is
called to
question.

318 female
patients, ages
ranging from
15 -91.

All symptom scores
were significantly
increased in
symptomatic
women. The CLSS
described the
symptom profile of
patients with
distinct conditions.
The scores of
corresponding
symptoms on the
three questionnaires
were significantly
correlated (r=0.510.85; all P<0.0001).
Multivariate
logistic regression
modeling proved
five CLSS
symptoms (daytime
frequency, nocturia,
urgency
incontinence,

The IPSS was
designed for
men with BPH
and may have
a limited
ability to
illustrate
female LUTS,
such as
incontinence
symptoms.
The Bristol
Female Lower
Urinary Tract
Symptoms
(BFLUTS) is a
questionnaire
for women, but
may not be
readily
accepted for
daily use by
clinicians

The IPSS
alone does
not fully
evaluate
female
LUTS,
with a
possible
negative
impact on
QOL.
Using the
CLSS
questionna
ire would
enable a
simple
and
comprehe
nsive
assessmen
t of female
LUTS.

stress
incontinence,
pelvic organ
prolapse,
interstitial
Retrieved
cystitis, bacterial
from Web of
cystitis,
Science
underactive
http://apps.we bladder and
bofknowledge. other. Simple
com.pallas2.tc statistics and the
l.sc.edu/full_r relationship
ecord.do?prod between
uct=WOS&se symptom scores
and poor QOL
arch-mode
(QOL Index≥4)
Comparative
were examined.
Study
Journal of
Urology,
18(11)778784.
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Evidence
Level: IIIb
Quality: Good

straining, and
owing to a
urethral pain) as
large burden.
independent
predictors of poor
QOL, with hazard
ratios ranging from
2.0 to 4.2. The IPSS
included only two
(urgency and
straining)
significant
symptoms.

15.

127

Kinsey, D.,
Pretorius, S.,
Glover, L.,
Alexander, T.
(2016). The
psychological
impact of
overactive
bladder: A
systematic
review.
Journal of
Health
Psychology,
21(1)69-81.
Retrieve from
PsycINFO
http://sagepub.
co.uk/journals
Permissions.n
av
Systematic
review

Electronic
databases (Web
of Knowledge,
PsycINFO,
MEDLINE and
CINAHL) were
searched for
published articles
evaluating the
impact of OAB
on psychological
well-being.
All studies were
cross-sectional.

Most studies
in this review
were
assessed
using selfreport
questionnaire
s. This may
have led to
participants
being
included/
excluded
from OAB
group on the
basis of
different
individual
views of
“urgency”,
skewing the
results.

Electronic
searches
generated 3699
results.

Majority of studies
investigated nine
areas: depression,
anxiety,
embarrassment/
32 articles on
shame, self-esteem,
psychological
sleep, relationships
impact of OAB and impact on
were included others, sexual
in the review.
relationships, social
life and QoL.

Research has
suggested that
there is
disagreement
among
physicians I
the way OAB
is and should
be defined.
The lack of
clarity about
the definition
of OAB may
also create
difficulties in
researching the
condition,
particularly as
OAB’s key
symptom,
urgency,
cannot be
assessed
objectively.

This
review
provides
an
overview
of the
current
research
on the
psycholog
ical
impact of
OAB.
Psycholog
ical health
should be
considered
an
important
aspect of
managing
OAB, and
further
research is
required
to
determine

Evidence
Level: Ib

how to
best
provide
psycholog
ical care
and
support in
this area.

Quality: Good

16.
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Cardozo, L.,
Staskin, D.,
Currie, B.,
Wiklund, I.,
Globe, D.,
Signori, M.,
Dmochowski,
R.,
MacDiarmid,
S., Nitti,
V.W.,
Noblett, K.
(2014).
Validation of
a bladder
symptom
screening tool
in women

Prospective,
observational
study.
100 women
completed the
Actionable
Bladder
Symptoms
Screener Tool
(ABSST), OAB
Questionnaire
Short Form
(OAB-q SF), and
a patient global
impression of
severity (PGI-S)
scale. Half of the

A subset of
10 patients
with OAB
and UUI also
participated
in a one-toone cognitive
interview
during the
study visit.
This is too
small a
sample size
to draw
definitive
conclusions
and as a such
the

100 women
from six
gynecological
clinics located
in the USA.
Clinic staff
identified
potential study
participants
through
database and
chart reviews
and then, using
a standard
recruitment
and screening
script,
contacted

53 women with
UUI/OAB and 47
controls took part
(71& Caucasian).
Patients with
UUI/OAB were
older (54.6 vs 40.4
years), had a higher
body mass index
(31.1 vs
26.4kg/m²), and
more comorbid
conditions. The
Cronbach’s alpha
reliability of
ABSST was 0.90.
High correlations
with OAB-q SF

Qualitative
results should
be interpreted
with some
caution, as it is
difficult to
draw definitive
conclusions
around content
validity with a
sample of 10
patients.
The women
enrolled in the
study
represented a
group of

The
previous
MS
ABSST
scoring
algorithm
was
validated
in a nonneurogeni
c female
population
. ABSST
is a
reliable,
valid, and
sensitive
tool for
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with
incontinence
due to
overactive
bladder.
International
Urogynecolog
ic Journal,
25:16551663.
Retrieved
from Web of
Science.
Doi:10.1007/s
001192-0142417-7

Evidence
Level: IIb
Quality: Good

sample had
urinary urgency
incontinence
(UUI), while the
other half did not.
Descriptive
statistics,
reliability, and
validity were
examined, as was
sensitivity and
specificity of the
previous cut-off
score established
in patients with
multiple sclerosis.
IRB was
approved for 6
clinics.

generalizabili
ty to lower
educated
women is
limited. Most
women who
participated
were
relatively
highly
educated.
However, the
results
showed that
the ABSST
was a
reliable
instrument,
as
demonstrated
by its high
internal
consistency
coefficient.

prospective
participants to
gauge interest
in participation
and ascertain
eligibility for
the study.

Symptom Bother
and Health Related
Quality of Life
(r=0.83 and -0.81
respectively)
supported
concurrent validity.
Using the PGI-S
severity scores as a
reference, the
ABSST was able to
distinguish patients
with differing
severity levels
(known-group
validity). Physician
assessment of the
need for further
evaluation/treatmen
t showed sensitivity
(79%) and
specificity (98%),
supporting a cut-off
score of greater
than or equal to 3.

patients who
were relatively
well educated
and also
willing to
discuss their
lower urinary
tract symptoms
in a research
setting.
Study
participants’
responses may
not be
reflective of
patients who
have not
presented for
treatment
and/or who
would be less
willing to
discuss their
symptoms with

women
with
UUI/OAB
.

a healthcare
provider.
The diagnosis
of OAB was
based on the
clinician’s
report without
a consistent
definition
across
clinicians.
130

There was no
inter-rater
reliability of
diagnosis or
referral for
treatment was
evaluated.

17.

Jongen, P.J.,
Blok, B.F.,
Heesakkers,
J.P., Heerings,
M., Lemmens,

Observational
noninterventional
web-based study

Generalizabil
ity of results
as this were
patients with
multiple

141 MS
patients from
Netherlands.
106 females
and 35 males.

For cut-off point 3
the outcomes (Test
1 and 2) were: Test
Positive (TP)
43.26%, 40.88%;

Data was
acquired via
patient selfreport.

The study
findings
suggest
that in MS
patients
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W.A.,
Donders, R.
(2015).
Simplified
scoring of the
Actionable 8item
screening
questionnaire
for
neurogenic
bladder
overactivity in
multiple
sclerosis: a
comparative
analysis of
test
performance
at different
cut-off points.
BMC
Urology, 15
(106).
Retrieved
from

Assessed the testretest reliability
and concurrent
validity of a
Dutch version of
the English
Actionable
questionnaire.
Compared the test
performance of
the simplified
scoring with cutoff point 3 with
that of cut-off
point 2, using the
original scoring
with cut-off point
6 as a gold
standard.
Associations
between positive
test result and
urological
treatment, and
bladder-specific

sclerosis
(MS) in
Netherlands.

Test negative (TN)
29.79%, 32.85%;
False Positive (FP)
0.00%, 0.00%;
False Negative
(FN)26.95%,
26.28%; Sensitivity
0.62, 0.61;
Specificity 1.00,
1.00; Positive
Predictive Value
(PPV) 1.00, 1.00;
Negative Predictive
Inclusion
Value (NPV) 0.53,
criteria used:
0.55; Accuracy
(1) have an MS 0.73, 0.74; and for
diagnosis (2)
cut-off point 2: TP
no relapse in
59.97%, 59.85%;
last 30 days (3) TN 26.95%,
willing and
31.39%; FP 2.84%,
able to comply 1.46%; FN 10.63%,
with
7.30%; Sensitivity
requirement of 0.85, 0.89;
the protocol,
Specificity 0.90,
i.e. online
0.96; PPV 0.95,
completion of
0.98; NPV 0.72,
questionnaires
Ages ranged
from 24 years
to 73 years.
Recruited from
January 2015
to May 2015.
Patients gave
informed
consent prior
to participating
in web-based
study.

Given
prevalence of
cognitive
impairments in
MS patients,
this may
interfere with
the quality of
the data and
conclusions.

the
simplified
Actionabl
e scoring
is more
accurate
with cutoff point
2, by
reducing
false
negative
outcomes;
while in
OAB
patients a
cut-off
point of 3
strongly
distinguis
hes
between
patients
who
should be
treated vs.
those who

bmcurol.biom
edcentral.com
/articles/10.11
86/s12894015-0100-z

Observational
study
Evidence
Level:
132

IIIa

drug treatment
were calculated.

and having the
Expanded
Disability
Status Scale
score assessed
by phone.

0.81; Accuracy
0.87, 0.91.
Cut-off 3
completely
prevented FP
outcomes, but
wrongly classified
26% of the patients
as negative (FN).
Cut-off 2 reduced
the FN to 7-10%,
with low FP values
(2.84-1.46%).

Quality: High
With cut-off 2, the
percentage of
patients screened
positive was higher
in the Progressive
group (75%) than in
the Relapsing
Remitting group
(56.25%)
(P=0.0331), which

do not
require
treatment.

was not the case
with cut-off 3.
Only a positive test
according to the
original scoring
was associated with
both urological
treatment
(P=0.0119) and
bladder-specific
medication
(P=0.0328).
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18.

Eapen, R.S.,
Radomski, S.
B. (2016).
Gender
differences in
overactive
bladder. The
Canadian
Journal of
Urology,
23(1):2-9.

The article
discusses various
LUTS and OAB
studies and
describes ways to
evaluate and treat
patients who
present with
symptoms
suggestive of
OAB.

None noted

The article
discussed fours
studies OAB
symptoms,
their findings
and prevalence
and impact on
quality of life.

Prevalence of OAB
and its symptoms
increases with
increasing age in
both genders.
Urinary urge
incontinence more
common in women.
Treatment should
take on a
multidisplinary
approach with

None noted

OAB is
common
in both
men and
women.

Retrieved
from google
scholar.

implementation of
lifestyle
modification s and
behavioral therapies
alongside
pharmacotherapy
for most optimal
outcome.

Clinical
practice
guidelines
Evidence
level IVa
Quality: High
19.
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Jafarabadi,
M.,
Jafarabadi, L.,
Shariat, M.,
Rabie
Salehi,G.,
Haghollahi,
F., Rashidi,
B.H.(2015).
Considering
the prominent
complaint as a
guide in
medical
therapy for

Randomized,
double-blind,
parallel group
trial
The study was
designed to
determine the
effectiveness of
oxybutynin (5mg
immediate
release{IR}
tablet, three times
a day) versus
tolterodine (2mg

Generalizabil
ity of study
findings to
other
countries
with diverse
populations.

410 patients
screened
301
randomized.

151 and 150
patients in the
oxybutynin
This study
and tolterodine
was
performed on groups,
respectively.
patients in a
women’s
Exclusion
clinic in
criteria:
Tehran, Iran. lactation,

Mean
improvements in
the terms of
urgency (P=0.64)
and urge
incontinence
(P=0.75) showed an
insignificantly
larger score in
patients who were
treated by
oxybutynin.
Improvement in
night-time urinary

Small sample
size, short
follow-up
duration and
the subjective
nature of the
follow up

Oxybutyni
n and
tolterodine
showed
similar
efficacy
on
daytime
symptoms
of
overactive
bladder
and
similar
side

overactive
bladder
syndrome in
women over
45 years.
Journal of
Obstetrics &
Gynaecology
Research,
41(1):120-126
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DOI:http://dx.
doi.org.pallas
2.tcl.sc.edu/10
.1111/jog.124
83
Randomized
clinic trial
study
Evidence
Level: Ib
Quality: Good

IR tablet every 12
hours) in a 12week treatment of
OAB in women
over 45 years.

suspicion of
pregnancy,
glaucoma,
acute or
repetitive
urinary
infection,
significant
stress urinary
incontinence,
myasthenia
gravis,
neuropathy,
mental
disorder, gross
renal, hepatitis
or
cardiovascular
disorders,
obstruction in
urinary bladder
outlet, history
of
genitourinary
operations,
interstitial
cystitis,

urgency and
nocturia (41.2%
and 54.3% vs
39.7% and 40.1%
in oxybutynin vs
tolterodine groups,
respectively) were
shown to be more
improved by
tolterodine in
comparision to
oxybutynin (P=0.72
and 0.04 for nighttime urinary
urgency and
nocturia,
respectively)
Discontinuation of
treatment due to
adverse events was
not significantly
different in the two
groups.

effects in
perimenop
ausal
patients.
For
patient
with the
chief
complaint
of
nocturnal
frequency,
prescriptio
n of
tolterodine
is
preferably
suggested.
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unexplained
hematuria,
urinary
catheterization,
concomitant
antimuscarinic
medication,
electrostimulati
on therapy or
bladder
training,
allergy to
oxybutynin or
tolterodine, or
treatment with
this drugs in
the 3 months
before
randomization
and exposure
to any other
investigational
drug in the
preceding 2
months

20.
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Palma, T.,
Raimondi, M.,
Souto, S.,
Fozzatti, C.,
Palma, P.,
Riccetto, C.
(2013).
Prospective
study of
prevalence of
overactive
bladder
symptoms and
child-bearing
in women in
reproductive
age. Journal
of Obstetrics
&
Gynaecology
Research,
39(8):13241329.
DOI:
http://dx.doi.o
rg.pallas2tcl.s

Premenopausal
women were
interviewed to
ascertain the
prevalence of
OAB symptoms.
Patients were
approached to
complete the
International
Consultation on
Incontinence
QuestionnareOveractive
Bladder (ICIQOAB)
questionnaire.
A validated ICIQOAB Portuguese
version, with
specific
questionnaire for
the demographics.

External
validity due
to
generalizatio
n of results
as
questionnaire
performed in
public
places.

1052 women
of childbearing age
(20-45 years)
in Campinas,
Brazil,
1400
questionnaires
were filled.
348 were
excluded as
they did not
meet the
inclusion
criteria.

Multiparous and
primiparous women
showed
significantly higher
scores in the ICIQOAB questionnaire
than nulliparous
women,

The nonparametric
analysis.

Study
performed in
mostly public
places, which
made it
Multiparous women impossible to
perform
presented more
physical
frequency than
nulliparous women assessments in
participants.
(P<0.0001).

No significant
difference was
found in urgency
Exclusion
(P=0.0682), and
criteria:
multiparous women
diabetes
presented more
mellitus,
urgency
chronic lung
incontinence than
disease, history nulliparous ones
of recurrent
(P=0.0313).
urinary tract
infections,
current urinary

Nulliparou
s women
presented
fewer
OAB
symptoms
than
primiparo
us women.

Multiparo
us women
presented
more
symptoms
Data relied on than the
the information other two
given by the
groups.
women in the
questionnaires. No
significant
difference
s between
cesarean
and
vaginal
delivery,

c.edu/10.1111
/jog.12063
Epidemiologi
cal study
Evidence
Level:IIIb
Quality: Good

138

tract infection,
neurological
diseases and
other
conditions that
can predispose
to neurogenic
detrusor
overactivity,
and patients
who underwent
surgery for
urinary
incontinence
and other
major pelvic
surgery.

but the
scores of
women
who had
vaginal
delivery
were
higher
than those
who had
cesareans.
Both types
of
delivery
were
related to
higher
ICIQOAB
questionna
ire scores
than those
of
nulliparou
s women.

21.
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Al-Ghazo,
M.A.,
Ghalayani, I.
F., Al-Azab,
R., Hani, O.
B., Matani,
Y.S., Haddad,
Y. (2011).
Urodynamic
detrusor
overactivity in
patients with
overactive
bladder
symptoms.
International
Neurourology
Journal,
15:48-54.

A study to
evaluate the
relationship
between
urodynamic
detrusor
overactivity (DO)
and OAB
symptoms in men
and women.
Records were
reviewed of
patients who
attended a tertiary
referral center for
urodynamic
evaluation of
OAB syndrome
symptoms with

Generalizabil
ity of the
results to the
entire
population

Results
reviewed of
209 adult nonneurogenic
patients (117
men and 92
women) in a
urodynamic
specialist
referral testing
center.

Incidence of DO
was 76.1% and
58.7% in male and
female OAB
patients,
respectively.

Performed
between
February 2002
and February
2007.

Of men 63% and
61% of women
with urgency (OAB
dry) had DO, while
93% of men and
69.8% of women
with urgency and
urgency urinary
incontinence (OAB
wet) had DO.

Exclusion
criteria:
neurological,

Of women, 58%
who were OAB wet
had stress urinary

The study was
retrospective.

There was
better
correlation
A validated
in results
urgency scale
between
that measures
OAB
urgency rather symptoms
than bladder
and the
sensation was
urodynami
needed.
c
diagnosis
The study
of DO in
compares
men than
subjective
symptoms with in women,
more so in
objective
OAB wet
parameters.
than in
Follow-up data OAB dry.
was lacking in
some patients.

DOI:10.5213/
inj.2011.15.1.
48
Retrospective
Study
Evidence
Level: IIIb
Quality: Good

the presence or
absence of DO.
DO was
calculated for
symptoms alone
or in
combinations.

vesical,
bladder outlet
and pelvic
floor diseases
or surgery.

incontinence
symptom with
26.4% having
urodynamic stress
incontinence.
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6% of men and
6.5% of women
with OAB
symptoms had
urodynamic
diagnosis of
voiding difficulties
with post-void
residual greater
than 100ml.
Combination of
symptoms is more
accurate in
predicting DO in
OAB patients.
The multivariate
disease model for
males included urge
urinary
incontinence (UUI)

There was not
adequate
information
regarding
whether or not
urodynamic
findings
altered
management
for these
patients.

Combinati
on of
symptoms
of OAB
syndrome
seems to
have a
better
correlation
with
objective
parameter
s from the
bladder
diary,
filling
cystometr
y, and
with the
occurrenc
e of DO.

and urgency while
for females it
included UUI and
nocturia.

141

The results were
statistically
evaluated using
Mann-Whitney and
Fisher’s exact
probability tests for
comparison of the
findings between
DO and no DO
patients, and for
comparison
between symptoms
and urodynamic
findings.
22.

Reynolds,
W.S.,
McPheeters,
M., Blume, J.,
Surawicz, T.,
Worley,
K.,Wang, L.,

Multiple
reviewers
screened original
research
published in
English on
community

Bias, as 98%
of the studies
reported
funding by
industry.

5 Data sources:
MEDLINE,
EMBASE,
Cumulative
Index to
Nursing and
Allied Health

Effects of
medication and
placebo was
assessed and no
individual agent
demonstrated

None noted

Evidence
from more
than
27000
women
participati
ng in
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Hartmann, K.
(2015).
Comparative
effectiveness
of
anticholinergi
c therapy for
overactive
bladder in
women: A
systematic
review and
meta-analysis.
(Review).
Obstetrics
and
Gynecology,1
25(6):14231432

dwelling women
with nonneurogenic OAB
undergoing
pharmacotherapy
with medications
available in the
USA.

Literature, and
ClinicalTrials.
gov

superiority over
another.

randomize
d
controlled
clinical
trials
suggests
improvem
ent in
symptoms
with
anticholin
ergic
manageme
nt of
overactive
bladder is
modest
and rarely
fully
resolves
symptoms
.

Exclusion
criteria: studies
in which
women
comprised less
than 75% of
population;
small sample
size less than
50.

Study design
included
randomized
controlled trial for
meta-analysis and
cohorts, casecontrol, and case
series for harms
data.

Evidence
Level IIIb
Quality: Good
23.

Yamaguchi,
O., Marui, E.,
Kakizaki, H.,

Randomized,
double-blind,
placebo-

Bias as some
of the
researchers

1139 patients
in multiple

Mirabegron was
found to be
significantly

None noted in
article.

Mirabegro
n 50mg
daily is an
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Homma, Y.,
Igawa,
Y.,Takeda,
M.,
Nishizawa,
O., Gotoh,
M., Yoshida,
M.,Yokoyama
, O., Seki,
Na., Ikeda,
Y., Ohkawa,
S. (2014).
Phase III,
randomized,
double-blind,
placebocontrolled
study of the
βᶾadrenoceptor
agonist
mirabegron,
50mg once
daily, in
Japanese
patients with
overactive

controlled phase
III study enrolled
Japanese patients
experiencing
OAB symptoms
for ≥ 24 weeks.
Patients with ≥ 8
micturitions/24
hours and ≥ 1
urgency
episode/24 hours
or ≥1 urgency
incontinence
episode/ 24 hours
were randomized
to once daily
placebo,
mirabegron 50mg
or tolterodine
4mg (as an active
comparator,
without testing
for non-inferiority
of efficacy and

were
consultants
for industry.

centers in
Japan.

Receiving
Generalizabil placebo,
ity of results n=381.
to other
Receiving
countries
with diverse mirabegron
50mg, n=380.
populations
Receiving
tolterodine
4mg,
N=378.
Demographic
and baseline
characteristics
were similar
among the
treatment
groups.

superior to placebo
in terms of mean
(SD) change from
baseline in number
of micturitions/24
hours (-1.67 [2.212]
vs -0.86 [2.354];
P<0.001) and mean
[SD] change from
baseline in number
of urgency
episodes/24 hours
(-1.85) [2.555] vs 1.37 [3.191];
P=0.025),
incontinence
episodes/24 hours
(-1.12[1.475] vs 0.66 [1.861];
P=0.003), urgency
incontinence
episodes/ 24 hours
(-1.01 [1.338] vs 0.60 [1.745];
P=0.008), and
volume
voided/micturition

effective
treatment
for OAB
symptoms
, with a
low
occurrenc
e of side
effects in
a Japanese
population
.

bladder. BJU
International,
113:951-960
Randomized
clinic trial
study
Evidence
Level: Ib
Quality: Good

safety) for 12
weeks.
Primary endpoint
was change in
mean number of
micturations/ 24
hours from
baseline to final
assessment.
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Secondary
endpoints
included
micturition
variables related
to urgency and/or
incontinence and
QOL domain
scores on the
King’s Health
Questionnaire.
Safety assessment
included adverse
events (AEs),
post-void residual
urine volume,

(24.300 [35.4767]
vs 9.715 [29.0864]
ml; P< 0.001).
Adverse events
(AE) incidence
were similar in both
mirabegron and
placebo groups.
Most AEs were
mild and none were
severe.

laboratory
variables, vital
signs and 12 lead
electrocardiogram
.
24.
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Cardozo, L.,
Hebdorfer, E.,
Milani, R.,
Arano, P.,
Dewilde, L.,
Slack, M.,
Drogendijk,
T., Wright,
M.,
Bolodeoku, J.
(2008).
Solifenacin in
the treatment
of urgency
and other
symptoms of
overactive
bladder:
results from a
randomized,
double-blind,

The study
(SUNRISE,
solifenacin in the
treatment of
urgency
symptoms of
OAB in a rising
dose, randomized,
placebocontrolled,
double-blind,
efficacy trial) was
randomized,
double-blind, 16week, placebocontrolled,
multicenter study
of solifenacin
5/10 mg in
patients with
symptoms of

Potential
bias, as the
study was
supported by
industry

863 patients in
105 centers in
14 European
countries

Solifenacin 5/10
None noted.
mg was
significantly more
effective than
placebo in reducing
the mean number of
episodes of severe
urgency with or
without
incontinence per 24
hours from baseline
to endpoint (-2.6 vs
-1.8, P<0.001).
There were also
statistically
significant
differences in favor
of solifenacin 5/10
mg over placebo for
all secondary
variables measured

Solifenaci
n
significant
ly reduced
the
number of
urgency
episodes
and the
extent of
urgency
bother,
and was
well
tolerated;
it was
effective
as early as
day 3 of
treatment.

placebocontrolled,
rising-dose
trial. BJU
International,
102 (11201127).
DOI:10.1111/
j.1464410X.2008.07
939.x
146

Randomized
clinical trial
study
Evidence
Level: Ib
Quality: Good

OAB for ≥
3months.
The primary
efficacy variable
was the change
from baseline to
endpoint in the
number of
episodes of severe
urgency with or
without urgency
incontinence per
24 hours, as
measured using
the Patient
Perception of
Intensity of
Urgency Scale,
grade 3+4.
Secondary
efficacy variables
included patientreported
outcomes for
bladder condition,

at endpoint,
including patientreported outcomes.
There was a
significant
improvement in
urgency as early as
day 3 of treatment.
Treatmentemergent adverse
events with
solifenacin 5/10 mg
were mainly mild
or moderate in
severity, and only
led to
discontinuation in
3.6% of patients.

urgency bother
and treatment
satisfaction.
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A 3-day voiding
diary was used to
record micturition
frequency and
episodes of
urgency and
incontinence. A
7-day diary was
used to assess
speed of onset of
effect.
25.

Nguyen, K.,
Hunter, K.F.,
Wagg, A.
(2013).
Knowledge
and
understanding
of urinary
incontinence:
Survey of
family

A cross-sectional
survey, using
randomly selected
sample of family
physicians in
Alberta, Canada.
Family physicians
were selected
from the publicly
available
directory

The findings
may not be
generalizable
due to a low
response rate
of
practitioners.
An
honorarium
of $50 was
offered to

Of 158 of 1488
family
practitioners
contacted
participated.
All
practitioners
completed the
questionnaire

Survey response
rate was 10.6%
(158 of 1488);
84.2% (133 of 158)
of respondents
practiced in urban
settings, 44.9% (71
of 158) had been in
practice for fewer
than 15 years,
24.1% (38 of 158)

Low response
rate.
Declining
response rates
to surveys
owing to
survey fatigue.

There
continues
to be
considerab
le
variation
in
knowledg
e about
urinary
incontine-

practitioners
in northern
Alberta.
Canadian
Family
Physician
59(7):e330e337

published by the
College of
Physicians and
Surgeons of
Alberta using
computergenerated random
number list.
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Retrieved
Standardized
from
validated survey
www.cfp.ca.p used.
allas2.tcl.sc.e
du/content/59/
7/e330
Descriptive
survey

Evidence
Level:
IIIb
Quality: Good

complete the
survey and
may
potentially
create a bias

via telephone,
and fax

reported having no
training in urinary
incontinence (UI)
management since
graduation, and
53.8% (85 of 158)
reported that they
proactively
discussed UI with
their patients.
Overall, 70.0% of
respondents felt
fairly confident in
managing UI. Most
family physicians
referred patients for
specialist care, with
few referrals to
community
services.
Respondents
thought that
continence services
were scarce, with
long waiting times,

nce
management and
a relative
overreliance on
specialist
care,
despite
well
recognized
difficulties
in gaining
access to
services.
Responde
nts
believed
that
increased
awareness
among
patients
and health
care
providers

and that such
services were
generally
overstretched; they
believed that
although high
quality continence
care was a personal
priority, it was not a
priority for their
practice
partnerships or
networks.
149

In terms of the
highest ranked
areas for
improvement in UI
management,
increased
awareness and
understanding
among physicians
(ranked first by
28.5% of
respondents),
followed by

coupled
with
greater
access to
continence
services
were key
factors in
improving
care
delivery.

dedicated
incontinence clinics
or nurses for
referral (17.7%)
and improving
patient awareness
and understanding
(12.0%).
26.
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Teunissen, D.
T. A. M.,
Stegeman,
M.M., Bor, H.
H., LagroJanssen,
A.L.M.
(2015).
Treatment by
a nurse
practitioner in
primary care
improves the
severity and
impact of
urinary
incontinence
in women. An

An observational
study examining
how nurse
practitioners
(NPs)treated
female patients
with UI.
All patients were
examined and
referred by the
General
Practitioner (GP)
the NP working
in the same
practice.
At baseline the
severity of the UI

The
generalizabili
ty of the
study cannot
be but is
assumed to
have
improved the
women’s life
after three
months of
therapy.

16 nurse
practitioners
working with a
GP’s office in
the
Netherlands,
undertook a
training
program in
which they
learned how to
manage female
patients with
UI.

103 women were
included, mean age
55 years (SD 12.6).
The Sandvik
severity categories
improved
significantly
(P<0.001), as did
the impact on daily
life (2.54 points,
P=0.012). Among
the IIQ score the
impact on daily
activities increased
0.73 points
(P=0.032), on
social functioning
0.60 points

The dropout
rate in this
study was 32%
which is
considered
high.
No control
group was
involved as a
RCT which
received care
by the GP.
The training
program for
patients with
UI is time
consuming,

Treatment
by a
trained NP
seems to
have a
small
positive
affect the
severity of
the UI and
the impact
on the
quality of
life. NPs
involved
in the care
of patients
generally

observational
study.
BioMed
Central,15:51.
DOI:10.1186/
s12894-0150047-0
Observational
study
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Evidence
Level: IIIb
Quality: Good

(Sandvik-score),
the impact of the
quality of life
(IIQ) and the
impressed
severity (PGIS)
was measured and
repeated after
three months.
Differences were
tested by the
paired t and the
NcNemar test.
Reasons for not
completing
treatment were
documented by
the nurse
practitioner and
differences
between the
group that
completed
treatment and the

(P=0.030) and on
emotional wellbeing 0.63 points
(P=0.031). The
PGIS -score
improved in 41.3%
of the patients.
The most important
reasons for not
completing the
treatment were lack
of improvement of
the UI and
difficulties in
performing the
exercises. Women
who withdraw from
guidance by the
nurse practitioner
perceived more
impact on daily life
(P=0.036), in
particular on the
scores for social
functioning
(P=0.015) and

and not always
easy to sustain
and difficult to
implement in
daily life.

leads to an
improvem
ent of
health
outcomes
and
patient
satisfactio
n.
Women
who did
not
complete
treatment
suffer
from more
impact on
quality of
life,
experience
not
enough
improvem
ent and
mention
difficulties

drop-out group
were tested.
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AlbersHeitner, C.P.,
LagroJanssen,
A.L.M.,
Venema, P.L.,
Berghmans,
L.C.M., de
Jonge, A.,
Joore, M.A.
(2010).
Experiences
and attitudes
of nurse
specialists in
primary care
regarding
their role in
care for
patients with
urinary
incontinence.

A focus group
conducted with
nurse specialists
who were trained
in caring for
patients with UI
in a randomized
clinical trial.
The aim was to
explore
experiences and
attitudes of nurse
specialists in
primary care.
The focus group
interview was
audio-taped and
transcribed
verbatim.

emotional wellbeing (P=0.015).

There may
have been
some bias, as
all were
interested
participants.
Due to the
small sample
size the
generalizabil
-ity of the
study was
limited.

16 nurse
specialists in
four Dutch
regions who
provided care
to patients with
UI.
The study was
carried out
from May
2005 until
Mache 2008.
All
consecutive
patients
consulting
their GP for UI
within 1 year
and patients
already
diagnosed with

in
performin
g
exercises.

Descriptive
statistics was used.

A small size
was used.

To increase
dependability and
confirmability, the
interview was
transcribed
verbatim.

Only one focus
group was
conducted.

To improve
consistency and
reliability analysis,
the external
moderator and the
researcher analyzed
the transcript
independently of
each other.
To promote
trustworthiness, the
researchers

The
participants
may have
made socially
desirable
comments
because they
knew
interviewers
may have an
interest in the
subject.

The focus
group
trained
nurse
specialist
appeared
to feel
competent
and
satisfied
to support
GPs in
caring for
patients
with UI.
They also
felt highly
appreciate
d by both
patients
and GPs.

Scandinavian
Journal of
Caring
Science.
25:303-310.
DOI:10.1111/
j.14716712.2010.00
827.x
Focus group
study
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Evidence
Level:IVb
Quality: Good

A questionnaire
was filled out
prior to the focus
group.
The data was
analyzed using
qualitative
content analysis
to identify
themes.
To understand
obstacles and
incentives for
change, the
researchers relied
on an existing
‘implementation
model.’

UI were
eligible.

discussed data
fragments in the
light of ‘potential
Approval was
barriers and
sought from
facilitators for
the Medical
quality of care and
Ethical
change’ related to
Committees of the individual’s
all the involved cognitive,
medical
educational and
centers and
motivational
hospitals.
attributes as well as
to social,
organizational and
economic factors.
Nurse specialists
value continuous
education and
feedback in daily
care of patients
with UI.

Nurse
specialist
sometimes
noticed
the GPs
lack of
interest in
UI.
Having
personal
contact
with GPs,
availabilit
y of
enough
time,
adequate
equipment
and
financial
resources
are
important
preconditi
ons for
effective

nurse
specialist
care.
28.
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Keilman, L.J.,
Dunn, S. K.
(2010).
Knowledge,
attitudes, and
perceptions of
advanced
practice
nurses
regarding
urinary
incontinence
in older adult
women.
Research and
Theory for
Nursing
Pratice: An
International
Journal, 24
(4):260-279.

Across-sectional,
descriptive,
correlational
design was used
to study
purposive sample
of APNs who
were identified
from personal and
professional
contacts and an
APN organization
membership list.
Eligible
participants had
completed a
master’s degree in
nursing from an
accredited
university, had
achieved national
certification as a

A small
sample size
may limit the
generalizabili
ty of the
findings.
Self-reported
data may
create a bias

72 APNS
initially agreed
to participate;
however, only
56
questionnaires
were returned.
2
questionnaires
were not
excluded for
failing to
complete the
questionnaire.
The study
sample of 54
participants or
a 75%
response rate,
Majority of
participants

Data was analyzed
using SPSS17.0
computer software.
Approximately
57% (n=31) of the
APNs reported
diagnosing UI in
their clinical
practice.
Of the APNS who
diagnosed UI, 60%
also treat, manage,
educate, and
counsel patients
regarding their
condition.
Only 48.1% felt
their education on
the topic was
adequate. This
group of APNs

Sample was
not a true
representation
of the entire
population of
APNs.
There were
148 questions,
which took
approximately
1-2 hours to
complete.

Continuou
s
education
is a crucial
componen
t in the
manageme
nt of UI.
APNs can
make a
difference
in the
manageme
nt of UI in
women if
they are
taught the
essentials
and UI
practice
guidelines
within

DOI:10.1891/ nurse practitioner,
1541clinical nurse
6277.24.4.260 specialist, or
midwife, and
Crossworked with older
sectional,
adult women.
descriptive,
and
IRB approval was
correlational
sought prior to
design study
recruitment.
Evidence
Level IIIb
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Quality: Good

Participants
where initially
consulted by
telephone, email
or in-person.
The study
purpose, process,
estimated
timeframe for the
questionnaire
completion, and
consent were then
explained to
participants.

were female
(n=51, 94.4%),
Caucasian
(n=46, 85.2%),
married (n=40,
84.1%).
Age of the
participants
ranged from
31.7 to 72.8
years with a
mean of 53.0
(SD=10.25)
Upon data
entry, 2
participants
failed to
complete the
questionnaire
appropriately.

reported learning
more about UI
through attending
conferences where
UI was offered as a
topic (n=30,
72.2%); consulting
a UI specialist
n=21, 38.9%); or
acquiring specific
information through
reading
professional
journals (n=48,
88.9%).
UI guidelines were
used regularly in
practice by only
24.1% (n=13)) of
the APNs.
Participants also
reported the
prevalent gender of
older adult patients
treated for UI was

their
graduate
education.
Researche
rs have
found that
enhancing
UI content
with
graduate
curriculu
m may be
warranted.
Perhaps
the single
most
important
action that
APNs can
take is to
ask every
older adult
about UI
and then
follow

female (n=39,
72.2%) and more
than 50% of those
individuals were 66
years of age and
older.
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All participants did
not necessarily feel
confident in their
assessment/diagnostic skills related to
UI (M=3.50,
SD=0.95) and in
managing and/or
treating UI
independently.
APNS who
reported a higher
level of education
regarding UI had
more accurate
perceptions, more
positive attitudes,
and more
knowledge

with the
basic
approache
s to
evaluation
and
management.

regarding older
adult women with
UI than those who
reported lesser
levels of education.
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Reliability of the
KAPUIOW scale
was estimated by
Cronbach’s alpha.
Total scale estimate
was α=0.86, with
α=0.81 for the
Attitudes/Perceptio
n subscale, and
α=0.77 for the
Knowledge
subscale.
29.

Duralde, E.R.,
Walter, L.C.,
Van Den
Eeden, S.K.,
Nakagawa, S.,
Subak, L.L.,
Brown, J.S.,
Thom, D.H.,

An observational
cohort study from
2003-2012.
Women aged 40
years and older
enrolled in a
Northern
California

The
generalizabili
ty of the
study may be
limited as the
women in
this study
had few

969 women in
a Northern
California
integrated
health care
delivery
system.

Mean age of the
participants was
59.9 years and 55%
were racial/ethnic
minorities (171
black, 233 Latina,
133 Asian or Native
American). Fifty-

Researchers
relied on
participants
report on
incontinence
status,
comorbid
conditions and

Lower
income
women
and
diabetic
women
were less
likely to
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Huang, A.J.
(2016).
Bridging the
gap:
determinants
of
undiagnosed
or untreated
urinary
incontinence
in women.
American
Journal of
Obstetrics &
Gynecology,2
14:266.e1-9
Retrieved
from
http://dx.doi.o
rg/10.1016/j.a
jog.2015.08.0
72
Evidence
Level IIIb

integrated health
care delivery
system who
reported at least
weekly
incontinence.
Structured
questionnaires
were used to
assess clinical
severity, type,
treatment, and
discussion of
incontinence.

barriers to
care, were
insurance,
with
relatively
easy access
to affordable
primary care
specialists.

five percent
reported discussing
their incontinence
with a health care
provider, 36%
within 1 year of
symptom onset, and
with only 3%
indicating that their
provider initiated
the discussion.
More than half
(52%) reported
being at least
moderately
bothered by their
incontinence. Of
these women, 324
(65%) discussed
their incontinence
with a clinician,
with 200 (40%)
doing so within 1
year of symptom
onset. In a
multivariate

discuss
incontinen
ce issues
with their
providers.
Researchers
The
utilized
findings
interviews in
provide
data collection, support
which have
for
been
systematic
associated with screening
poorer
of women
reporting of
by
sensitive topics providers
such as
to
incontinence.
overcome
barriers to
Only women
evaluation
with a least
and
weekly
treatment.
incontinence
participated,
and did not
include women
who had
previously
provider
interactions
around
incontinence.

Quality: Good
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analysis, women
were less likely to
have discussed their
incontinence if they
had a household
income <$30,000
vs ≥ 120,000/year
(adjusted odds ratio
[AOR], 0.49, 95%
confidence interval
(CI), 0.28-0.86) or
were diabetic
(AOR, 0.71, 95%
CI, 0.51-0.99).
They were more
likely to have
discussed
incontinence if they
had clinically
severe incontinence
(AOR, 3.09, 95%
CI, 1.89-5.07),
depression (AOR,
1.71, 95% CI, 1.202.44), pelvic organ
prolapse (AOR,

suffered from
incontinence,
underwent
evaluation, and
were
successfully
treated, or
those with less
frequent
incontinence.

1.98, 95% CI,1.133.46), or arthritis
(AOR, 1.44, 95%
CI, 1.06-1.95).
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Among the subset
of women reporting
at least moderate
subjective bother
from incontinence,
black race (AOR,
0.45 95%CI, 0.250.82, vs white race)
and income <
$30000/ year
(AOR, 0.37, 95%
CI 0.17-0.81, vs ≥
$120000/year) were
associated with a
reduced likelihood
of discussing
incontinence. Those
with clinically
severe incontinence
(AOR, 2.93, 95%
CI, 1.53-5.61, vs
low to moderate

incontinence by the
Sandvik scale) were
more likely to
discuss it with a
clinician.
30.
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Carcio, H.A.
(2014).
Calming the
overactive
bladder: a
nurse
practitioner
perspective.
Women’s
Healthcare: A
clinical
journal for
NPs, 2(3):2627 & 49.
Retrieved
from
www.NPWo
menshealthcar
e.com

The article
explores the
assessment and
management of
OAB by NPs

None noted

The article
discussed a
survey done by
the National
Association of
Nurse
Practitioners in
Women’s
Health on 300
NPs to
ascertain their
own level of
recognition
and treatment
of OAB in
their practice

OAB is lifestyle
None noted
threatening and
patients need not
suffer with it, if
OAB symptoms are
identified quickly,
by a NP or patient.
The assessment
includes a health
history, focused
physical
examination that
includes a
gynecological exam
to assess the
bladder and pelvic
floor muscles.

NPs have
an
opportunit
y to
emerge as
front-line
practitione
rs in
educating
patients
about
OAB.
Continued
emphasis
on OAB
in
academic
programs
and
national

Evidence
Level: IVb

conferenc
es will
increase
NP
knowledg
e and
confidenc
e in
assisting
patients
with
OAB.

Quality: Good
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31.

Filipetto, F.
A., Holthusen,
A. E.,
McKeithen,
T. M.,
McFadden, P.
(2014). The
patient
perspective on
overactive
bladder: a
mixed-method
needs
assessment.

Mixed methods
qualitative/quantit
ative needs
assessment of
patients with
OAB and/or
urinary
symptoms.
Researchers
conducted indepth qualitative
interviews via
telephone with 40
patients.

Internal
validity of
the study
may be
affected due
to selection
bias of
participants

194
participants, 98
were men and
96 were
female.
200 surveys
filled out, 6
were invalid.
Most
participants
had a primary
care provider

Statistical and
qualitative analysis
of results were
conducted.

The survey
was developed
using
responses from
the qualitative
Among survey
interviews. The
respondents, an
survey was not
average of 3.5 years pilot tested and
elapsed between
was not
symptom onset and validated.
seeking diagnosis
by a physician. In
Participants
the long term, most were recruited
patients do not
using a

The
significant
time gap
between
symptom
onset and
diagnosis
indicates
ongoing
need for
screening
and
diagnosis
of

Interview
respondents who
had previously
identified
Doi:10.1186/1 themselves as
47-2296-15having OAB or
96
bladder problems.

BMC Family
Practice,
15:96
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Mixed
methods
qualitative/qu
antitative
needs
assessment

Evidence
Level:IIb
Quality:Good

experience
improvement in
symptoms.
Several men
Medication nonwere treated by adherence is
urologist, and
common and is
two women
related to therapy
were cared for effectiveness and
by
adverse effects.
urogynecologi- Patients clearly
sts.
indicated that
communication and
patient/provider
relationships are
important to them
and they would
prefer the clinician
initiate the
conversation on
overactive bladder.
Patient experiences,
perspectives, and
attitudes toward
their bladder
symptoms differ in
many ways from
managing their
symptoms.

company that
compiles
panels of
participants.

overactive
bladder.
Contrary
to
guideline
recommen
dations,
urinalysis
and
physical
examinati
on are not
widely
used in
clinical
practice.
Many
patients
experience
no
improvem
ent in
symptoms
over time.
Patients
indicate
that

provider
assumptions.

clinician/p
atient
relationshi
p and
communic
ation
regarding
the
condition
are
important.
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APPENDIX C: ACTIONABLE BLADDER SYMPTOM SCREENER (ABSST)
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APPENDIX D: OAB CLASS CLIMATE SURVEY
ORGANIZATION: University of South Carolina
AUTHOR: Helen, Ngigi
College of Nursing
SURVEY: OAB Survey
Activate contrast mode

Activate contrast mode

1Knowledge of Overactive Bladder and Perception of the
Screening Tool Effectiveness Demographic

DO NOT ADD YOUR NAME anywhere on the Survey.
1.1 Please provide your mother’s birthdate starting with month, and then followed by year below
so that we can link the pre-and post-survey to same provider.

1.2 What is your age range?
25-35 years

36-45 years

46-55 years

Greater than 56 years

1.3 Number of years of practice in a primary care setting
1-3 years

4-7 years

Greater than 8 years

1.4What is your gender?
Male Question

Female

Not applicable

1.5 What is your title?
NP

PA

MD

Please mark the box for the response that best reflects your opinion of the following statement.

Strongly Disagree Disagree Neither Disagree or Agree Agree Strongly Agree
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1.6 OAB is a common condition affecting many women globally and in the US
Strongly Disagree
Agree

Disagree

Neither Disagree or Agree

Agree

Strongly

1.7 Women with urinary incontinence problems often seek treatment immediately
Strongly Disagree
Agree

Disagree

Neither Disagree or Agree

Agree

Strongly

1.8 The validated overactive bladder screening tool (ABSST) is effective in highlighting
the presence of bladder symptoms consistent with OAB

Strongly Disagree
Agree

Disagree

Neither Disagree or Agree

Agree

Strongly

1.9 The ABSST is effective in facilitating critical communication between patient and provider

Strongly Disagree
Agree

Disagree

Neither Disagree or Agree

Agree

Strongly

1.10 How strongly would you agree or disagree that the following are barriers to assessing your
patients for OAB symptoms?

Strongly Disagree Disagree Neither Disagree or Agree Agree Strongly Agree
1.11 Lack of provider information about OAB symptoms
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Strongly Disagree
Agree

Disagree

Neither Disagree or Agree

Agree

Strongly

Disagree

Neither Disagree or Agree

Agree

Strongly

1.11 Not enough time

Strongly Disagree
Agree

1.12 Patients are uncomfortable bringing up the topic of OAB
Strongly Disagree

Disagree

Neither Disagree or Agree

Agree Strongly Agree

Submit

Licensed to UNIV OF SOUTH CAROLINA - Class Climate V6.1 (2051) - Scantron Corporation, All rights
reserved. Copyright © 2015 Electric Paper Evaluations system GmbH
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APPENDIX E: COVER LETTER AND INFORMATION SHEET PRE-SURVEY
Overactive Bladder Assessment Tool Project
Cover Letter and Information Sheet
Principle Investigator: Helen Ngigi
December 2nd, 2016
Dear HCC Providers,
As part of my Doctor of Nursing scholarly project, I will be conducting a quality
improvement project on overactive bladder symptoms in women who present at the HCC.
Your participation in this project will play an important role in its success. The benefit
will be to identify women who may have overactive bladder in order to improve
outcomes. I will be conducting a quality improvement project on the effectiveness of the
Actionable Bladder Symptom Screener tool when used by providers in the HCC. This
project will be strictly voluntary. Participation is anonymous, and no provider personal
identifiers will be collected. You will not receive any financial benefit for participating.
As part of the project, your mother’s birthdate, using month and year, as in 101940, for
example, will used to link the pre- and post-survey. The pre- and post-survey will be
merged by using your mother’s birthdate. Your implied consent to participate in this
project begins with the completion of the pre-survey that will be sent to you via email
from Class Climate.
Please click on this link to complete the pre-survey:
https://classclimate.uts.sc.edu/classclimate/online.php?p=OABSURVEYPRE
If the link above does not work, please copy and paste it to your browser.
Instructions
The Actionable Bladder Screening Tool will be sent to you once you complete the OAB
Grand Rounds recording. This tool is a validated tool that has been used in many
primary care settings.
o The participant provider will screen any eligible female patients that comes into
the clinic on any given day with or without complaints of urinary symptoms.
o Inclusion criteria are females age 40 years or greater with urinary tract infection
complaints.
o If a patient is found to meet the criteria for assessment, the provider will further
evaluate the patient using the ABSST.
o This form should be completed by the provider, not the patient. Also, under no
circumstances should the ABSST tool form be scanned into the patient chart. It is
only for this quality improvement project only.
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o The forms will be used in the clinics for a four- week duration. All participating
providers will receive reminder emails weekly of when to start and stop using the
ABSST tool.
o There is a OAB grand rounds educational teaching module that the researcher
conducted on October 27th 2016, and I encourage all participants to access the
recording via Healthstreams Grand Rounds. This grand round on overactive
bladder discussed strategies of assessing and managing symptoms.
o Upon completion of the study, participants will receive a post survey via Class
Climate, to assess the effectiveness of the tool.
Thank you for your participation on this project.
Sincerely,
Helen Ngigi, MSN, FNP-C
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APPENDIX F: OAB INSTRUCTION LETTER TO USE ABSST

Dear Providers,
Thank you for completing the pre-survey and OAB grand rounds. The next step in the
study is to utilize The Actionable Bladder Screening Tool starting today.
Attached are two documents:
1. OAB instructions – this has the instruction of all screening questions and the
criteria for further follow-up
2. OAB tool (ABSST) – this is the tool you will need to print and start using with
your patients who meet the criteria.
See instructions below:
1. Any female patients age 40 years or greater that comes into the clinic on any
given day with or without complaints of urinary symptoms is eligible for
screening.
2. The OAB tool (ABSST)will be used in the clinics for a four- week duration.
3. This OAB tool (ABSST) should be completed by the provider only, not the patient.
4. Under no circumstances should the OAB tool (ABSST) be scanned into the
patient chart.
5. Upon completion of the study, you will receive a post survey via Class Climate,
to assess the effectiveness of the tool.
Please feel free to reach out to me if you have any questions.

Helen Ngigi

Helen Ngigi, MSN, FNP-C
Clinic Manager for Healthcare Clinics in Austell and Smyrna
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APPENDIX G: COVER LETTER AND INFORMATION SHEET POSTSURVEY
Overactive Bladder Assessment Tool Project
Cover Letter and Information Sheet
Principle Investigator: Helen Ngigi
Dear HCC Providers,
As part of my Doctor of Nursing scholarly project, I have conducted a quality
improvement project on overactive bladder symptoms in women who present at the HCC.
Your participation in this project has played an important role in its success. The benefit
was to identify women who may have overactive bladder in order to improve outcomes. I
have conducted a quality improvement project on the effectiveness of the Actionable
Bladder Symptom Screener tool when used by providers in the HCC. This project was
strictly voluntary. Participation was anonymous, and no provider personal identifiers
were collected. You did not receive any financial benefit for participating. As part of the
project, your mother’s birthdate, using month and year, as in 101940, for example, will
used to link the pre- and post-survey. The pre- and post-survey will be merged by using
your mother’s birthdate. Your implied consent to participate in this project began with the
completion of the pre-survey that was sent to you via email from Class Climate. The
conclusion of your part in the study is completing the post-survey.
Please click on this link to complete the post-survey:
https://classclimate.uts.sc.edu/classclimate/online.php?p=OABSURVEYPO
If the link above does not work, please copy and paste it to your browser.
Instructions
The Actionable Bladder Screening Tool has already been sent to you and you completed
the OAB Grand Rounds recording. This tool is a validated tool that has been used in
many primary care settings.
o As the participant provider you have screened any eligible female patients that
came into the clinic on any given day with or without complaints of urinary
symptoms.
o Inclusion criteria was females age 40 years or greater with urinary tract infection
complaints.
o If a patient was found to meet the criteria for assessment, you as the participant
provider further evaluated the patient using the ABSST.
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o This form should only have been completed by the provider, not the patient. Also,
under no circumstances was the ABSST tool form to be scanned into the patient
chart. It was only for this quality improvement project only.
o The forms were to be used in the clinics for a four- week duration. All
participating providers received reminder emails of when to start and stop using
the ABSST tool.
o There is a OAB grand rounds educational teaching module that the researcher
conducted on October 27th, 2016, and encouraged all participants to access the
recording via Healthstreams GrandRounds. This grand round on overactive
bladder discussed strategies of assessing and managing symptoms.
o Upon completion of the study, you are now receiving a post survey via Class
Climate, to assess the effectiveness of the tool.
Thank you for your participation on this project.
Sincerely,

Helen Ngigi, MSN, FNP-C
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APPENDIX H: POWER POINT OAB EDUCATIONAL MODULE
PRESENTATION
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